Original Article
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
N Engl J Med 2002; 347:408-415August 8, 2002
- Abstract
Background
Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis.
Methods
In this randomized, unblinded trial, patients received either intravenous voriconazole (two doses of 6 mg per kilogram of body weight on day 1, then 4 mg per kilogram twice daily for at least seven days) followed by 200 mg orally twice daily or intravenous amphotericin B deoxycholate (1 to 1.5 mg per kilogram per day). Other licensed antifungal treatments were allowed if the initial therapy failed or if the patient had an intolerance to the first drug used. A complete or partial response was considered to be a successful outcome.
Results
A total of 144 patients in the voriconazole group and 133 patients in the amphotericin B group with definite or probable aspergillosis received at least one dose of treatment. In most of the patients, the underlying condition was allogeneic hematopoietic-cell transplantation, acute leukemia, or other hematologic diseases. At week 12, there were successful outcomes in 52.8 percent of the patients in the voriconazole group (complete responses in 20.8 percent and partial responses in 31.9 percent) and 31.6 percent of those in the amphotericin B group (complete responses in 16.5 percent and partial responses in 15.0 percent; absolute difference, 21.2 percentage points; 95 percent confidence interval, 10.4 to 32.9). The survival rate at 12 weeks was 70.8 percent in the voriconazole group and 57.9 percent in the amphotericin B group (hazard ratio, 0.59; 95 percent confidence interval, 0.40 to 0.88). Voriconazole-treated patients had significantly fewer severe drug-related adverse events, but transient visual disturbances were common with voriconazole (occurring in 44.8 percent of patients).
Conclusions
In patients with invasive aspergillosis, initial therapy with voriconazole led to better responses and improved survival and resulted in fewer severe side effects than the standard approach of initial therapy with amphotericin B.
Media in This Article
Figure 2
Survival Curves for the Modified Intention-to-Treat Population According to Treatment Group.Figure 1
Response Rates in the Modified Intention-to-Treat Population, According to the Study Protocol, Site of Infection, Underlying Condition, Neutropenic Status, and Degree of Certainty of the Diagnosis, and in the Intention-to-Treat Population.Article Activity
- Article
Invasive aspergillosis is a major infectious complication in patients with prolonged neutropenia and in transplant recipients. Its incidence ranges from 5 percent to more than 20 percent in high-risk groups.1 For decades, amphotericin B deoxycholate has been the standard therapy for invasive aspergillosis, although responses are suboptimal (less than 40 percent) in severely immunosuppressed patients.1-3 Amphotericin B is associated with multiple side effects, which may be ameliorated with the use of lipid formulations.4-6
Voriconazole is a new broad-spectrum triazole that is active in vitro against various yeasts and molds, including aspergillus species.7 A noncomparative study demonstrated a response rate of 48 percent among patients with acute invasive aspergillosis.8 We undertook an open, randomized trial comparing the efficacy, safety, and tolerability of voriconazole with those of amphotericin B for the primary therapy of acute invasive aspergillosis in immunocompromised patients; both types of therapy were followed by other licensed antifungal therapy when toxic effects or insufficient response dictated.
Methods
Conduct of the Study
Two identical protocols (protocol 150-307 in Europe, Israel, and Australia and protocol 150-602 in the United States, Canada, Mexico, Brazil, and India) were designed under the aegis of an international steering committee that included the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer (EORTC). The protocols were approved by the appropriate institutional review boards, and written informed consent was obtained from all patients or their parents or guardians. The studies were assessed by an independent data review committee consisting of eight clinicians and four radiologists and were monitored by two data and safety monitoring boards. Statistical analysis was conducted by the EORTC Data Center. The study's sponsor, Pfizer, allowed the investigators independence in study design and analysis. The data were held at the EORTC Data Center in Brussels, Belgium, and at Pfizer.
Study Patients
Eligible patients were those with definite or probable invasive aspergillosis who were 12 years of age or older and were immunocompromised because of one of the following: allogeneic hematopoietic-cell transplantation; autologous hematopoietic-cell transplantation, hematologic cancer, aplastic anemia, or myelodysplastic syndrome; or other immunocompromising conditions, including the acquired immunodeficiency syndrome (AIDS), receipt of corticosteroid therapy, and solid-organ transplantation.
Definite invasive aspergillosis was defined as a clinically compatible illness plus one or more of the following: isolation of aspergillus species from a normally sterile site; hyphae consistent with the presence of aspergillus in a biopsy specimen or aspirate, plus culture of aspergillus from the same organ; radiologic evidence of pulmonary lesions that were not attributable to other factors and a culture of bronchoalveolar-lavage fluid that was positive for aspergillus in a patient who had undergone allogeneic hematopoietic-cell transplantation or who had a neutropenic hematologic condition; or tracheobronchial lesions confirmed by bronchoscopy, with a positive culture for aspergillus. Neutropenia was defined by a neutrophil count of less than 500 per cubic millimeter at some point during the previous two weeks.
Probable invasive aspergillosis was defined as a clinically compatible illness plus one or more of the following: hyphae consistent with the presence of aspergillus in a biopsy specimen or aspirate but without culture; the presence of a halo or an air-crescent sign on a computed tomographic (CT) scan of the lung9 in a patient who had undergone allogeneic hematopoietic-cell transplantation or who had a neutropenic hematologic condition; radiologic evidence of new pulmonary lesions that were not attributable to other factors in a patient who had undergone allogeneic hematopoietic-cell transplantation or who had a neutropenic hematologic condition with either hyphae consistent with the presence of aspergillus in bronchoalveolar-lavage fluid or sputum or a sputum culture that was positive for aspergillus; clinical evidence of sinusitis, opacification of a sinus on CT or magnetic resonance imaging, and positive histopathological examination or culture of aspergillus from a lesion in the nose or paranasal sinus in a patient who had undergone allogeneic hematopoietic-cell transplantation or who had a neutropenic hematologic condition; radiologic evidence of new pulmonary lesions that were not attributable to other factors and bronchoalveolar-lavage fluid that was positive for aspergillus on a smear or culture in a patient with another immunocompromising condition (other than lung transplantation); or tracheobronchial lesions confirmed by bronchoscopy and a positive finding on histopathological or microscopic examination of a biopsy specimen or bronchoalveolar lavage fluid.
Patients were ineligible if they had chronic aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis or had received systemic therapy for more than 96 hours with more than 0.5 mg of amphotericin B per kilogram of body weight per day (including lipid derivatives) or more than 200 mg of itraconazole per day during the preceding 14 days. Patients were also ineligible if they had received or were receiving interacting drugs (e.g., rifampin), were hypersensitive to azoles or amphotericin B, or had an aminotransferase, bilirubin, or alkaline phosphatase level higher than five times the upper limit of normal or a serum creatinine level higher than 2.5 mg per deciliter (221 μmol per liter). Patients who were receiving artificial ventilation, who had a life expectancy of less than 72 hours, or who were pregnant or lactating were also ineligible.
Study Design
With the use of central randomization according to the minimization technique,10 patients were assigned to treatment groups, with stratification according to the center, the site of infection (pulmonary or other), the underlying condition (allogeneic hematopoietic-cell transplantation, hematologic condition, or other immunocompromising condition), and the base-line neutropenic status (neutropenic or nonneutropenic). Patients received primary therapy with either voriconazole (6 mg per kilogram intravenously twice a day on day 1, followed by 4 mg per kilogram intravenously twice daily for at least seven days, after which time patients could switch to oral voriconazole, 200 mg twice daily) or intravenous amphotericin B deoxycholate (1.0 to 1.5 mg per kilogram once daily). Patients with an intolerance or no response to the initial therapy could be switched to other licensed antifungal therapy and continue to be included in the analyses. The planned duration of therapy was 12 weeks. Administration of study drugs was discontinued in cases of severe adverse events, an increase in the serum creatinine level to double the base-line value or more than 3.0 mg per deciliter (265 μmol per liter) if the base-line value was higher than 1.5 mg per deciliter (133 μmol per liter), or an increase in aminotransferase levels to more than 5 times the upper limit of normal or 10 times the upper limit of normal if the base-line value was more than 2 times the upper limit of normal.
The data-review committee, which was blinded to the study-drug assignment and to adverse events and laboratory abnormalities whose presence would suggest the use of a particular study drug, assessed the certainty of the diagnosis at study entry and the response to treatment on the basis of predefined criteria. The committee assessed the global response at week 12 and at the end of the initial period of randomized therapy.
Digitized radiologic images were reviewed by the radiologists on the data-review committee. Lesions were evaluated visually for changes with the use of computerized planimetry for assistance in estimating the percentage change. Complete responses were defined by the resolution of all clinical signs and symptoms and more than 90 percent of the lesions due to invasive aspergillosis that were visible on radiology. Partial responses were defined by clinical improvement and greater than 50 percent improvement in findings on radiology. Stable responses were defined by the absence of change from base line or an improvement of less than 50 percent. Failure of therapy was defined by worsening disease. Complete and partial responses were classified as successful outcomes. Stable and indeterminate responses and failures of therapy were regarded as unsuccessful outcomes.
Statistical Analysis
Before the two studies began, we planned to combine the results of both in a predefined analysis. The intention-to-treat population consisted of all patients who underwent randomization. The modified intention-to-treat population consisted of those who received at least one dose of the medication they were initially assigned to receive and who had a base-line diagnosis of definite or probable invasive aspergillosis as confirmed by the data-review committee. The population included in the safety analysis consisted of all patients who received their initial study medication.
The primary objective of the studies was to demonstrate the noninferiority of voriconazole as compared with amphotericin B at week 12 in the modified intention-to-treat population. We estimated that the rate of successful outcomes with amphotericin B at week 12 would be 50 percent. Voriconazole would be considered not to be inferior to amphotericin B if the lower limit of the two-sided 95 percent confidence interval for the difference in voriconazole response rate minus the difference in amphotericin B response rate was above –20 percentage points.
One secondary objective was the demonstration of the superiority of the response to voriconazole at the end of the initial therapy in the modified intention-to-treat population — as indicated by a two-sided 95 percent confidence interval entirely above zero for the difference between the proportion with a complete or partial response in the voriconazole group and the proportion in the amphotericin B group. Other secondary objectives were to compare the safety of the two drugs and the duration of survival in the two groups up to week 12.
A sample size of 276 was required to assess the primary end point with at least 90 percent power. We compared the responses by calculating the estimated difference between the response rates, with stratification according to study protocol (150-307 or 150-602), and the corresponding approximate two-sided 95 percent confidence interval. The hazard ratio for death was estimated by the Cox proportional-hazards model, with stratification according to study. The numbers of adverse events were compared by Fisher's exact test. The mean numbers of adverse events were compared by the Wilcoxon rank-sum test. All tests were two-sided.
Results
Enrollment and Base-Line Characteristics of the Patients
Between July 1997 and October 2000, a total of 391 patients recruited by 95 centers in 19 countries underwent randomization in the studies: 252 patients were recruited in the 150-307 protocol and 139 in the 150-602 protocol.
A total of 197 patients were assigned to the voriconazole group, and 194 patients were assigned to the amphotericin B group; these patients comprised the intention-to-treat population. Twelve patients (three in the voriconazole group and nine in the amphotericin B group) did not receive any treatment and were excluded from the safety analyses. A total of 102 patients (50 in the voriconazole group and 52 in the amphotericin B group) were excluded from the modified intention-to-treat population because they did not have a confirmed diagnosis of invasive aspergillosis at base line. The most common reason for the lack of confirmation was the inability of the data-review committee to confirm the presence of a halo or air-crescent sign at base line in patients with no supporting mycologic or pathological evidence (35 in the voriconazole group and 25 in the amphotericin B group). Other reasons included inadequate mycologic evidence (in 10 patients in the voriconazole group and 15 in the amphotericin B group), no radiologic evidence of pulmonary or sinus infection (in 1 patient in the voriconazole group and 4 in the amphotericin B group), and absence of documentation of neutropenia or immunocompromised condition before base line (in 4 patients in the voriconazole group and 8 in the amphotericin B group).
The demographic characteristics and underlying conditions of the patients in the modified intention-to-treat population are summarized in Table 1Table 1
Characteristics of the Patients in the Modified Intention-to-Treat Population.. The two groups were well matched, and there was no significant difference in these characteristics between the intention-to-treat population and the modified intention-to-treat population. Patients enrolled according to the 150-602 protocol were more likely than those enrolled according to the 150-307 protocol to have undergone allogeneic hematopoietic-cell transplantation (41 of 107 [38.3 percent] vs. 26 of 170 [15.3 percent], P<0.001), to have graft-versus-host disease (31 of 107 [29.0 percent] vs. 16 of 170 [9.4 percent], P<0.001), and to have received a definite diagnosis of invasive aspergillosis (51 of 107 [47.7 percent] vs. 57 of 170 [33.5 percent], P=0.02), and they were less likely to have neutropenia (28 of 107 [26.2 percent] vs. 95 of 170 [55.9 percent], P<0.001).Base-Line Characteristics of the Infection
Characteristics of the patients in terms of the site of the infection, the level of certainty of the diagnosis, and the evidence supporting the diagnosis are summarized in Table 2Table 2
Site of the Infection, Degree of Certainty, and Evidence Supporting Base-Line Diagnosis in the Modified Intention-to-Treat Population.. The only significant difference between groups was that the voriconazole group had a higher proportion of definite cases of invasive aspergillosis (P=0.01). In the 110 infections in which the species was identified at base line, the species was Aspergillus fumigatus (in 85 patients), A. niger (in 9 patients), A. flavus (in 7 patients), A. terreus (in 6 patients), A. glaucus (in 1 patient), A. nidulans (in 1 patient), and A. sydowii (in 1 patient).Course of Therapy in the Modified Intention-to-Treat Population
The median duration of voriconazole treatment was 77 days (range, 2 to 84), of which intravenous therapy accounted for a median of 10 days (range, 2 to 78). The mean daily doses were 7.87 mg per kilogram (range, 4.48 to 10.87) during the intravenous phase and 416 mg (range, 200 to 750) during the oral phase. Other licensed antifungal therapy was given to 52 patients in the voriconazole group. The first other licensed antifungal therapy was amphotericin B deoxycholate in 20 patients, a lipid formulation of amphotericin B in 14, itraconazole in 17, and a combination in 1.
The median duration of amphotericin B treatment was 10 days (range, 1 to 84), and the mean daily dose was 0.97 mg per kilogram (range, 0.27 to 1.50). During the first 14 days of therapy, administration of amphotericin B was suspended for more than 1 day in 13 patients. Other licensed antifungal therapy was given to 107 patients in the amphotericin B group. The first other licensed antifungal therapy was a lipid formulation of amphotericin B in 47 patients, itraconazole in 38, and another antifungal drug or a combination of drugs in 22.
Response
The outcome at week 12 in the modified intention-to-treat population was significantly better in patients receiving voriconazole, with a successful outcome in 76 of 144 patients (52.8 percent), as compared with 42 of 133 patients (31.6 percent) in the amphotericin B group (Table 3Table 3
Response Rate at Week 12 in the Modified Intention-to-Treat Population.). The absolute difference was 21.2 percent, with a 95 percent confidence interval for the difference between groups stratified according to the study protocol of 10.4 to 32.9 percentage points. Since the lower 95 percent confidence limit for the difference between voriconazole and amphotericin B was above zero, voriconazole was considered not only not to be inferior to amphotericin B, but also to be superior to it.Retrospective stratification according to the level of certainty of the diagnosis, the site of infection, the underlying condition, or the neutropenic status did not change the overall conclusions. Responses in patients receiving voriconazole appeared to be superior at week 12 in all the various subgroups (Figure 1Figure 1
Response Rates in the Modified Intention-to-Treat Population, According to the Study Protocol, Site of Infection, Underlying Condition, Neutropenic Status, and Degree of Certainty of the Diagnosis, and in the Intention-to-Treat Population.). Of 95 patients included with a diagnosis of probable aspergillosis that was based on the presence of a halo sign without microbiologic confirmation, 31 in the voriconazole group (67.4 percent) had a successful outcome, as compared with 21 (42.9 percent) in the amphotericin B group. The difference (24.5 percentage points in favor of voriconazole) was almost identical to that among all patients with probable aspergillosis — 22.7 percentage points in favor of voriconazole.In the intention-to-treat population, a successful outcome at week 12 was observed in 49.7 percent of the patients in the voriconazole group and 27.8 percent of those in the amphotericin B group (absolute difference, 21.9 percent; 95 percent confidence interval, 12.4 to 31.2).
At the end of the initial period of randomized therapy, 53.5 percent of the patients in the modified intention-to-treat population who were receiving voriconazole had a satisfactory response, as compared with 21.8 percent of the patients treated with amphotericin B (absolute difference, 31.7 percent; 95 percent confidence interval, 21.1 to 42.6). There were similar results in the intention-to-treat population.
Survival
At week 12, the survival rate was 70.8 percent in the patients in the modified intention-to-treat population who were treated with voriconazole, as compared with 57.9 percent in the amphotericin B group (hazard ratio, 0.59; 95 percent confidence interval, 0.40 to 0.88) (Figure 2Figure 2
Survival Curves for the Modified Intention-to-Treat Population According to Treatment Group.). Similar results were observed in the intention-to-treat population.Safety
Significantly fewer adverse events that were regarded by the investigators as potentially related to treatment were observed during voriconazole therapy (343 events) than during amphotericin B therapy (421 events, P=0.02), even though the median duration of therapy was much longer in the voriconazole group. Visual disturbances were more common in patients receiving voriconazole, occurring in 87 patients (44.8 percent), as compared with 8 patients in the amphotericin B group (4.3 percent, P<0.001). The most frequent descriptions of such disturbances were blurred vision, altered visual perception, altered color perception, and photophobia. All visual events were transient and resolved without intervention. Thirteen patients receiving voriconazole had hallucinations or confusion that was considered to be possibly related to the study drug, as compared with five patients in the amphotericin B group (P=0.09). There was no evidence of a relation between the episodes of hallucination or confusion and visual disturbance (P=0.20). Chills, fever, or both that were potentially related to the study drugs were recorded in six patients receiving voriconazole (3.1 percent), as compared with 46 patients receiving amphotericin B therapy (24.9 percent, P<0.001). Skin reactions (rash, pruritus, or photosensitivity) were observed in 16 patients in the voriconazole group (8.2 percent) and in 6 in the amphotericin B group (3.2 percent, P=0.05).
Fewer severe adverse events that were potentially related to the study drug occurred in the voriconazole group (26 patients [13.4 percent]) than in the amphotericin B group (45 patients [24.3 percent], P=0.008) (Table 4Table 4
Severe Adverse Events Potentially Related to Initial Randomized Therapy.). The most frequent events were renal impairment (in 19 patients) in the amphotericin B group and liver-function abnormalities (in 7 patients) in the voriconazole group.Discussion
We conducted a large randomized, comparative study of the efficacy of two different drugs in the primary treatment of invasive aspergillosis. Previous studies either compared two doses of liposomal amphotericin B or used historical controls.11,12 Definitions used in this study were determined by a consensus of international investigators and proved sufficiently clear for a blinded data-review committee to use for confirmation. The largest discrepancy between the diagnoses of investigators and the determinations of the data-review committee resulted not from misinterpretation of the diagnostic criteria but from the lack of confirmation by the radiologists on the data-review committee of the presence of a halo or air-crescent sign on a CT scan of the lungs in 60 cases.
This open study compared two management strategies for invasive aspergillosis, one of which reflects the common clinical practice of treating patients with conventional amphotericin B and then changing drugs as dictated by the occurrence of toxic effects or a lack of response. Patients treated according to this strategy fared worse in terms of efficacy, toxic effects, and survival than those who instead began treatment with voriconazole.
The superiority of voriconazole in our study was not the result of excessive interruptions of therapy or insufficient doses in patients receiving amphotericin B. The duration of treatment is unlikely to be the only factor contributing to the better overall results with voriconazole. Acute invasive aspergillosis is a rapidly progressive infection, and its outcome is determined early in the course of therapy. In the highly immunosuppressed patients enrolled in this study, initial therapy with voriconazole proved superior to initial therapy with conventional amphotericin B. The presence of more definite cases of aspergillosis among patients in the voriconazole group did not bias the results, because the superiority of voriconazole was similar in both definite and probable cases. The difference in the rate of successful outcomes between the 150-602 and 150-307 studies can be explained by the fact that the group involved in the former study included more patients who either had a diagnosis of definite aspergillosis or had undergone allogeneic hematopoietic-cell transplantation.
The efficacy of voriconazole in invasive aspergillosis shown in this trial is consistent with the results of the recently published comparison of voriconazole with liposomal amphotericin B for empirical antifungal therapy in persistently febrile patients with neutropenia.13 In that study, a secondary analysis found that among the 415 patients who received voriconazole, only 8 (1.9 percent) had breakthrough mycosis (4 of the cases involving aspergillus species), as compared with 21 (5.0 percent, 13 of the cases involving aspergillus species) among the 422 patients who received liposomal amphotericin B.
Voriconazole was better tolerated than amphotericin B, with fewer drug-related adverse events, severe adverse events, and discontinuations of therapy due to adverse events. Infusion-related adverse events and nephrotoxic effects are common in patients receiving amphotericin B but were not observed in patients receiving voriconazole.
Although visual adverse events were frequent in patients receiving voriconazole, they were transient and generally mild or moderate, and they seldom resulted in discontinuation of treatment. Hallucination and episodes of confusion were more frequent with voriconazole than with amphotericin B, although it is unclear whether the antifungal drug was the cause of such episodes in these critically ill patients. This study shows the superiority of voriconazole over amphotericin B as initial therapy for invasive aspergillosis, in terms of response rate, survival rate, and safety.
Presented in part at the 41st International Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001.
Supported by grants from Pfizer.
Drs. Herbrecht, Patterson, Bennett, Marr, de Pauw, Rubin, and Wingard have served as consultants for Pfizer. Drs. Hodges, Schlamm, and Troke are employees of Pfizer.
Source Information
From the Hôpital de Hautepierre, Strasbourg, France (R.H.); the University of Manchester, Manchester, United Kingdom (D.W.D.); the University of Texas Health Science Center, San Antonio (T.F.P.); the National Institute of Allergy and Infectious Diseases, Bethesda, Md. (J.E.B.); Massachusetts General Hospital, Boston (R.E.G.); Charité, Campus Virchow-Klinikum, Berlin, Germany (J.-W.O.); Medizinische Universitätsklinik, Freiburg, Germany (W.V.K.); Fred Hutchinson Cancer Research Center, Seattle (K.A.M.); Hôpital Saint-Louis, Paris (P.R.); Institut Pasteur, Paris (O.L.); the European Organisation for Research and Treatment of Cancer, Brussels, Belgium (R.S.); Brigham and Women's Hospital, Boston (R.H.R.); the University of Florida College of Medicine, Gainesville (J.R.W.); the University of California at San Diego, San Diego (P.S.); Hôpital du Bocage, Dijon, France (C.D., D.C.); University Hospital Benjamin Franklin, Berlin, Germany (E.T.); Wayne State University School of Medicine, Detroit (P.H.C.); Pfizer Global Research and Development, New York (M.R.H., H.T.S.) and Sandwich, United Kingdom (P.F.T.); and University Medical Center, Nijmegen, the Netherlands (B.P.).
Address reprint requests to Dr. Herbrecht at the Département d'Hématologie et d'Oncologie, Hôpital de Hautepierre, Ave. Molière, 67098 Strasbourg CEDEX, France, or at raoul.herbrecht@chru-strasbourg.fr.
Other members of the study are listed in the Appendix.
Appendix
In addition to the authors, members of the study who recruited patients were as follows: R. Allen (Sacramento, Calif.), M. Aoun (Brussels, Belgium), C. Aul (Düsseldorf, Germany), M. Bjorkholm (Stockholm, Sweden), K.L. Blanchard (Shreveport, La.), M. Boogaerts (Leuven, Belgium), E. Bouza (Madrid), E.J. Bow (Winnipeg, Man.), H.R. Brodt (Frankfurt, Germany), J. Brown (Stanford, Calif.), D. Buchheidt (Mannheim, Germany), J.Y. Cahn (Besançon, France), A. Calmaggi (La Plata, Argentina), J.M. Cisneros (Seville, Spain), C. Cordonnier (Créteil, France), J. Daly (Worcester, Mass.), C.A. Da Cunha (Curitiba, Brazil), R. De Bock (Antwerp, Belgium), A. Del Favero (Perugia, Italy), J. Diaz Mediavilla (Madrid), M.C. Dignani (Buenos Aires, Argentina), C. Doyen (Yvoir, Belgium), J.S. Dummer (Nashville), B. Dupont (Paris), M. Egyed (Kaposvar, Hungary), D. Engelhard (Jerusalem, Israel), G. Fätkenheuer (Cologne, Germany), R. Feld (Toronto), D. Fière (Lyons, France), G. Fioritoni (Pescara, Italy), G. Garber (Ottawa, Ont.), Z. Gasztonyi (Gyor, Hungary), K. Godder (Columbia, S.C.), D. Graham (Springfield, Ill.), A. Gratwohl (Basel, Switzerland), R. Greenberg (Lexington, Ky.), K. High (Winston-Salem, N.C.), F. Jacobs (Brussels, Belgium), V. Krcmery (Bratislava, Slovakia), P. Kumar (Washington, D.C.), W. Langer (Essen, Germany), M. Laverdiere (Montreal), P. Ljungman (Huddinge, Sweden), H. Lode (Berlin, Germany), A. Louie (Albany, N.Y.), D. Maki (Madison, Wis.), J.P. Marie (Paris), D.J.E. Marriott (Sydney, Australia), D.S. McKinsey (Kansas City, Mo.), R. Mertelsmann (Freiburg, Germany), M.K. Nair (New Delhi, India), N. Milpied (Nantes, France), A. Nagler (Jerusalem, Israel), D. Niederwieser (Leipzig, Germany), L. Pagano (Rome), P. Pappas (Birmingham, Ala.), J. Perfect (Durham, N.C.), J. Pottage (Chicago), V. Raina (New Delhi, India), J. Reinhardt (Newark, Del.), S. Richardson (Toronto), L. Rickman (San Diego, Calif.), M. Ruhnke (Berlin, Germany), I. Salit (Toronto), W.M. Scheld (Charlottesville, Va.), S. Schuler (Dresden, Germany), M. Schuster (Philadelphia), R. Schwerdtfeger (Wiesbaden, Germany), S.D. Shafran (Edmonton, Alta.), B. Simmons (Memphis, Tenn.), M. Slavin (Parkville, Australia), M. Sokol-Anderson (St. Louis), P. Tebas (St. Louis), C. Tsoukas (Montreal), A. Ullmann (Mainz, Germany), J. Van Burik (Minneapolis), J.W. Van't Wout (Leiden, the Netherlands), E.C. Vinaya Kumar (Hyderabad, India), P. Volkow-Fernandez (Mexico City, Mexico), C. Wallrauch (Munich, Germany), H. Wandt (Nuremberg, Germany); EORTC Data Center (Brussels, Belgium): A. Marinus, C. Coens, R. Sylvester; Data-Review Committee: J.E. Bennett, D.W. Denning, C. Durand, R.E. Greene, R. Herbrecht, O. Lortholary, J.W. Oestmann, T.F. Patterson, P. Ribaud, R.H. Rubin, P. Stark, J.R. Wingard.
Data and Safety Monitoring Boards: D.G. Altman (Oxford, United Kingdom), J. Cohen (London), R.J. Duma (Daytona Beach, Fla.), F. Meunier (Brussels, Belgium), R.B. Pollard (Galveston, Tex.), A.S. Sugar (Boston), J. Verter (Rockville, Md.), J. Wittes (Washington, D.C.); Voriconazole team at Pfizer: M. Andrews, C. Gorman, M.R. Hodges, R. Mundayat, H.T. Schlamm, K. Smith, T. Spain, C. Suggars, P.F. Troke, J. Winslade.
- References
References
1
Denning DW . Invasive aspergillosis. Clin Infect Dis 1998;26:781-803
CrossRef | Web of Science | Medline2
Stevens DA ,Kan VL ,Judson MA , et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000;30:696-709
CrossRef | Web of Science | Medline3
Patterson TF ,Kirkpatrick WR ,White M , et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000;79:250-260
CrossRef | Web of Science | Medline4
Wingard JR ,Kubilis P ,Lee L , et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-1407
CrossRef | Web of Science | Medline5
Bates DW ,Su L ,Yu DT , et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-693
CrossRef | Web of Science | Medline6
Tiphine M ,Letscher-Bru V ,Herbrecht R . Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1999;1:273-283
CrossRef | Medline7
Espinel-Ingroff A . In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001;39:954-958
CrossRef | Web of Science | Medline8
Denning DW ,Ribaud P ,Milpied N , et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-571
CrossRef | Web of Science | Medline9
Kuhlman JE ,Fishman EK ,Siegelman SS . Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis. Radiology 1985;157:611-614
Web of Science | Medline10
Freedman LS ,White SJ . On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 1976;32:691-694
CrossRef | Web of Science | Medline11
Ellis M ,Spence D ,de Pauw B , et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998;27:1406-1412
CrossRef | Web of Science | Medline12
White MH ,Anaissie EJ ,Kusne S , et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997;24:635-642
CrossRef | Web of Science | Medline13
Walsh TJ ,Pappas P ,Winston DJ , et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-234
Full Text | Web of Science | Medline
- Citing Articles (891)
Citing Articles
1
Inès Hadrich, Fattouma Makni, Sourour Neji, Salma Abbes, Fatma Cheikhrouhou, Houaida Trabelsi, Hayet Sellami, Ali Ayadi. (2012) Invasive Aspergillosis: Resistance to Antifungal Drugs. Mycopathologia
CrossRef2
D. P. Kontoyiannis, R. E. Lewis, O. Lotholary, B. Spellberg, G. Petrikkos, E. Roillides, A. Ibrahim, T. J. Walsh. (2012) Future Directions in Mucormycosis Research. Clinical Infectious Diseases 54:suppl 1, S79-S85
CrossRef3
Nhareet Somchit, Jun Hung Chung, Azhar Yaacob, Zuraini Ahmad, Zainul A. Zakaria, Arifah A. Kadir. (2012) Lack of hepato- and nephrotoxicity induced by antifungal drug voriconazole in laboratory rats. Drug and Chemical Toxicology1-6
CrossRef4
J. J. Vehreschild, C. Müller, F. Farowski, M. J. G. T. Vehreschild, O. A. Cornely, U. Fuhr, K.-A. Kreuzer, M. Hallek, V. Kohl. (2012) Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. European Journal of Clinical Pharmacology
CrossRef5
Markus Ruhnke, Peter Kujath, Dirk Vogelaers. (2012) Aspergillus in the Intensive Care Unit. Current Fungal Infection Reports
CrossRef6
Atsuhiko Uno, Junko Murata, Suetaka Nishiike, Hiroshi Nishimura, Takao Imai, Yumi Ota, Katsuhisa Ikeda, Hidenori Inohara. (2012) Two Cases of Fungal Rhinosinusitis Infiltrating the Adjacent Structures Successfully Treated by Endoscopic Surgery and Antifugal Agents. Practica Oto-Rhino-Laryngologica 105:1, 21-26
CrossRef7
P. Soler-Palacin, M. A. Frick, A. Martin-Nalda, M. Lanaspa, L. Pou, E. Rosello, C. Diaz de Heredia, C. Figueras. (2011) Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. Journal of Antimicrobial Chemotherapy
CrossRef8
Robert L. Bettiker, Jason C. Gallagher. 2011. Antibiotic Development. .
CrossRef9
S. Blumental, R. Mouy, N. Mahlaoui, M.-E. Bougnoux, M. Debre, J. Beaute, O. Lortholary, S. Blanche, A. Fischer. (2011) Invasive Mold Infections in Chronic Granulomatous Disease: A 25-Year Retrospective Survey. Clinical Infectious Diseases 53:12, e159-e169
CrossRef10
R. Herbrecht, M.-N. Roedlich. (2011) Earlier Diagnosis of Angioinvasive Pulmonary Mold Disease: Is Computed Tomography Pulmonary Angiography a New Step?. Clinical Infectious Diseases
CrossRef11
Giovanna Cannas, Cécile Pautas, Emmanuel Raffoux, Bruno Quesnel, Stéphane de Botton, Thierry de Revel, Oumedaly Reman, Claude Gardin, Mohamed Elhamri, Nicolas Boissel, Pierre Fenaux, Mauricette Michallet, Sylvie Castaigne, Hervé Dombret, Xavier Thomas. (2011) Infectious complications in adult acute myeloid leukemia: Analysis of the prospective multicenter clinical trial ALFA-9802. Leukemia & Lymphoma1-25
CrossRef12
Tasneem Taj, Ravindra R. Kamble, Pramod P. Kattimani, Bharati V. Badami. (2011) Synthetic utility of sydnones: synthesis of pyrazolines derivatized with 1,2,4-triazoles as antihyperglymic, antioxidant agents and their DNA cleavage study. Medicinal Chemistry Research
CrossRef13
Sushil Mandhaniya, Chetanya Swaroop, Sanjay Thulkar, Sreenivas Vishnubhatla, Sushil K. Kabra, Immaculata Xess, Sameer Bakhshi. (2011) Oral Voriconazole Versus Intravenous Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction. Journal of Pediatric Hematology/Oncology 33:8, e333-e341
CrossRef14
Shivaprakash M. Rudramurthy, Arunaloke Chakrabarti, Erik Geertsen, Johan W. Mouton, Jacques F. Meis. (2011) In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagnostic Microbiology and Infectious Disease 71:4, 370-377
CrossRef15
O. Lortholary, J.-P. Gangneux, K. Sitbon, B. Lebeau, F. de Monbrison, Y. Le Strat, B. Coignard, F. Dromer, S. Bretagne, . (2011) Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clinical Microbiology and Infection 17:12, 1882-1889
CrossRef16
Barbara D. Alexander, Thomas P. Winkler, Shuai Shi, Elizabeth S. Dodds Ashley, Anthony J. Hickey. (2011) In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols. Pharmaceutical Development and Technology 16:6, 577-582
CrossRef17
Cornelius J. Clancy, M. Hong Nguyen. (2011) Long-Term Voriconazole and Skin Cancer: Is There Cause for Concern?. Current Infectious Disease Reports 13:6, 536-543
CrossRef18
Jean El Cheikh. (2011) Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients. Current Infectious Disease Reports 13:6, 528-535
CrossRef19
Sandra Saleiro, Luís Rocha. (2011) Invasive pulmonary aspergillosis in a patient with seminomatous testicular cancer. Mycoses 54, 16-19
CrossRef20
J. Auberger, G. Russ, R. Greil, A. Egle. (2011) Treatment of invasive aspergillosis in cancer patients. memo - Magazine of European Medical Oncology 4:4, 266-272
CrossRef21
Musa A. Garbati, Faisal A. Alasmari, Mohammad A. Al-Tannir, Imad M. Tleyjeh. (2011) The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review. International Journal of Infectious Diseases
CrossRef22
Chung Kil Song, Prabagar Balakrishnan, Chang-Koo Shim, Suk-Jae Chung, Saeho Chong, Dae-Duk Kim. (2011) A novel vesicular carrier, transethosome, for enhanced skin delivery of voriconazole: Characterization and in vitro/in vivo evaluation. Colloids and Surfaces B: Biointerfaces
CrossRef23
Jesús Fortún. (2011) Actualización en terapia antifúngica: nuevos fármacos e indicaciones. Enfermedades Infecciosas y Microbiología Clínica 29, 38-44
CrossRef24
Shimin Zhang, Venkateswaran C. Pillai, Sripal Reddy Mada, Steve Strom, Raman Venkataramanan. (2011) Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica1-8
CrossRef25
A. Tragiannidis, E. Roilides, T. J. Walsh, A. H. Groll. (2011) Invasive Aspergillosis in Children With Acquired Immunodeficiencies. Clinical Infectious Diseases
CrossRef26
David I. Marks, Antonio Pagliuca, Christopher C. Kibbler, Axel Glasmacher, Claus-Peter Heussel, Michal Kantecki, Paul J.S. Miller, Patricia Ribaud, Haran T. Schlamm, Carlos Solano, Gordon Cook, . (2011) Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. British Journal of Haematology 155:3, 318-327
CrossRef27
Sun Hee Park, Su-Mi Choi, Dong-Gun Lee, Jung-Hyun Choi, Si-Hyun Kim, Jae-Cheol Kwon, Jin-Hong Yoo, Hee-Je Kim, Seok Lee, Ki-Seong Eom, Woo-Sung Min. (2011) Serum galactomannan strongly correlates with outcome of invasive aspergillosis in acute leukaemia patients. Mycoses 54:6, 523-530
CrossRef28
O. Epaulard, M.-T. Leccia, S. Blanche, O. Chosidow, M.-F. Mamzer-Bruneel, P. Ravaud, A. Thiebaut, C. Villier, O. Lortholary. (2011) Phototoxicity and photocarcinogenesis associated with voriconazole. Médecine et Maladies Infectieuses
CrossRef29
Si-Hyun Kim, Dong-Seok Yim, Su-Mi Choi, Jae-Cheol Kwon, Seunghoon Han, Dong-Gun Lee, Chulmin Park, Eun-Young Kwon, Sun Hee Park, Jung-Hyun Choi, Jin-Hong Yoo. (2011) Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. International Journal of Infectious Diseases 15:11, e753-e758
CrossRef30
Corrado Girmenia, Erica Finolezzi. (2011) New-generation triazole antifungal drugs: review of the Phase II and III trials. Clinical Investigation 1:11, 1577-1594
CrossRef31
C. Wintenberger. (2011) Actualités sur la prise en charge des infections fongiques invasives. Médecine et Maladies Infectieuses
CrossRef32
Cornelia Lass-Flörl. (2011) Triazole Antifungal Agents in Invasive Fungal Infections. Drugs1
CrossRef33
C. Wintenberger. (2011) Vers une prise en charge ciblée de l’aspergillose invasive. Médecine et Maladies Infectieuses
CrossRef34
Luis Eduardo LÓPEZ-CORTÉS, Carolina GARCIA-VIDAL, Josefina AYATS ARDITE, Carlota GUDIOL GONZALEZ, Marta BODRO MARIMONT, Isabel SÁNCHEZ-ORTEGA, Carmen PEÑA MIRALLES, Jordi CARRATALÁ FERNÁNDEZ. (2011) Aspergilosis invasora con afectación extrapulmonar: patogenia, características clínicas y pronóstico. Revista Iberoamericana de Micología
CrossRef35
CORNÉ H. W. KLAASSEN, JOHN G. GIBBONS, NATALIE D. FEDOROVA, JACQUES F. MEIS, ANTONIS ROKAS. (2011) Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogen Aspergillus fumigatus. Molecular Ecologyno-no
CrossRef36
A. Safdar, D. Armstrong. (2011) Infections in Patients With Hematologic Neoplasms and Hematopoietic Stem Cell Transplantation: Neutropenia, Humoral, and Splenic Defects. Clinical Infectious Diseases 53:8, 798-806
CrossRef37
2011. Antifungal Agents and Therapy. , 75-106.
CrossRef38
2011. Aspergillosis. , 357-396.
CrossRef39
F. Jacobs, D. Selleslag, M. Aoun, A. Sonet, A. Gadisseur. (2011) An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole. European Journal of Clinical Microbiology & Infectious Diseases
CrossRef40
L. Gury-Paquet, J. Vicente, B. Delannoy, A.L. Bienvenu, Y. Berthezène. (2011) Aspergillose invasive disséminée. Réponse du e-quid de juillet–août. Journal de Radiologie 92:10, 945-950
CrossRef41
Lina Yang, Xiaoguang Dong, Xianggen Wu, Lixin Xie, Xiaojie Min. (2011) INTRAVITREALLY IMPLANTABLE VORICONAZOLE DELIVERY SYSTEM FOR EXPERIMENTAL FUNGAL ENDOPHTHALMITIS. Retina 31:9, 1791-1800
CrossRef42
F. Saghrouni, Y. Ben Youssef, S. Gheith, Z. Bouabid, J. Ben Abdeljelil, I. Khammari, A. Fathallah, A. Khlif, M. Ben Saïd. (2011) Twenty-nine cases of invasive aspergillosis in neutropenic patients. Médecine et Maladies Infectieuses
CrossRef43
C. Girmenia, P. Guerrisi, A. M. Frustaci, A. Fama, E. Finolezzi, S. Perrone, G. Gentile, F. Collerone, S. Brocchieri, V. Guerrisi. (2011) New category of probable invasive pulmonary aspergillosis in haematological patients. Clinical Microbiology and Infectionno-no
CrossRef44
Gaston Burghi, Virginie Lemiale, Amélie Seguin, Jérôme Lambert, Claire Lacroix, Emmanuel Canet, Anne-Sophie Moreau, Patricia Ribaud, David Schnell, Eric Mariotte, Benoît Schlemmer, Elie Azoulay. (2011) Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis. Intensive Care Medicine 37:10, 1605-1612
CrossRef45
I. Rossouw, D. Goedhals, J. van der Merwe, V. Stallenberg, N. Govender. (2011) A rare, fatal case of invasive spinal aspergillosis in an antiretroviral-naive, HIV-infected man with pre-existing lung colonization. Journal of Medical Microbiology 60:10, 1534-1538
CrossRef46
S. A. Nouer, M. Nucci, N. S. Kumar, M. Grazziutti, B. Barlogie, E. Anaissie. (2011) Earlier Response Assessment in Invasive Aspergillosis Based on the Kinetics of Serum Aspergillus Galactomannan: Proposal for a New Definition. Clinical Infectious Diseases 53:7, 671-676
CrossRef47
J. J. Castón, M. J. Linares, A. Rivero, M. Casal, J. Torre-Cisneros. (2011) Clinical differences between invasive pulmonary infection by Scedosporium apiospermum and invasive pulmonary aspergillosis. Mycoses 54:5, e468-e473
CrossRef48
E. Gaïes, N. Jebabli, I. Salouage, S. Trabelsi, R. Charfi, M. Lakhal, A. Klouz. (2011) Hallucinations auditives induites par le voriconazole : illustration par le monitorage plasmatique. Journal de Mycologie Médicale / Journal of Medical Mycology 21:3, 214-216
CrossRef49
Joerg Steinmann, Joerg Huelsewede, Jan Buer, Peter-Michael Rath. (2011) Comparison and evaluation of a novel bioassay and high-performance liquid chromatography for the clinical measurement of serum voriconazole concentrations. Mycoses 54:5, e421-e428
CrossRef50
B. J. Kullberg, P. E. Verweij, M. Akova, M. C. Arendrup, J. Bille, T. Calandra, M. Cuenca-Estrella, R. Herbrecht, F. Jacobs, M. Kalin, C. C. Kibbler, O. Lortholary, P. Martino, J. F. Meis, P. Muñoz, F. C. Odds, B. E. De Pauw, J. H. Rex, E. Roilides, T. R. Rogers, M. Ruhnke, A. J. Ullmann, Ö. Uzun, K. Vandewoude, J.-L. Vincent, J. P. Donnelly. (2011) European expert opinion on the management of invasive candidiasis in adults. Clinical Microbiology and Infection 17, 1-12
CrossRef51
DH Dockrell, R Breen, M Lipman, RF Miller. (2011) 3 Pulmonary opportunistic infections. HIV Medicine 12, 25-42
CrossRef52
M. J. G. T. Rüping, J. J. Vehreschild, A. Groll, C. Lass-Flörl, H. Ostermann, M. Ruhnke, O. A. Cornely. (2011) Current issues in the clinical management of invasive aspergillosis - the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009. Mycoses 54:5, e557-e568
CrossRef53
A. Glöckner, M. Karthaus. (2011) Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients. Mycoses 54:5, 420-433
CrossRef54
A. Glöckner. (2011) Innovative Antimykotika zur Therapie invasiver Pilzinfektionen. Der Internist 52:9, 1118-1126
CrossRef55
R. Bellmann, S. Weiler. (2011) Treatment of invasive fungal infections. memo - Magazine of European Medical Oncology 4:3, 169-173
CrossRef56
Aryun Kim, David P. Nicolau, Joseph L. Kuti. (2011) Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses 54:5, e301-e312
CrossRef57
Peter G Pappas. (2011) The role of azoles in the treatment of invasive mycoses: review of the Infectious Diseases Society of America guidelines. Current Opinion in Infectious Diseases 24, S1-S13
CrossRef58
Victor E. Mulanovich, Dimitrios P. Kontoyiannis. (2011) Fungal pneumonia in patients with hematologic malignancies. Current Opinion in Infectious Diseases 24:4, 323-332
CrossRef59
Elizabeth Dodds Ashley. (2011) Pharmacoeconomics of antifungal therapy: current considerations. Current Opinion in Infectious Diseases 24, S30-S40
CrossRef60
Jorge Vila Arteaga, Mayerling Mercedes Suriano, Oana Stirbu. (2011) Intravitreal voriconazole for the treatment of Aspergillus chorioretinitis. International Ophthalmology 31:4, 341-344
CrossRef61
Rishi H. Dhillon, John Clark. (2011) Fungal infections in the critically ill. Trends in Anaesthesia and Critical Care 1:4, 210-218
CrossRef62
John R Perfect. (2011) Azoles: back to the future. Current Opinion in Infectious Diseases 24, S41-S58
CrossRef63
R. E. Lewis. (2011) Current Concepts in Antifungal Pharmacology. Mayo Clinic Proceedings 86:8, 805-817
CrossRef64
Christina T. Rieger, Saskia Huppmann, Lisa Peterson, Heidi Rieger, Helmut Ostermann. (2011) Classification of invasive fungal disease in patients with acute myeloid leukaemia. Mycoses 54:4, e92-e98
CrossRef65
Tami Wisniewski, Nikolay Klimko, Michel Laverdiere, Sasisopin Kiertiburanakul, Galina Kliasova, Rudolf Trenschel, Ritesh N. Kumar. (2011) Retrospective evaluation of caspofungin therapy in invasive aspergillosis (RECAM-IA). Mycoses 54:4, e148-e153
CrossRef66
Yong-Li Pan, Nan-Haw Chow, Tsung Chain Chang, Hsien-Chang Chang. (2011) Identification of lethal Aspergillus at early growth stages based on matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Diagnostic Microbiology and Infectious Disease 70:3, 344-354
CrossRef67
Michael A. Pfaller, David Andes, Maiken C. Arendrup, Daniel J. Diekema, Ana Espinel-Ingroff, Barbara D. Alexander, Steven D. Brown, Vishnu Chaturvedi, Cynthia L. Fowler, Mahmoud A. Ghannoum, Elizabeth M. Johnson, Cynthia C. Knapp, Mary R. Motyl, Luis Ostrosky-Zeichner, Thomas J. Walsh. (2011) Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagnostic Microbiology and Infectious Disease 70:3, 330-343
CrossRef68
R. Lecointre, N. Bleyzac. (2011) Infection fongique invasive en oncologie et hématologie pédiatrique : analyse de la littérature et étude médicoéconomique des coûts de prise en charge. Annales Pharmaceutiques Françaises 69:4, 214-220
CrossRef69
L. Hasseine, P.M. Roger, S. Novellas, F. De Salvador, C. Dunyach, S. Bertout, M. Gari-Toussaint. (2011) Invasive periodic multivisceral aspergillosis in HIV-infected patient with normal CD4+ cell count. Journal de Mycologie Médicale / Journal of Medical Mycology 21:2, 146-151
CrossRef70
Chao-Lan Hsu, Cheng-Wei Chen, Hua-Kung Wang. (2011) Iatrogenic invasive otomycosis. Tzu Chi Medical Journal 23:2, 66-68
CrossRef71
Thomas R. Rogers, Monica A. Slavin, J. Peter Donnelly. (2011) Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?. British Journal of Haematology 153:6, 681-697
CrossRef72
Jesús Fortún, Jordi Carratalá, Joan Gavaldá, Manuel Lizasoain, Miguel Salavert, Rafael de la Cámara, Marcio Borges, Carlos Cervera, José Garnacho, Álvaro Lassaleta, Carlos Lumbreras, Miguel Ángel Sanz, José T. Ramos, Julián Torre-Cisneros, José M. Aguado, Manuel Cuenca-Estrella. (2011) Recomendaciones sobre el tratamiento de la enfermedad fúngica invasiva por Aspergillus spp. y otros hongos filamentosos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011. Enfermedades Infecciosas y Microbiología Clínica 29:6, 435-454
CrossRef73
David H. Dockrell, Simon Edwards, Martin Fisher, Ian Williams, Mark Nelson. (2011) Evolving controversies and challenges in the management of opportunistic infections in HIV-seropositive individuals. Journal of Infection
CrossRef74
S. Schwartz, A. Reisman, P. F. Troke. (2011) The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection 39:3, 201-210
CrossRef75
Aspasia Katragkou, Emmanuel Roilides. (2011) Best practice in treating infants and children with proven, probable or suspected invasive fungal infections. Current Opinion in Infectious Diseases 24:3, 225-229
CrossRef76
Karl V. Clemons, Julie A. Schwartz, David A. Stevens. (2011) Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. Medical Mycology1-14
CrossRef77
J Maertens, O Marchetti, R Herbrecht, O A Cornely, U Flückiger, P Frêre, B Gachot, W J Heinz, C Lass-Flörl, P Ribaud, A Thiebaut, C Cordonnier. (2011) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 Update. Bone Marrow Transplantation 46:5, 709-718
CrossRef78
W. Wang, C. Y. Zhao, J. Y. Zhou, Y. D. Wang, C. Shen, D. F. Zhou, H. Z. Yin. (2011) Invasive pulmonary aspergillosis in patients with HBV-related liver failure. European Journal of Clinical Microbiology & Infectious Diseases 30:5, 661-667
CrossRef79
A. Alanio, J.-L. Beretti, B. Dauphin, E. Mellado, G. Quesne, C. Lacroix, A. Amara, P. Berche, X. Nassif, M.-E. Bougnoux. (2011) Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for fast and accurate identification of clinically relevant Aspergillus species. Clinical Microbiology and Infection 17:5, 750-755
CrossRef80
Deniz Yilmaz, Can Balkan, Yilmaz Ay, Mehmet Akin, Bulent Karapinar, Kaan Kavakli. (2011) A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections. Mycoses 54:3, 234-242
CrossRef81
George Psevdos, Jose Fefer, Vishal Patel, Swati Srivastava, Victoria Sharp. (2011) Aspergillus Fumigatus Otomastoiditis and Skull Base Osteomyelitis in a Patient With Advanced Acquired Immunodeficiency Syndrome. Infectious Diseases in Clinical Practice 19:3, 218-220
CrossRef82
Maria J. G. T. Rüping, Carsten Müller, Jörg J. Vehreschild, Angelika Böhme, Sabine Mousset, Urs Harnischmacher, Peter Frommolt, Gernot Wassmer, Ivonne Drzisga, Michael Hallek, Oliver A. Cornely. (2011) Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients. Mycoses 54:3, 230-233
CrossRef83
Louis Yi-Ann Chai, Li-Yang Hsu. (2011) Recent advances in invasive pulmonary aspergillosis. Current Opinion in Pulmonary Medicine 17:3, 160-166
CrossRef84
S. P. Georgiadou, N. V. Sipsas, E. M. Marom, D. P. Kontoyiannis. (2011) The Diagnostic Value of Halo and Reversed Halo Signs for Invasive Mold Infections in Compromised Hosts. Clinical Infectious Diseases 52:9, 1144-1155
CrossRef85
Agata Mikolajewska, Stefan Schwartz, Markus Ruhnke. (2011) Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy. Mycosesno-no
CrossRef86
Wu Xiang-Gen, Yang Li-Na, Xin Meng, Jiang Hao-Ran. (2011) Anti-infectious activity of intravitreal injectable voriconazole microspheres on experimental rabbit fungal endophthalmitis caused by aspergillus fumigatus. Journal of Pharmaceutical Sciences 100:5, 1745-1759
CrossRef87
Joseph Pidala, Claudio Anasetti. 2011. Advances in Allogeneic Hematopoietic Cell Transplantation: Progress in Transplantation Technology and Disease-Specific Outcomes. , 367-383.
CrossRef88
B. des Champs-Bro, A. Leroy-Cotteau, F. Mazingue, F. Pasquier, N. François, S. Corm, L. Lemaitre, D. Poulain, I. Yakoub-Agha, S. Alfandari, B. Sendid. (2011) Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology. Journal of Clinical Pharmacy and Therapeutics 36:2, 152-160
CrossRef89
K. Kerl, B. Koch, W. Fegeler, C. Rossig, K. Ehlert, A.H. Groll. (2011) Catheter-associated aspergillosis of the chest wall following allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease 13:2, 182-185
CrossRef90
William J. Steinbach, Praveen R. Juvvadi, Jarrod R. Fortwendel, Luise E. Rogg. (2011) Newer combination antifungal therapies for invasive aspergillosis. Medical Mycology 49:S1, S77-S81
CrossRef91
John W. Baddley. (2011) Clinical risk factors for invasive aspergillosis. Medical Mycology 49:S1, S7-S12
CrossRef92
E. Kazan, J. Maertens, R. Herbrecht, M. Weisser, B. Gachot, A. Vekhoff, D. Caillot, E. Raffoux, T. Fagot, O. Reman, F. Isnard, A. Thiebaut, S. Bretagne, C. Cordonnier. (2011) A retrospective series of gut aspergillosis in haematology patients. Clinical Microbiology and Infection 17:4, 588-594
CrossRef93
Jenna J Ferrara, Conan MacDougall, Jason C Gallagher. (2011) Empiric Antifungal Therapy in Patients with Febrile Neutropenia. Pharmacotherapy 31:4, 369-385
CrossRef94
Melanie W. Pound, Mary L. Townsend, Vincent Dimondi, Dustin Wilson, Richard H. Drew. (2011) Overview of treatment options for invasive fungal infections. Medical Mycology1-20
CrossRef95
Isabel Ruiz-Camps. (2011) Tratamiento combinado de la aspergilosis invasora. ¿Una oportunidad para micafungina?. Enfermedades Infecciosas y Microbiología Clínica 29, 38-42
CrossRef96
Nuran Salman, Selda H Törün, Bahar Budan, Ayper Somer. (2011) Invasive aspergillosis in hematopoietic stem cell and solid organ transplantation. Expert Review of Anti-infective Therapy 9:3, 307-315
CrossRef97
Eveline Snelders, Willem JG Melchers, Paul E Verweij. (2011) Azole resistance in Aspergillus fumigatus : a new challenge in the management of invasive aspergillosis?. Future Microbiology 6:3, 335-347
CrossRef98
Maud Berge, Romain Guillemain, David A. Trégouet, Catherine Amrein, Veronique Boussaud, Patrick Chevalier, Agnes Lillo-Lelouet, Christine Beller, Pierre Laurent-Puig, Philippe H. Beaune, Eliane M. Billaud, Marie-Anne Loriot. (2011) Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. European Journal of Clinical Pharmacology 67:3, 253-260
CrossRef99
Nadine Kawel, Georg M. Schorer, Lotus Desbiolles, Burkhardt Seifert, Borut Marincek, Thomas Boehm. (2011) Discrimination between invasive pulmonary aspergillosis and pulmonary lymphoma using CT. European Journal of Radiology 77:3, 417-425
CrossRef100
P. Chandrasekar. (2011) Management of invasive fungal infections: a role for polyenes. Journal of Antimicrobial Chemotherapy 66:3, 457-465
CrossRef101
Georg Maschmeyer. (2011) Invasive fungal disease: better survival through early diagnosis and therapeutic intervention. Expert Review of Anti-infective Therapy 9:3, 279-281
CrossRef102
Necdet Kuyucu. (2011) Amphotericin B use in children: conventional and lipid-based formulations. Expert Review of Anti-infective Therapy 9:3, 357-367
CrossRef103
Jutta Auberger, Cornelia Lass-Flörl. (2011) Current evidence for the treatment of invasive fungal infections in immunocompromised patients. Clinical Investigation 1:3, 447-457
CrossRef104
Andreas H. Groll. (2011) Efficacy and safety of antifungals in pediatric patients. Early Human Development 87, S71-S74
CrossRef105
Yvonne Kline, Karl V. Clemons, Leslie Woods, David A. Stevens, Lisa A. Tell. (2011) Pharmacokinetics of voriconazole in adult mallard ducks ( Anas platyrhynchos ). Medical Mycology1-13
CrossRef106
A. G. Freifeld, E. J. Bow, K. A. Sepkowitz, M. J. Boeckh, J. I. Ito, C. A. Mullen, I. I. Raad, K. V. Rolston, J.-A. H. Young, J. R. Wingard. (2011) Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 52:4, e56-e93
CrossRef107
A. G. Freifeld, E. J. Bow, K. A. Sepkowitz, M. J. Boeckh, J. I. Ito, C. A. Mullen, I. I. Raad, K. V. Rolston, J.-A. H. Young, J. R. Wingard. (2011) Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases 52:4, 427-431
CrossRef108
C Orla Morrissey, Sharon C.-A. Chen, Tania C. Sorrell, Kenneth F. Bradstock, Jeffrey Szer, Catriona L. Halliday, Nicole M. Gilroy, Anthony P. Schwarer, Monica A. Slavin. (2011) Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. Leukemia & Lymphoma 52:2, 179-193
CrossRef109
Werner J. Heinz, Gerda Silling, Angelika Böhme. (2011) Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice. Current Medical Research and Opinion 27:2, 335-342
CrossRef110
Anna K. Person, Dimitrios P. Kontoyiannis, Barbara D. Alexander. (2011) Fungal Infections in Transplant and Oncology Patients. Hematology/Oncology Clinics of North America 25:1, 193-213
CrossRef111
Patricia Muñoz, Loreto Rojas, Carlos Cervera, Gregorio Garrido, Maria Carmen Fariñas, Maricela Valerio, Maddalena Giannella, Emilio Bouza, . (2011) Poor compliance with antifungal drug use guidelines by transplant physicians: a framework for educational guidelines and an international consensus on patient safety. Clinical Transplantationno-no
CrossRef112
J. Maertens, A. H. Groll, C. Cordonnier, R. de la Camara, E. Roilides, O. Marchetti. (2011) Treatment and timing in invasive mould disease. Journal of Antimicrobial Chemotherapy 66:Supplement 1, i37-i43
CrossRef113
Meinolf Karthaus, Marcus Hentrich. (2011) Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis. Mycoses 54, 1-6
CrossRef114
Julien Beauté, Gaëlle Obenga, Loïc Le Mignot, Nizar Mahlaoui, Marie-Elisabeth Bougnoux, Richard Mouy, Marie-Anne Gougerot-Pocidalo, Vincent Barlogis, Felipe Suarez, Fanny Lanternier, Olivier Hermine, Marc Lecuit, Stéphane Blanche, Alain Fischer, Olivier Lortholary. (2011) Epidemiology and Outcome of Invasive Fungal Diseases in Patients With Chronic Granulomatous Disease. The Pediatric Infectious Disease Journal 30:1, 57-62
CrossRef115
Yvonne A. Maldonado. 2011. Pneumocystis and Other Less Common Fungal Infections. , 1078-1123.
CrossRef116
Chien-Chang Yang, Po-Chang Hsu, Chun-Wen Cheng, Ming-Hsun Lee. (2011) Coexistence of Fatal Disseminated Invasive Aspergillosis and Pyoderma Gangrenosum: A Case Report. Medical Principles and Practice 20:4, 380-383
CrossRef117
Seung-Heon Shin. (2011) Clinical Characteristics and Treatment of Fungal Rhinosinusitis. Korean Journal of Otorhinolaryngology-Head and Neck Surgery 54:7, 454
CrossRef118
Minoru Yoshida, Nobu Akiyama, Hiroyuki Fujita, Katsuhiro Miura, Jun-ichi Miyatake, Hiroshi Handa, Katsuyuki Kito, Masatomo Takahashi, Kazuyuki Shigeno, Yoshinobu Kanda, Naoko Hatsumi, Shigeki Ohtake, Hisashi Sakamaki, Kazunori Ohnishi, Shuichi Miyawaki, Ryuzo Ohno, Tomoki Naoe. (2011) Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group. International Journal of Hematology 93:1, 66-73
CrossRef119
B. E. de Pauw, C. Viscoli. (2011) Managing invasive fungal infections: relying on clinical instincts or on a rational navigation system?. Journal of Antimicrobial Chemotherapy 66:Supplement 1, i55-i58
CrossRef120
Elie Azoulay, Marcio Soares, Michael Darmon, Dominique Benoit, Stephen Pastores, Bekele Afessa. (2011) Intensive care of the cancer patient: recent achievements and remaining challenges. Annals of Intensive Care 1:1, 5
CrossRef121
Gloria N. Mattiuzzi, Jorge Cortes, Gladys Alvarado, Srdan Verstovsek, Charles Koller, Sherry Pierce, Deborah Blamble, Stefan Faderl, Lianchun Xiao, Mike Hernandez, Hagop Kantarjian. (2011) Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Supportive Care in Cancer 19:1, 19-26
CrossRef122
A. Studemeister, D. A. Stevens. (2011) Aspergillus Vertebral Osteomyelitis in Immunocompetent Hosts: Role of Triazole Antifungal Therapy. Clinical Infectious Diseases 52:1, e1-e6
CrossRef123
Friederike Traunmüller, Martin Popovic, Karl-Heinz Konz, Freyja-Maria Smolle-Jüttner, Christian Joukhadar. (2011) Efficacy and Safety of Current Drug Therapies for Invasive Aspergillosis. Pharmacology 88:3-4, 213-224
CrossRef124
N. Freemantle, P. Tharmanathan, R. Herbrecht. (2011) Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. Journal of Antimicrobial Chemotherapy 66:Supplement 1, i25-i35
CrossRef125
Takeshi Ikuno, Sakae Enomoto, Kenji Yamamoto, Taizo Sakamoto. (2011) Aspergillus Pseudoaneurysm and Endocarditis of the Aortic Valve after Coronary Artery Bypass Graft Surgery. Japanese Journal of Cardiovascular Surgery 40:3, 120-124
CrossRef126
Shigefumi Maesaki. (2011) Aspergillosis. Nippon Ishinkin Gakkai Zasshi 52:2, 97-105
CrossRef127
Naoki Sawai, Futoshi Watanabe, Masahiro Komori. (2011) A Case of Sphenoid Sinus Aspergillosis Accompanied by Multiple Brain Abscesses. Practica Oto-Rhino-Laryngologica 104:5, 335-339
CrossRef128
Min-Ju Kim, Moon-Hee Youn, Sang-Bae Kim, Yul Hee Cho, Min-Young Lee, Sung-Yeon Cho, Jae-Cheol Kwon, Si-Hyun Kim, Yoo-Jin Kim, Dong-Gun Lee. (2011) A Case of Visual and Auditory Hallucinations during Intravenous Voriconazole Therapy. Infection and Chemotherapy 43:5, 421
CrossRef129
M Sandherr, G Maschmeyer. (2011) Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature. European Journal of Medical Research 16:4, 139
CrossRef130
M Karthaus. (2011) Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature. European Journal of Medical Research 16:4, 145
CrossRef131
A Mayr, C Lass-Flörl. (2011) Epidemiology and antifungal resistance in invasive aspergillosis according to primary disease - review of the literature. European Journal of Medical Research 16:4, 153
CrossRef132
S. Perkhofer, C. Lass-Flörl, M. Hell, G. Russ, R. Krause, M. Hönigl, C. Geltner, J. Auberger, G. Gastl, M. Mitterbauer, B. Willinger, P. Knöbl, G. Resch, R. Waldner, A. Makrai, G. Hartmann, M. Girschikofsky, R. Greil. (2010) The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. International Journal of Antimicrobial Agents 36:6, 531-536
CrossRef133
Alexander W. Schüttelkopf, Ludovic Gros, David E. Blair, Julie A. Frearson, Daan M.F. van Aalten, Ian H. Gilbert. (2010) Acetazolamide-based fungal chitinase inhibitors. Bioorganic & Medicinal Chemistry 18:23, 8334-8340
CrossRef134
Daoud Al-Badriyeh, Siow Chin Heng, Chin Fen Neoh, Monica Slavin, Kay Stewart, David CM Kong. (2010) Pharmacoeconomics of voriconazole in the management of invasive fungal infections. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, 623-636
CrossRef135
Alan M. Laties, Frederick T. Fraunfelder, Konrad Tomaszewski, James Goodrich, Ana Tereza Moreira, Mario T. Sato, Flâvio de Queiroz-Telles. (2010) Long-term visual safety of voriconazole in adult patients with paracoccidioidomycosis. Clinical Therapeutics 32:13, 2207-2217
CrossRef136
Ameeta S. Kalokhe, Nadine Rouphael, Mikhael F. El Chami, Kimberly A. Workowski, Geeta Ganesh, Jesse T. Jacob. (2010) Aspergillus endocarditis: a review of the literature. International Journal of Infectious Diseases 14:12, e1040-e1047
CrossRef137
Christopher C Blyth, Katherine Hale, Pamela Palasanthiran, Tracey O'Brien, Michael H Bennett. (2010) Cochrane review: Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Evidence-Based Child Health: A Cochrane Review Journal 5:4, 1916-1998
CrossRef138
Brandon J. Webb, Holenarasipur R. Vikram. (2010) Chronic Invasive Sinus Aspergillosis in Immunocompetent Hosts: A Geographic Comparison. Mycopathologia 170:6, 403-410
CrossRef139
Wenke Liu, Haifeng Chen, Bowen Cai, Guoping Li, Chao You, Hao Li. (2010) Successful treatment of sellar aspergillus abscess. Journal of Clinical Neuroscience 17:12, 1587-1589
CrossRef140
Nikolaos G Almyroudis, Brahm H Segal. (2010) Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients. Expert Review of Anti-infective Therapy 8:12, 1451-1466
CrossRef141
E. Mokaddas, M. H. A. Burhamah, S. Ahmad, Z. U. Khan. (2010) Invasive pulmonary aspergillosis due to Aspergillus terreus: value of DNA, galactomannan and (1->3)- -D-glucan detection in serum samples as an adjunct to diagnosis. Journal of Medical Microbiology 59:12, 1519-1523
CrossRef142
Florence Ader. (2010) Invasive Pulmonary Aspergillosis in Patients with Chronic Obstructive Pulmonary Disease: An Emerging Fungal Disease. Current Infectious Disease Reports 12:6, 409-416
CrossRef143
Srinivasan Senthilkumari, Prajna Lalitha, Namperumalsamy Venkatesh Prajna, Aravind Haripriya, Jeyabalan Nirmal, Pankaj Gupta, Thirumurthy Velpandian. (2010) Single and Multidose Ocular Kinetics and Stability Analysis of Extemporaneous Formulation of Topical Voriconazole in Humans. Current Eye Research 35:11, 953-960
CrossRef144
Hui-Yan Shi, Jin Yan, Wen-Hui Zhu, Guo-Ping Yang, Zhi-Rong Tan, Wei-Hua Wu, Gan Zhou, Xiao-Ping Chen, Dong-Sheng Ouyang. (2010) Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. European Journal of Clinical Pharmacology 66:11, 1131-1136
CrossRef145
J. W. Hiemenz, I. I. Raad, J. A. Maertens, R. Y. Hachem, A. J. Saah, C. A. Sable, J. A. Chodakewitz, M. E. Severino, P. Saddier, R. S. Berman, D. M. Ryan, M. J. DiNubile, T. F. Patterson, D. W. Denning, T. J. Walsh. (2010) Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. European Journal of Clinical Microbiology & Infectious Diseases 29:11, 1387-1394
CrossRef146
Spiros Miyakis, Sebastiaan J van Hal, Carl Jacob S Solvag, John Ray, Deborah Marriott. (2010) Clinician Ordering Practices for Voriconazole Therapeutic Drug Monitoring: Experiences of a Referral Laboratory. Therapeutic Drug Monitoring 32:5, 661-664
CrossRef147
William J. Steinbach. (2010) Pediatric Invasive Aspergillosis. The Pediatric Infectious Disease Journal 29:10, 964-965
CrossRef148
Hana Hakim, Jerry L Shenep. (2010) Managing fungal and viral infections in pediatric leukemia. Expert Review of Hematology 3:5, 603-624
CrossRef149
L. Pagano, M. Caira, M. Offidani, B. Martino, A. Candoni, C. G. Valentini, G. Specchia, A. Nosari, M. E. Tosti, G. Leone, M. Luppi, F. Aversa. (2010) Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: feasibility and utility (SEIFEM-2008B study). Journal of Antimicrobial Chemotherapy 65:9, 2013-2018
CrossRef150
Fedja Farowski, Jörg J Vehreschild, Oliver A Cornely, Maria JGT Vehreschild. (2010) Micafungin in a nutshell: state of affairs on the pharmacological and clinical aspects of the novel echinocandin. Therapy 7:5, 555-563
CrossRef151
W. J. Steinbach. (2010) Epidemiology of invasive fungal infections in neonates and children. Clinical Microbiology and Infection 16:9, 1321-1327
CrossRef152
Yosr Hicheri, Andréa Toma, Sébastien Maury, Cécile Pautas, Hassina Mallek-Kaci, Catherine Cordonnier. (2010) Updated guidelines for managing fungal diseases in hematology patients. Expert Review of Anti-infective Therapy 8:9, 1049-1060
CrossRef153
Anthony J. Ricketti, Dennis J. Cleri, Mehul Desai, John R. Vernaleo, David W. Unkle, Peter A. Ricketti. (2010) Right Upper Lobe Nodules in a Patient With Emphysema. Infectious Diseases in Clinical Practice 18:5, 325-328
CrossRef154
Peter G. Pappas. (2010) Opportunistic Fungi: A View to the Future. The American Journal of the Medical Sciences 340:3, 253-257
CrossRef155
Ghassan S. Skaf, Zeina A. Kanafani, George F. Araj, Souha S. Kanj. (2010) Non-pyogenic infections of the spine. International Journal of Antimicrobial Agents 36:2, 99-105
CrossRef156
A. K. Person, S. M. Chudgar, B. L. Norton, B. C. Tong, J. E. Stout. (2010) Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis. Journal of Medical Microbiology 59:7, 834-838
CrossRef157
Patrizia Zappasodi, Marianna Rossi, Carlo Castagnola, Fabio Pagella, Elina Matti, Caterina Cavanna, Alessandro Corso, Maurizio Bonfichi, Mario Lazzarino. (2010) Resolution of invasive fungal sinusitis in immunocompromised patients: neutrophil count is crucial beside a combined medical and surgical approach. Annals of Hematology 89:7, 737-739
CrossRef158
R Herbrecht, J Maertens, L Baila, M Aoun, W Heinz, R Martino, S Schwartz, A J Ullmann, L Meert, M Paesmans, O Marchetti, H Akan, L Ameye, M Shivaprakash, C Viscoli. (2010) Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplantation 45:7, 1227-1233
CrossRef159
S S Egger, S Meier, C Leu, S Christen, A Gratwohl, S Krähenbühl, M Haschke. (2010) Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplantation 45:7, 1197-1203
CrossRef160
Matthew Pellan Cheng, Katryn Paquette, Larry C. Lands, Philippe Ovetchkine, Yves Théoret, Caroline Quach. (2010) Voriconazole inhibition of vitamin A metabolism: Are adverse events increased in cystic fibrosis patients?. Pediatric Pulmonology 45:7, 661-666
CrossRef161
Mark L. Warwas, Juliana H. F. Yeung, Deepani Indurugalla, Arne Ø. Mooers, Andrew J. Bennet, Margo M. Moore. (2010) Cloning and characterization of a sialidase from the filamentous fungus, Aspergillus fumigatus. Glycoconjugate Journal 27:5, 533-548
CrossRef162
J. J. Vehreschild, M. J. G. T. Ruping, H. Wisplinghoff, F. Farowski, A. Steinbach, R. Sims, A. Stollorz, K.- A. Kreuzer, M. Hallek, C. Bangard, O. A. Cornely. (2010) Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. Journal of Antimicrobial Chemotherapy 65:7, 1466-1471
CrossRef163
William J. Steinbach. (2010) Invasive aspergillosis in pediatric patients. Current Medical Research and Opinion 26:7, 1779-1787
CrossRef164
M. Winkler, J. Pratschke, U. Schulz, S. Zheng, M. Zhang, W. Li, M. Lu, D. Sgarabotto, G. Sganga, P. Kaskel, S. Chandwani, L. Ma, J. Petrovic, M. Shivaprakash. (2010) Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study. Transplant Infectious Disease 12:3, 230-237
CrossRef165
Melissa D. Johnson, John R. Perfect. (2010) Use of Antifungal Combination Therapy: Agents, Order, and Timing. Current Fungal Infection Reports 4:2, 87-95
CrossRef166
Scarlett Geunes-Boyer, Joseph Heitman, Jo Rae Wright, William J. Steinbach. (2010) Surfactant protein D binding to Aspergillus fumigatus hyphae is calcineurin-sensitive. Medical Mycology 48:4, 580-588
CrossRef167
Young Kyung Yoon, Eun Hae Kang, Kwang Ho In, Min Ja Kim. (2010) Unilateral ureteral obstruction caused by Aspergillus , subgenus Nidulantes in a patient on steroid therapy: a case report and review of the literature. Medical Mycology 48:4, 647-652
CrossRef168
Jason M. Cota, David S. Burgess. (2010) Antifungal Dose Adjustment in Renal and Hepatic Dysfunction: Pharmacokinetic and Pharmacodynamic Considerations. Current Fungal Infection Reports 4:2, 120-128
CrossRef169
Anna K. Person, Dimitrios P. Kontoyiannis, Barbara D. Alexander. (2010) Fungal Infections in Transplant and Oncology Patients. Infectious Disease Clinics of North America 24:2, 439-459
CrossRef170
Cornelia Lass-Flörl. (2010) In vitro susceptibility testing in Aspergillus species: an update. Future Microbiology 5:5, 789-799
CrossRef171
L. Jost, F. Roila, . (2010) Management of cancer pain: ESMO Clinical Practice Guidelines. Annals of Oncology 21:Supplement 5, v257-v260
CrossRef172
Oriana Hoi Yun Yu, Annick Wong Wong Keet, Donald C. Sheppard, Timothy Brewer. (2010) Articular aspergillosis: case report and review of the literature. International Journal of Infectious Diseases 14:5, e433-e435
CrossRef173
David W. Denning, William W. Hope. (2010) Therapy for fungal diseases: opportunities and priorities. Trends in Microbiology 18:5, 195-204
CrossRef174
Louis Y. A. Chai, Frank van de Veerdonk, Renoud J. Marijnissen, Shih-Chin Cheng, Ai Leng Khoo, Magda Hectors, Katrien Lagrou, Alieke G. Vonk, Johan Maertens, Leo A. B. Joosten, Bart-Jan Kullberg, Mihai G. Netea. (2010) Anti- Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology 130:1, 46-54
CrossRef175
Supha K. Arthurs, Albert J. Eid, Paul J. Deziel, William F. Marshall, Stephen D. Cassivi, Randall C. Walker, Raymund R. Razonable. (2010) The impact of invasive fungal diseases on survival after lung transplantation. Clinical Transplantation 24:3, 341-348
CrossRef176
J. de Naurois, I. Novitzky-Basso, M. J. Gill, F. M. Marti, M. H. Cullen, F. Roila, . (2010) Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Annals of Oncology 21:Supplement 5, v252-v256
CrossRef177
Yuki Asano-Mori. (2010) Fungal infections after hematopoietic stem cell transplantation. International Journal of Hematology 91:4, 576-587
CrossRef178
M. Karthaus. (2010) Leitliniengerechte Therapie der invasiven Aspergillose. Mycoses 53, 36-43
CrossRef179
Benjamin Thonar, Mark Yoder, Constance Cleaves. (2010) Not Your Typical Chronic Obstructive Pulmonary Disease Exacerbation: Aspergillus Tracheobronchitis in a Nonclassical Immunocompromised Host. Southern Medical Journal 103:4, 361-365
CrossRef180
David Sanchez-Migallon Guzman, Keven Flammer, Mark G. Papich, Amy M. Grooters, Shannon Shaw, Jeff Applegate, Thomas N. Tully. (2010) Pharmacokinetics of voriconazole after oral administration of single and multiple doses in Hispaniolan Amazon parrots ( Amazona ventralis ). American Journal of Veterinary Research 71:4, 460-467
CrossRef181
C. Hahn-Ast, A. Glasmacher, S. Muckter, A. Schmitz, A. Kraemer, G. Marklein, P. Brossart, M. von Lilienfeld-Toal. (2010) Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. Journal of Antimicrobial Chemotherapy 65:4, 761-768
CrossRef182
Peter G. Pappas. 2010. Principles of Antifungal Therapy. .
CrossRef183
Sanjay G. Revankar, John R. Graybill, Thomas F. Patterson. 2010. Antifungal Agents and Antifungal Susceptibility Testing. .
CrossRef184
Pranatharthi H. Chandrasekar. (2010) Prophylaxis Versus a Preemptive Approach for Invasive Aspergillosis. Current Fungal Infection Reports 4:1, 30-37
CrossRef185
Claudia Michael, Uta Bierbach, Katrin Frenzel, Thoralf Lange, Nadezda Basara, Dietger Niederwieser, Christine Mauz-Körholz, Rainer Preiss. (2010) Determination of Saliva Trough Levels for Monitoring Voriconazole Therapy in Immunocompromised Children and Adults. Therapeutic Drug Monitoring1
CrossRef186
Livio Pagano, Morena Caira, Caterina Giovanna Valentini, Brunella Posteraro, Luana Fianchi. (2010) Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Reviews 24:2, 51-61
CrossRef187
Jennifer Christoff, Jodi-Lynn Galaydick, Charulata Ramaprasad, David Pitrak, Kathleen M. Mullane. (2010) Current Diagnosis and Management of Mucormycoses. Current Fungal Infection Reports 4:1, 8-16
CrossRef188
Amar Safdar. (2010) Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation. Current Fungal Infection Reports 4:1, 1-7
CrossRef189
Lisa A. Tell, Karl V. Clemons, Yvonne Kline, Leslie Woods, Philip H. Kass, Marife Martinez, David A. Stevens. (2010) Efficacy of voriconazole in Japanese quail ( Coturnix japonica ) experimentally infected with Aspergillus fumigatus. Medical Mycology 48:2, 234-244
CrossRef190
Christopher C Blyth, Katherine Hale, Pamela Palasanthiran, Tracey O'Brien, Michael H Bennett, Christopher C Blyth. 2010. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. .
CrossRef191
Takaaki Okamoto, Katsuyoshi Koh, Junko Takita, Ayaka Furuya, Motohiro Kato, Kohmei Ida. (2010) Voriconazole-micafungin combination therapy for acute lymphoblastic leukemia. Pediatrics International 52:1, 137-141
CrossRef192
Michael A. Pfaller, Daniel J. Diekema. (2010) Epidemiology of Invasive Mycoses in North America. Critical Reviews in Microbiology 36:1, 1-53
CrossRef193
Peter A. Warn, Andrew Sharp, Graham Morrissey, David W. Denning. (2010) Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus. International Journal of Antimicrobial Agents 35:2, 146-151
CrossRef194
A. Thomas, V. Korb, R. Guillemain, T. Caruba, V. Boussaud, E. Billaud, P. Prognon, D. Begué, B. Sabatier. (2010) Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. Journal of Clinical Pharmacy and Therapeutics 35:1, 49-53
CrossRef195
Cornelia Lass-Flörl. (2010) Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. Expert Review of Anti-infective Therapy 8:2, 127-135
CrossRef196
A. S. Ibrahim, T. Gebremariam, S. W. French, J. E. Edwards, B. Spellberg. (2010) The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy 65:2, 289-292
CrossRef197
M. J. G. T. Ruping, W. J. Heinz, A. J. Kindo, V. Rickerts, C. Lass-Florl, C. Beisel, R. Herbrecht, Y. Roth, G. Silling, A. J. Ullmann, K. Borchert, G. Egerer, J. Maertens, G. Maschmeyer, A. Simon, M. Wattad, G. Fischer, J. J. Vehreschild, O. A. Cornely. (2010) Forty-one recent cases of invasive zygomycosis from a global clinical registry. Journal of Antimicrobial Chemotherapy 65:2, 296-302
CrossRef198
Haruko Shima, Masashi Miharu, Tomoo Osumi, Takao Takahashi, Hiroyuki Shimada. (2010) Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatric Blood & Cancern/a-n/a
CrossRef199
Anthony K. Leung. (2010) Two Drugs Better Than One? Combination Antifungal Therapy Revisited. Infectious Diseases in Clinical Practice 18:1, 1-2
CrossRef200
Jong Man Kim, Choon Hyuck David Kwon, Jae-Won Joh, Sanghyun Song, Milljae Shin, Sung Joo Kim, Seung Heui Hong, Bok Nyeo Kim, Suk-Koo Lee. (2010) Aspergillosis in Liver Transplant Recipients: A Single Center Experience. Journal of the Korean Surgical Society 79:4, 267
CrossRef201
Hyunsung Park, Mi Jung Lee, Yundeok Kim, Yoo Hong Min, Soo Jeong Kim, Dokyung Kim. (2010) Primary renal aspergillosis and renal stones in both kidneys associated with hematopoietic stem cell transplant. The Korean Journal of Hematology 45:4, 275
CrossRef202
Chan Woong Kim, Jae Seung Seo, Mi-Kyung Kim, Eun Ju Jun, Jae Chol Choi, Byoung Whui Choi. (2010) Secondary cutaneous aspergillosis disseminated from the lungs of a patient with asthma on 1 month steroid treatment. Diagnostic Microbiology and Infectious Disease 66:1, 104-107
CrossRef203
P. Eggimann, D. Pittet. (2010) Candidemia e candidosi generalizzata. EMC - Anestesia-Rianimazione 15:2, 1-24
CrossRef204
Sang Il Kim, Moon Won Kang. (2010) Current Usage and Prospect of New Antifungal agents in Korea. Infection and Chemotherapy 42:4, 209
CrossRef205
Edward W. Cowen, Josephine C. Nguyen, Daniel D. Miller, Diana McShane, Sarah T. Arron, Neil S. Prose, Maria L. Turner, Lindy P. Fox. (2010) Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. Journal of the American Academy of Dermatology 62:1, 31-37
CrossRef206
C. Lichtenstern, S. Swoboda, M. Hirschburger, E. Domann, T. Hoppe-Tichy, M. Winkler, C. Lass-Flörl, M.A. Weigand. (2010) Update: invasive Pilzinfektionen. Der Anaesthesist 59:1, 30-52
CrossRef207
Maria J. G. T. Rüping, Jörg J. Vehreschild, Oliver A. Cornely. (2010) Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome – still an open question?. Leukemia & Lymphoma 51:1, 20-26
CrossRef208
Eun Lee, Seak Hee Oh, Ji Won Kwon, Byoung Ju Kim, Jinho Yu, Chan Jeoung Park, Soo Jong Hong. (2010) A case report of chronic granulomatous disease presenting with aspergillus pneumonia in a 2-month old girl. Korean Journal of Pediatrics 53:6, 722
CrossRef209
M Aguilar-Guisado, I Espigado, E Cordero, M Noguer, R Parody, J Pachón, J M Cisneros. (2010) Empirical antifungal therapy in selected patients with persistent febrile neutropenia. Bone Marrow Transplantation 45:1, 159-164
CrossRef210
Raghukumar Thirumala, Madhusudanan Ramaswamy, Sanjay Chawla. (2010) Diagnosis and Management of Infectious Complications in Critically Ill Patients with Cancer. Critical Care Clinics 26:1, 59-91
CrossRef211
J.W.C. Alffenaar, A.M.A. Wessels, K. van Hateren, B. Greijdanus, J.G.W. Kosterink, D.R.A. Uges. (2010) Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. Journal of Chromatography B 878:1, 39-44
CrossRef212
Michael Cohen-Wolkowiez, Cassandra Moran, Daniel K Benjamin, Phillip B Smith. (2009) Pediatric antifungal agents. Current Opinion in Infectious Diseases 22:6, 553-558
CrossRef213
Maja Agnieszka Klaudel-Dreszler, Krzysztof Kalwak, Magdalena Kurenko-Deptuch, Beata Wolska-Kusnierz, Edyta Heropolitanska-Pliszka, Barbara Pietrucha, Bożena Mikoluc, Ewa Gorczyńska, Marek Ussowicz, Alicja Chybicka, Ewa Bernatowska. (2009) Treosulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC. International Journal of Hematology 90:5, 571-575
CrossRef214
Saro H. Armenian, Kevin A. Nash, Neena Kapoor, Janet L. Franklin, Paul S. Gaynon, Lawrence A. Ross, Jill A. Hoffman. (2009) Prospective Monitoring for Invasive Aspergillosis Using Galactomannan and Polymerase Chain Reaction in High Risk Pediatric Patients. Journal of Pediatric Hematology/Oncology 31:12, 920-926
CrossRef215
Dustin T. Wilson, Richard H. Drew, John R. Perfect. (2009) Antifungal Therapy for Invasive Fungal Diseases in Allogeneic Stem Cell Transplant Recipients: An Update. Mycopathologia 168:6, 313-327
CrossRef216
Paul E. Verweij, Susan J. Howard, Willem J.G. Melchers, David W. Denning. (2009) Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints. Drug Resistance Updates 12:6, 141-147
CrossRef217
N. Singh, S. Husain, . (2009) Invasive Aspergillosis in Solid Organ Transplant Recipients. American Journal of Transplantation 9, S180-S191
CrossRef218
Elpis Hatziagorou, Thomas J. Walsh, John N. Tsanakas, Emmanuel Roilides. (2009) Aspergillus and the paediatric lung. Paediatric Respiratory Reviews 10:4, 178-185
CrossRef219
Cornelia Lass-Flörl. (2009) Azole resistance in aspergillosis: The next threat?. Current Fungal Infection Reports 3:4, 236-242
CrossRef220
T. Saito, N. Shime, K. Itoh, N. Fujita, Y. Saito, M. Shinozaki, K. Shibuya, K. Makimura, S. Hashimoto. (2009) Disseminated Aspergillosis Following Resolution of Pneumocystis Pneumonia with Sustained Elevation of Beta-Glucan in an Intensive Care Unit: a Case Report. Infection 37:6, 547-550
CrossRef221
PH Chandrasekar, Mayur Ramesh. (2009) Challenges in the management of invasive aspergillosis in hematopoietic stem cell transplantation. Expert Review of Anti-infective Therapy 7:10, 1151-1153
CrossRef222
Patrick Chu, Shalal Sadullah. (2009) The current role of amphotericin B lipid complex in managing systemic fungal infections. Current Medical Research and Opinion 25:12, 3011-3020
CrossRef223
C. Viscoli, R. Herbrecht, H. Akan, L. Baila, A. Sonet, A. Gallamini, A. Giagounidis, O. Marchetti, R. Martino, L. Meert, M. Paesmans, L. Ameye, M. Shivaprakash, A. J. Ullmann, J. Maertens, . (2009) An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. Journal of Antimicrobial Chemotherapy 64:6, 1274-1281
CrossRef224
Jay Yeh, Casey Culbertson, Ann M. Petru. (2009) Purulent Pericardial Effusion in a 14-Year-Old Girl. The Pediatric Infectious Disease Journal 28:12, 1140, 1147-1148
CrossRef225
Aneesh K Mehta, Amelia A Langston. (2009) Use of posaconazole in the treatment of invasive fungal infections. Expert Review of Hematology 2:6, 619-630
CrossRef226
Jörg J. Vehreschild, Michal Sieniawski, Stefan Reuter, Dorothee Arenz, Dietmar Reichert, Johan Maertens, Angelika Böhme, Gerda Silling, Rodrigo Martino, Georg Maschmeyer, Maria J.G.T. Rüping, Andrew J. Ullmann, Oliver A. Cornely. (2009) Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. International Journal of Antimicrobial Agents 34:5, 446-450
CrossRef227
E Hardak, M Yigla, I Avivi, O Fruchter, H Sprecher, I Oren. (2009) Impact of PCR-based diagnosis of invasive pulmonary aspergillosis on clinical outcome. Bone Marrow Transplantation 44:9, 595-599
CrossRef228
Mariano Pennisi, Massimo Antonelli. (2009) Clinical Aspects of Invasive Candidiasis in Critically Ill Patients. Drugs 69:Supplement 1, 21-28
CrossRef229
Jeannina A. Smith. (2009) What is the role of therapeutic drug monitoring in antifungal therapy?. Current Infectious Disease Reports 11:6, 439-446
CrossRef230
Abdullah Ayçiçek, Zafer Çetinkaya, Halil Kiyici, Fethullah Kenar, Gülşah Aşik, Nuri Kiraz. (2009) The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus. European Archives of Oto-Rhino-Laryngology 266:11, 1703-1709
CrossRef231
Victoria K. Shanmugam, Cal Matsumoto, Edward Pien, Jessica Rosen, Princy Kumar, Sean Whelton, Virginia Steen. (2009) Voriconazole-Associated Myositis. JCR: Journal of Clinical Rheumatology 15:7, 350-353
CrossRef232
(2009) Brennpunkt Infektiologie. Wiener klinisches Magazin 12:5, 48-51
CrossRef233
F. Moosig, K. Dalhoff. (2009) Pulmonale infektiöse Komplikationen rheumatischer Erkrankungen. Zeitschrift für Rheumatologie 68:8, 658-664
CrossRef234
Ludwik K. Branski, Ahmed Al-Mousawi, Haidy Rivero, Marc G. Jeschke, Arthur P. Sanford, David N. Herndon. (2009) Emerging Infections in Burns. Surgical Infections 10:5, 389-397
CrossRef235
M. Hummel, B. Spiess, J. Roder, G. von Komorowski, M. Durken, K. Kentouche, H. J. Laws, H. Morz, R. Hehlmann, D. Buchheidt. (2009) Detection of Aspergillus DNA by a nested PCR assay is able to improve the diagnosis of invasive aspergillosis in paediatric patients. Journal of Medical Microbiology 58:10, 1291-1297
CrossRef236
S. Miyakis, S. J. van Hal, J. Ray, D. Marriott. (2009) Voriconazole concentrations and outcome of invasive fungal infections. Clinical Microbiology and Infection
CrossRef237
G. N. Pongas, R. E. Lewis, G. Samonis, D. P. Kontoyiannis. (2009) Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?. Clinical Microbiology and Infection 15, 93-97
CrossRef238
Pedro M. Rubio, Julián Sevilla, Marta González-Vicent, Alvaro Lassaletta, Manuel Cuenca-Estrella, Miguel A. Díaz, Susana Riesco, Luis Madero. (2009) Increasing Incidence of Invasive Aspergillosis in Pediatric Hematology Oncology Patients Over the Last Decade. Journal of Pediatric Hematology/Oncology 31:9, 642-646
CrossRef239
J. Cadena, D. J. Levine, L. F. Angel, P. R. Maxwell, R. Brady, J. F. Sanchez, J. E. Michalek, S. M. Levine, M. I. Restrepo. (2009) Antifungal Prophylaxis with Voriconazole or Itraconazole in Lung Transplant Recipients: Hepatotoxicity and Effectiveness. American Journal of Transplantation 9:9, 2085-2091
CrossRef240
Francesco G. Rosa, Pierpaolo Terragni, Daniela Pasero, Anna C. Trompeo, Rosario Urbino, Anna Barbui, Giovanni Di Perri, V. Marco Ranieri. (2009) Combination antifungal treatment of pseudomembranous tracheobronchial invasive aspergillosis: a case report. Intensive Care Medicine 35:9, 1641-1643
CrossRef241
Justin A. Tolman, Nicole A. Nelson, Stephanie Bosselmann, Jay I. Peters, Jacqueline J. Coalson, Nathan P. Wiederhold, Robert O. Williams. (2009) Dose tolerability of chronically inhaled voriconazole solution in rodents. International Journal of Pharmaceutics 379:1, 25-31
CrossRef242
H. Roze, M. Lafargue, O. Joannes-Boyau, H. Batoz, C. Dromer, D. Breilh, G. Janvier. (2009) Toxicokinetics of voriconazole during massive intentional poisoning. Journal of Antimicrobial Chemotherapy 64:3, 662-663
CrossRef243
M Mikulska, A M Raiola, B Bruno, E Furfaro, M T Van Lint, S Bregante, A Ibatici, V Del Bono, A Bacigalupo, C Viscoli. (2009) Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplantation 44:6, 361-370
CrossRef244
K. Dalhoff, D. Drömann. (2009) Aspergillusinfektionen. Der Pneumologe 6:5, 306-311
CrossRef245
T Mori, Y Aisa, J Kato, Y Nakamura, Y Ikeda, S Okamoto. (2009) Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation 44:6, 371-374
CrossRef246
Hiroyuki Fujita, Minoru Yoshida, Katsuhiro Miura, Tetsuaki Sano, Katsuyuki Kito, Masatomo Takahashi, Kazuyuki Shigeno, Yoshinobu Kanda, Nobu Akiyama, Naoko Hatsumi, Kazunori Ohnishi, Shuichi Miyawaki, Tomoki Naoe. (2009) Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group. International Journal of Hematology 90:2, 191-198
CrossRef247
Marya D. Zilberberg, Andrew F. Shorr. (2009) Fungal Infections in the ICU. Infectious Disease Clinics of North America 23:3, 625-642
CrossRef248
Rocio Parody, Rodrigo Martino, Ferran Sánchez, Maricel Subirá, Alberto Hidalgo, Jorge Sierra. (2009) Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. American Journal of Hematology 84:9, 571-578
CrossRef249
Georg Maschmeyer, Thomas Beinert, Dieter Buchheidt, Oliver A. Cornely, Hermann Einsele, Werner Heinz, Claus Peter Heussel, Christoph Kahl, Michael Kiehl, Joachim Lorenz, Herbert Hof, Gloria Mattiuzzi. (2009) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. European Journal of Cancer 45:14, 2462-2472
CrossRef250
M. Rosenhagen, R. Feldhues, J. Schmidt, T. Hoppe-Tichy, H. K. Geiss. (2009) A Risk Profile for Invasive Aspergillosis in Liver Transplant Recipients. Infection 37:4, 313-319
CrossRef251
Hans Jürgen Dornbusch, Paolo Manzoni, Emmanuel Roilides, Thomas J. Walsh, Andreas H. Groll. (2009) Invasive Fungal Infections in Children. The Pediatric Infectious Disease Journal 28:8, 734-737
CrossRef252
Werner Neubauer, Armin König, Richard Bolek, Rainer Trittler, Monika Engelhardt, Manfred Jung, Klaus Kümmerer. (2009) Determination of the antifungal agent posaconazole in human serum by HPLC with parallel column-switching technique. Journal of Chromatography B 877:24, 2493-2498
CrossRef253
Abdulkader Al-Rezqi, Michael Hawkes, John Doyle, Susan E. Richardson, Upton Allen. (2009) Invasive mold infections in iatrogenically immunocompromised children: An eight-yr review. Pediatric Transplantation 13:5, 545-552
CrossRef254
Nikolaos G Almyroudis, Brahm H Segal. (2009) Prevention and treatment of invasive fungal diseases in neutropenic patients. Current Opinion in Infectious Diseases 22:4, 385-393
CrossRef255
Isabel P Neuringer, Peadar Noone, Rebecca K Cicale, Ken Davis, Robert M Aris. (2009) Managing complications following lung transplantation. Expert Review of Respiratory Medicine 3:4, 403-423
CrossRef256
M. C. Arendrup, B. T. Fisher, T. E. Zaoutis. (2009) Invasive fungal infections in the paediatric and neonatal population: diagnostics and management issues. Clinical Microbiology and Infection 15:7, 613-624
CrossRef257
Andreas H. Groll, Athanasios Tragiannidis. (2009) Recent Advances in Antifungal Prevention and Treatment. Seminars in Hematology 46:3, 212-229
CrossRef258
Kyvan Q. Nguyen, Michelle G. Hawkins, Ian T. Taylor, Valerie J. Wiebe, Lisa A. Tell. (2009) Stability and uniformity of extemporaneous preparations of voriconazole in two liquid suspension vehicles at two storage temperatures. American Journal of Veterinary Research 70:7, 908-914
CrossRef259
BRITTANY CRAIGLOW, GINETTE HINDS, RICHARD ANTAYA, MICHAEL GIRARDI. (2009) Primary Cutaneous Aspergillosis in an Immunocompetent Patient: Successful Treatment with Oral Voriconazole. Pediatric Dermatology 26:4, 493-495
CrossRef260
Michael Darmon, Elie Azoulay. (2009) Critical care management of cancer patients: cause for optimism and need for objectivity. Current Opinion in Oncology 21:4, 318-326
CrossRef261
Jane A Cecil, Richard P Wenzel. (2009) Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections. Expert Review of Hematology 2:3, 237-254
CrossRef262
Mario Fernández-Ruiz, Francisco López-Medrano, Eduardo Gutiérrez, José María Aguado. (2009) Alucinaciones visuales complejas inducidas por voriconazol. Medicina Clínica 133:4, 156-157
CrossRef263
Shellee A. Grim, Nina M. Clark. (2009) The role of adjuvant agents in treating fungal diseases. Current Fungal Infection Reports 3:2, 117-126
CrossRef264
Koki Ueda, Yasuhito Nannya, Keiki Kumano, Akira Hangaishi, Tsuyoshi Takahashi, Yoichi Imai, Mineo Kurokawa. (2009) Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. International Journal of Hematology 89:5, 592-599
CrossRef265
James S. Lewis. (2009) Therapeutic drug monitoring of antifungal agents. Current Fungal Infection Reports 3:2, 96-102
CrossRef266
Marcio Nucci, Elias Anaissie. (2009) Fungal Infections in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation—Focus on Aspergillosis. Clinics in Chest Medicine 30:2, 295-306
CrossRef267
Isabel Ruiz-Camps, Manuel Cuenca-Estrella. (2009) Antifúngicos para uso sistémico. Enfermedades Infecciosas y Microbiología Clínica 27:6, 353-362
CrossRef268
George R. Thompson, Jose Cadena, Thomas F. Patterson. (2009) Overview of Antifungal Agents. Clinics in Chest Medicine 30:2, 203-215
CrossRef269
Luigi Tarani, Francesco Costantino, Gundula Notheis, Uwe Wintergerst, Mario Venditti, Claudio Di Biasi, Donata Friederici, Anna Maria Pasquino. (2009) Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl. Pediatric Diabetes 10:4, 289-293
CrossRef270
Sarah M. Wieczorkiewicz, Jacqueline Jourjy, Larry Danziger. (2009) An update on the pharmacoeconomics of antifungal pharmacotherapy. Current Fungal Infection Reports 3:2, 103-110
CrossRef271
Hester Vlaardingerbroek, Michiel van der Flier, Johannes A. Borgstein, Maarten H. Lequin, Inge M. van der Sluis. (2009) Fatal Aspergillus Rhinosinusitis During Induction Chemotherapy in a Child With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 31:5, 367-369
CrossRef272
April D. Miller, Molly E. Kent, Aaron M. Cook, Brian S. Murphy. (2009) Management of a Voriconazole-Phenobarbital Drug Interaction Using Voriconazole Concentration Monitoring. Infectious Diseases in Clinical Practice 17:3, 181-183
CrossRef273
Joerg Faber, Nikola Moritz, Nicole Henninger, Fred Zepp, Markus Knuf. (2009) Rapid detection of common pathogenic Aspergillus species by a novel real-time PCR approach. Mycoses 52:3, 228-233
CrossRef274
Oriol Gasch, Jaime Lora-Tamayo, Miguel Santín. (2009) Hematogenous spondylitis due to Aspergillus fumigatus in a patient with acquired immunodeficiency syndrome. Enfermedades Infecciosas y Microbiología Clínica 27:5, 303-305
CrossRef275
Robin K. Avery. (2009) Aspergillosis in hematopoietic stem cell transplant recipients: Risk factors, prophylaxis, and treatment. Current Infectious Disease Reports 11:3, 223-228
CrossRef276
Amparo Solé, Miguel Salavert. (2009) Fungal infections after lung transplantation. Current Opinion in Pulmonary Medicine 15:3, 243-253
CrossRef277
Sven Kohler, Undine Gerlach, Olaf Guckelberger, Igor M. Sauer, Dinah Jörres, Peter Neuhaus, Johann Pratschke, Andreas Pascher. (2009) Successful treatment of invasive sphenoidal, pulmonary and intracerebral aspergillosis after multivisceral transplantation. Transplant International 22:5, 589-591
CrossRef278
Justin A. Tolman, Nicole A. Nelson, Yoen Ju Son, Stephanie Bosselmann, Nathan P. Wiederhold, Jay I. Peters, Jason T. McConville, Robert O. Williams. (2009) Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. European Journal of Pharmaceutics and Biopharmaceutics 72:1, 199-205
CrossRef279
J. E. Bennett. (2009) Management of mycoses in neutropenic patients: a brief history, 1960-2008. Journal of Antimicrobial Chemotherapy 63:Supplement 1, i23-i26
CrossRef280
Roger S. Ho, Rahul M. Kohli, Lisa L. Maragakis. (2009) When to Think of Zebras. The American Journal of Medicine 122:5, 424-426
CrossRef281
Segal, Brahm H., . (2009) Aspergillosis. New England Journal of Medicine 360:18, 1870-1884
Full Text282
Johan Maertens, Wouter Meersseman, Pascal Van Bleyenbergh. (2009) New therapies for fungal pneumonia. Current Opinion in Infectious Diseases 22:2, 183-190
CrossRef283
Elizabeth Flynn, Anne Marciniak, Giuliana Barbabietola, Beryl A Oppenheim, Craig Roberts, Kenneth Barker. (2009) A multi-centre comparison of nursing staff time required for the preparation and administration of liposomal amphotericin B and amphotericin B deoxycholate vs. voriconazole. Journal of Clinical Nursing 18:8, 1168-1179
CrossRef284
George Dimopoulos, Irene Karampela. (2009) Pulmonary Aspergillosis. Clinical Pulmonary Medicine 16:2, 68-73
CrossRef285
Oriol Gasch, Nuria Fernández, Josefina Ayats, Miguel Santin. (2009) Cerebral aspergillosis in an HIV-infected patient: Unsuccessful outcome despite combined antifungal therapy. Enfermedades Infecciosas y Microbiología Clínica 27:3, 193-194
CrossRef286
Thomas Lehrnbecher, Sabine Mousset, Jan Sörensen, Angelika Böhme. (2009) Current practice of antifungal prophylaxis and treatment in immunocompromised children and adults with malignancies: a single centre approach. Mycoses 52:2, 107-117
CrossRef287
Thomas R. Rogers, Susanna Frost. (2009) Newer antifungal agents for invasive fungal infections in patients with haematological malignancy. British Journal of Haematology 144:5, 629-641
CrossRef288
Jun Kato, Takehiko Mori, Yukinori Nakamura, Masatoshi Sakurai, Yoshinobu Aisa, Yasuo Ikeda, Shinichiro Okamoto. (2009) Hypotension due to the drug interaction of voriconazole with eplerenone and nifedipine. European Journal of Clinical Pharmacology 65:3, 323-324
CrossRef289
D. Knüttgen, M. Kamp, M. Ströhlein, J. Matten, A. Chemaissani, K. Ernestus, S.G. Sakka, F. Wappler. (2009) Invasive pulmonale Aspergillose. Der Anaesthesist 58:3, 262-267
CrossRef290
Eric J. Bow, D. Bacteriol. (2009) The role of second-generation triazole antifungal agents voriconazole and posaconazole in patients with hematologic malignancies. Current Fungal Infection Reports 3:1, 32-39
CrossRef291
L. E. Cowen, S. D. Singh, J. R. Kohler, C. Collins, A. K. Zaas, W. A. Schell, H. Aziz, E. Mylonakis, J. R. Perfect, L. Whitesell, S. Lindquist. (2009) Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proceedings of the National Academy of Sciences 106:8, 2818-2823
CrossRef292
G. Maschmeyer, M. Sandherr. (2009) Infektionen in der Hämatologie und Onkologie. Der Internist 50:2, 187-202
CrossRef293
Daniel J. Diekema, Shawn A. Messer, Richard J. Hollis, Linda Boyken, Shailesh Tendolkar, Jennifer Kroeger, Ronald N. Jones, Michael A. Pfaller. (2009) A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.. Diagnostic Microbiology and Infectious Disease 63:2, 233-236
CrossRef294
Nina Naeger-Murphy, James C. Pile. (2009) Clinical indications for newer antifungal agents. Journal of Hospital Medicine 4:2, 102-111
CrossRef295
Angelika Böhme, Markus Ruhnke, Dieter Buchheidt, Oliver A. Cornely, Herrmann Einsele, Ruxandra Enzensberger, Holger Hebart, Werner Heinz, Christian Junghanss, Meinolf Karthaus, William Krüger, Utz Krug, Thomas Kubin, Olaf Penack, Dietmar Reichert, Stefan Reuter, Gerda Silling, Thomas Südhoff, Andrew J. Ullmann, Georg Maschmeyer. (2009) Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of Hematology 88:2, 97-110
CrossRef296
Thomas Elter, Janne J. Vehreschild, John Gribben, Oliver A. Cornely, Andreas Engert, Michael Hallek. (2009) Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Annals of Hematology 88:2, 121-132
CrossRef297
Christopher C. Porter, Amy E. Carver, Edythe A. Albano. (2009) Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. Pediatric Blood & Cancer 52:2, 298-300
CrossRef298
D. Neofytos, D. Horn, E. Anaissie, W. Steinbach, A. Olyaei, J. Fishman, M. Pfaller, C. Chang, K. Webster, K. Marr. (2009) Epidemiology and Outcome of Invasive Fungal Infection in Adult Hematopoietic Stem Cell Transplant Recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance Registry. Clinical Infectious Diseases 48:3, 265-273
CrossRef299
Johan Maertens, Kristel Buvé, Koen Theunissen, Wouter Meersseman, Eric Verbeken, Gregor Verhoef, Johan Van Eldere, Katrien Lagrou. (2009) Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer 115:2, 355-362
CrossRef300
Alessandro C. Pasqualotto. (2009) Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. Medical Mycology 47:s1, S261-S270
CrossRef301
Diana F. Florescu, Peter C. Iwen, Lisa A. Hill, Ioana Dumitru, Mohammed A. Quader, Andre C. Kalil, Alison G. Freifeld. (2009) Cerebral aspergillosis caused by Aspergillus ustus following orthotopic heart transplantation: case report and review of the literature. Clinical Transplantation 23:1, 116-120
CrossRef302
Marit D. Moen, Katherine A. Lyseng-Williamson, Lesley J. Scott. (2009) Liposomal Amphotericin B. Drugs 69:3, 361-392
CrossRef303
N. Singh. (2009) Evidence-based approach to challenging issues in the management of invasive aspergillosis. Medical Mycology 47:s1, S338-S342
CrossRef304
Asako Ueno, Tadanori Hamano, Akihiro Fujii, Akiko Matsunaga, Seiji Naganuma, Makoto Yoneda, Hiroshi Itoh, Masaru Kuriyama. (2009) The effects of voriconazole and vascular lesions in invasion of aspergillosis into the central nerve system. Rinsho Shinkeigaku 49:8, 468-473
CrossRef305
James I. Ito, Joseph M. Lyons, Diana Diaz-Arevalo, Teresa B. Hong, Markus Kalkum. (2009) Vaccine progress. Medical Mycology 47:s1, S394-S400
CrossRef306
Hyun Su Kim, Se Hyung Kim, Hyun Jung Kim, Sang Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Kyu Teak Lee, Seong Kyu Park, Jong Ho Won, Dae Sik Hong, Hee Sook Park, Eun Ju Choo. (2009) Successful Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome with Invasive Fungal Infection - A Case Report -. The Korean Journal of Hematology 44:4, 289
CrossRef307
Stephen T. Chambers, Mona Syhre, David R. Murdoch, Fiona McCartin, Michael J. Epton. (2009) Detection of 2-Pentylfuran in the breath of patients with Aspergillus fumigatus. Medical Mycology 47:5, 468-476
CrossRef308
(2009) Erratum. Medical Mycology 47:6, 670-670
CrossRef309
Marisa Miceli, Elias Anaissie. (2009) Clinical trial design for invasive aspergillosis: time to cast a different mold. Medical Mycology 47:s1, S343-S348
CrossRef310
Jae-Cheol Kwon, Si-Hyun Kim, Su-Mi Choi, Jae Ki Choi, Dong-Gun Lee, Sun Hee Park, Jung-Hyun Choi, Jin-Hong Yoo, Wan-Shik Shin. (2009) Efficacy and Safety Profile of Voriconazole as Salvage Therapy for Invasive Aspergillosis with Hematologic Diseases in Korea. Infection and Chemotherapy 42:1, 17
CrossRef311
Prapaporn PORNSURIYASAK, Septimiu MURGU, Henri COLT. (2009) Pseudomembranous aspergillus tracheobronchitis superimposed on post-tuberculosis tracheal stenosis. Respirology 14:1, 144-147
CrossRef312
Richard H. Drew. (2009) Aerosol and other novel administrations for prevention and treatment of invasive aspergillosis. Medical Mycology 47:s1, S355-S361
CrossRef313
Jong Sun Park, Jae-Joon Yim, Seok-Chul Yang, Chul-Gyu Yoo, Young Whan Kim, Sung Koo Han, Young-Soo Shim, Sang-Min Lee. (2009) Acute Respiratory Failure from Invasive Pulmonary Aspergillosis in an Immunocompetent Adult - A Case Report -. The Korean Journal of Critical Care Medicine 24:3, 172
CrossRef314
Richard D. Deshazo. (2009) Syndromes of invasive fungal sinusitis. Medical Mycology 47:s1, S309-S314
CrossRef315
Eilidh Mowat, Craig Williams, Brian Jones, Susan Mcchlery, Gordon Ramage. (2009) The characteristics of Aspergillus fumigatus mycetoma development: is this a biofilm?. Medical Mycology 47:s1, S120-S126
CrossRef316
Georg Maschmeyer, Thierry Calandra, Nina Singh, Joseph Wiley, John Perfect. (2009) Invasive mould infections: a multi-disciplinary update. Medical Mycology 47:6, 571-583
CrossRef317
Thomas F. Patterson. (2009) Risk stratification for invasive aspergillosis: early assessment of host susceptibility. Medical Mycology 47:s1, S255-S260
CrossRef318
Francisco M. Marty, Sophia Koo. (2009) Role of (1→3)-β-D-glucan in the diagnosis of invasive aspergillosis. Medical Mycology 47:s1, S233-S240
CrossRef319
&NA;. (2009) Prophylactic, empirical, pre-emptive and targeted antibacterial therapy all play a role in invasive aspergillosis. Drugs & Therapy Perspectives 25:1, 18-22
CrossRef320
Kazuo Tamura, Akio Urabe, Minoru Yoshida, Akihisa Kanamaru, Yoshihisa Kodera, Shinichiro Okamoto, Shigefumi Maesaki, Tohru Masaoka. (2009) Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leukemia & Lymphoma 50:1, 92-100
CrossRef321
Yasuki Kamai, Albert S. Lossinsky, Hong Liu, Donald C. Sheppard, Scott G. Filler. (2009) Polarized response of endothelial cells to invasion by Aspergillus fumigatus. Cellular Microbiology 11:1, 170-182
CrossRef322
Kyoung-Ho Song, Shinwon Lee, Hee-Chang Jang, Jae Hyun Jeon, Wan Beom Park, Kyoung Un Park, Sang-Won Park, Myoung-don Oh, Kang Won Choe. (2009) Diagnostic Usefulness of Galactomannan Assay for Invasive Aspergillosis. Infection and Chemotherapy 41:2, 82
CrossRef323
Kareem M. Abu-Elmagd, Guilherme Costa, Geoffrey J. Bond, Tong Wu, Noriko Murase, Adriana Zeevi, Richard Simmons, Kyle Soltys, Rakesh Sindhi, William Stein, Anthony Demetris, George Mazariegos. (2009) Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transplant International 22:1, 96-109
CrossRef324
Brahm H. Segal, Luigina R. Romani. (2009) Invasive aspergillosis in chronic granulomatous disease. Medical Mycology 47:s1, S282-S290
CrossRef325
Sang Joon Lee, Jung Joo Lee, Shin Dong Kim. (2009) Topical and Oral Voriconazole in the Treatment of Fungal Keratitis. Korean Journal of Ophthalmology 23:1, 46
CrossRef326
Lennert Slobbe, Suzanne Polinder, Jeanette K. Doorduijn, Pieternella J. Lugtenburg, Abdelilah el Barzouhi, Ewout W. Steyerberg, Bart J. A. Rijnders. (2008) Outcome and Medical Costs of Patients with Invasive Aspergillosis and Acute Myelogenous Leukemia–Myelodysplastic Syndrome Treated with Intensive Chemotherapy: An Observational Study. Clinical Infectious Diseases 47:12, 1507-1512
CrossRef327
G. Blum, S. Perkhofer, K. Grif, A. Mayr, G. Kropshofer, D. Nachbaur, R. Kafka-Ritsch, M. P. Dierich, C. Lass-Flörl. (2008) A 1-year Aspergillus terreus surveillance study at the University Hospital of Innsbruck: molecular typing of environmental and clinical isolates. Clinical Microbiology and Infection 14:12, 1146-1151
CrossRef328
Ignacio Gadea, José Mensa. (2008) Potencial de anidulafungina en la terapia combinada. Enfermedades Infecciosas y Microbiología Clínica 26, 51-55
CrossRef329
Márcio Borges Sá, José Garnacho Montero. (2008) Papel de anidulafungina en el paciente crítico. Enfermedades Infecciosas y Microbiología Clínica 26, 35-43
CrossRef330
Jutta Auberger, Cornelia Lass-Flörl, Hanno Ulmer, Elisabeth Nogler-Semenitz, Johannes Clausen, Eberhard Gunsilius, Hermann Einsele, Günther Gastl, David Nachbaur. (2008) Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. International Journal of Hematology 88:5, 508-515
CrossRef331
Lennert Slobbe, Eric Boersma, Bart J.A. Rijnders. (2008) Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: Data from a randomized placebo-controlled trial. Pulmonary Pharmacology & Therapeutics 21:6, 855-859
CrossRef332
Jesús Guinea, Emilio Bouza. (2008) Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiology 3:6, 603-615
CrossRef333
William W Hope, Eliane M Billaud, Jodie Lestner, David W Denning. (2008) Therapeutic drug monitoring for triazoles. Current Opinion in Infectious Diseases 21:6, 580-586
CrossRef334
Priya A. Prasad, Susan E. Coffin, Kateri H. Leckerman, Thomas J. Walsh, Theoklis E. Zaoutis. (2008) Pediatric Antifungal Utilization. The Pediatric Infectious Disease Journal 27:12, 1083-1088
CrossRef335
Helen W. Boucher. (2008) Is It Possible to Blind a Trial for Community‐Acquired Pneumonia?. Clinical Infectious Diseases 47:S3, S210-S215
CrossRef336
Z. Peto, R. Benko, M. Matuz, E. Csullog, A. Molnar, E. Hajdu. (2008) Results of a Local Antibiotic Management Program on Antibiotic Use in a Tertiary Intensive Care Unit in Hungary. Infection 36:6, 560-564
CrossRef337
Ashok Sarin. (2008) Fungal Infections in Renal Transplantation. Apollo Medicine 5:4, 345-347
CrossRef338
Shigeru Kohno. (2008) Editorial Commentary: High Mortality in Invasive Aspergillosis: What We Need to Know for Determination of Poor Prognosis and Next Countermeasures. Clinical Infectious Diseases 47:9, 1185-1187
CrossRef339
Yasmine Nivoix, Michel Velten, Valérie Letscher‐Bru, Alireza Moghaddam, Shanti Natarajan‐Amé, Cécile Fohrer, Bruno Lioure, Karin Bilger, Philippe Lutun, Luc Marcellin, Anne Launoy, Guy Freys, Jean‐Pierre Bergerat, Raoul Herbrecht. (2008) Factors Associated with Overall and Attributable Mortality in Invasive Aspergillosis. Clinical Infectious Diseases 47:9, 1176-1184
CrossRef340
Andreas H. Groll. (2008) Invasive opportunistic mycoses: Clinical trials review, 2007–2008. Current Infectious Disease Reports 10:6, 451-453
CrossRef341
Ben E. de Pauw, Juan J. Picazo. (2008) Present situation in the treatment of invasive fungal infection. International Journal of Antimicrobial Agents 32, S167-S171
CrossRef342
Jutta Auberger, Cornelia Lass-Flörl, Johannes Clausen, Romuald Bellmann, Walter Buzina, Günther Gastl, David Nachbaur. (2008) First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation. Diagnostic Microbiology and Infectious Disease 62:3, 336-339
CrossRef343
Christina T. Rieger, Helmut Ostermann, Hans-Jochem Kolb, Michael Fiegl, Saskia Huppmann, Nicole Morgenstern, Johanna Tischer. (2008) A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients. Annals of Hematology 87:11, 915-922
CrossRef344
Valerio Del Bono, Małgorzata Mikulska, Claudio Viscoli. (2008) Invasive aspergillosis: diagnosis, prophylaxis and treatment. Current Opinion in Hematology 15:6, 586-593
CrossRef345
Patricia Muñoz, Jesus Guinea, Marta Torres Narbona, Emilio Bouza. (2008) Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad Trial and other new data. International Journal of Antimicrobial Agents 32, S125-S131
CrossRef346
Hye Sun Choi, Jun Yong Choi, Jin Sook Yoon, Sung Joo Kim, Sang Yeul Lee. (2008) Clinical Characteristics and Prognosis of Orbital Invasive Aspergillosis. Ophthalmic Plastic & Reconstructive Surgery 24:6, 454-459
CrossRef347
A. Lupetti, J. T. Dissel, C. P. J. M. Brouwer, P. H. Nibbering. (2008) Human antimicrobial peptides’ antifungal activity against Aspergillus fumigatus. European Journal of Clinical Microbiology & Infectious Diseases 27:11, 1125-1129
CrossRef348
Sandro Vento, Francesca Cainelli, Zelalem Temesgen. (2008) Lung infections after cancer chemotherapy. The Lancet Oncology 9:10, 982-992
CrossRef349
Cornelia Lass-Flörl, Susanne Perkhofer. (2008) In vitro susceptibility-testing in Aspergillus species. Mycoses 51:5, 437-446
CrossRef350
Zlate Stojanoski, Aleksandra Pivkova, Sonja Genadieva-Stavrik, Lidija Cevreska, Milena Petrovska, Borche Georgievski. (2008) Antifungal Prophylaxis In Hematopoietic Stem Cell Transplant Recipients. Macedonian Journal of Medical Sciences 1:1, 50-58
CrossRef351
Brahm H. Segal, Raoul Herbrecht, David A. Stevens, Luis Ostrosky‐Zeichner, Jack Sobel, Claudio Viscoli, Thomas J. Walsh, Johan Maertens, Thomas F. Patterson, John R. Perfect, Bertrand Dupont, John R. Wingard, Thierry Calandra, Carol A. Kauffman, John R. Graybill, Lindsey R. Baden, Peter G. Pappas, John E. Bennett, Dimitrios P. Kontoyiannis, Catherine Cordonnier, Maria Anna Viviani, Jacques Bille, Nikolaos G. Almyroudis, L. Joseph Wheat, Wolfgang Graninger, Eric J. Bow, Steven M. Holland, Bart‐Jan Kullberg, William E. Dismukes, Ben E. De Pauw. (2008) Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clinical Infectious Diseases 47:5, 674-683
CrossRef352
J. Sainz, E. Pérez, S. Gómez-Lopera, M. Jurado. (2008) IL1 Gene Cluster Polymorphisms and Its Haplotypes may Predict the Risk to Develop Invasive Pulmonary Aspergillosis and Modulate C-reactive Protein Level. Journal of Clinical Immunology 28:5, 473-485
CrossRef353
Sébastien Hochart, Frédérique Barrier, Isabelle Durand-Joly, Sandrine Horrent, Bertrand Decaudin, Pascal Odou. (2008) Les antifongiques systémiques Partie 2 : éléments thérapeutiques. Le Pharmacien Hospitalier 43:174, 155-168
CrossRef354
Dominic Störzinger, Christoph Lichtenstern, Stefanie Swoboda, Markus A. Weigand, Torsten Hoppe-Tichy. (2008) Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation. Mycoses 51, 52-57
CrossRef355
Annelies M. Zwitserloot, Adilia Warris, Louis G. van't Hek, Lya E. van Die, Paul E. Verweij, Annelies M.C. Mavinkurve‐Groothuis. (2008) Disseminated aspergillosis in an adolescent with acute lymphoblastic leukemia. Pediatric Blood & Cancer 51:3, 423-426
CrossRef356
Maria J. G. T. Rüping, Jörg J. Vehreschild, Oliver A. Cornely. (2008) Antifungal treatment strategies in high risk patients. Mycoses 51, 46-51
CrossRef357
Eike Hollenbach. (2008) Invasive candidiasis in the ICU: evidence based and on the edge of evidence. Mycoses 51, 25-45
CrossRef358
S. Gencer, S. Ozer, G. Demirhan, O. Ak, A. Batirel. (2008) Angio-oedema as an unusual tolerable side effect of voriconazole therapy. Journal of Medical Microbiology 57:8, 1028-1031
CrossRef359
A. Bandera, D. Trabattoni, G. Ferrario, M. Cesari, F. Franzetti, M. Clerici, A. Gori. (2008) Interferon-γ and Granulocyte-Macrophage Colony Stimulating Factor Therapy in Three Patients with Pulmonary Aspergillosis. Infection 36:4, 368-373
CrossRef360
O. A. Cornely. (2008) Aspergillus to Zygomycetes: Causes, Risk Factors, Prevention, and Treatment of Invasive Fungal Infections. Infection 36:4, 296-313
CrossRef361
Osamu Imataki, Hiroaki Ohnishi, Akira Kitanaka, Yoshitsugu Kubota, Toshihiko Ishida, Terukazu Tanaka. (2008) Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population. International Journal of Hematology 88:1, 3-6
CrossRef362
Andrew J. Ullmann. (2008) Nephrotoxicity in the setting of invasive fungal diseases. Mycoses 51:s1, 25-30
CrossRef363
Dimitrios I. Zonios, Juan Gea‐Banacloche, Richard Childs, John E. Bennett. (2008) Hallucinations during Voriconazole Therapy. Clinical Infectious Diseases 47:1, e7-e10
CrossRef364
Daniel Podzamczer. (2008) Tratamiento de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad. Enfermedades Infecciosas y Microbiología Clínica 26:6, 356-379
CrossRef365
W. J. Heinz, H. Einsele. (2008) Caspofungin for treatment of invasive aspergillus infections. Mycoses 51:s1, 47-57
CrossRef366
Ben De Pauw, Thomas J. Walsh, J. Peter Donnelly, David A. Stevens, John E. Edwards, Thierry Calandra, Peter G. Pappas, Johan Maertens, Olivier Lortholary, Carol A. Kauffman, David W. Denning, Thomas F. Patterson, Georg Maschmeyer, Jacques Bille, William E. Dismukes, Raoul Herbrecht, William W. Hope, Christopher C. Kibbler, Bart Jan Kullberg, Kieren A. Marr, Patricia Muñoz, Frank C. Odds, John R. Perfect, Angela Restrepo, Markus Ruhnke, Brahm H. Segal, Jack D. Sobel, Tania C. Sorrell, Claudio Viscoli, John R. Wingard, Theoklis Zaoutis, John E. Bennett. (2008) Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases 46:12, 1813-1821
CrossRef367
Martine Piccart-Gebhardt, Francoise Meunier. 2008. European Organization for Research and Treatment of Cancer (EORTC). .
CrossRef368
John W. Baddley, Senu Apewokin. (2008) Prevention of invasive aspergillosis in high-risk patients: Universal versus preemptive, targeted treatment. Current Fungal Infection Reports 2:2, 61-68
CrossRef369
K.M. Ho, O. Duff, D. Chambers, R. Murray. (2008) Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals. Transplant Infectious Disease 10:3, 168-176
CrossRef370
G. Maschmeyer. (2008) Invasive aspergillosis in severely immunosuppressed patients: significant progress, but many unresolved problems. Transplant Infectious Disease 10:3, 151-155
CrossRef371
Hisham Wahba, Mylene T. Truong, Xiudong Lei, Dimitrios P. Kontoyiannis, Edith M. Marom. (2008) Reversed Halo Sign in Invasive Pulmonary Fungal Infections. Clinical Infectious Diseases 46:11, 1733-1737
CrossRef372
E. Jantunen, A. Nihtinen, V.-J. Anttila. (2008) Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients. Transplant Infectious Disease 10:3, 156-161
CrossRef373
Victoria A. Epstein, Robert C. Kern. (2008) Invasive Fungal Sinusitis and Complications of Rhinosinusitis. Otolaryngologic Clinics of North America 41:3, 497-524
CrossRef374
Jo-Anne H. Young. (2008) Infectious complications of acute and chronic GVHD. Best Practice & Research Clinical Haematology 21:2, 343-356
CrossRef375
Hiroto Narimatsu, Masahiro Kami. (2008) Management of fungal infections following allogeneic stem cell transplantation. Expert Review of Anti-infective Therapy 6:3, 373-384
CrossRef376
Dorothy Surowiec, Daryl D DePestel, Peggy L Carver. (2008) Concurrent Administration of Sirolimus and Voriconazole: A Pilot Study Assessing Safety and Approaches to Appropriate Management. Pharmacotherapy 28:6, 719-729
CrossRef377
R. Bellmann, R. Bellmann-Weiler, S. Weiler. (2008) Pulmonary mycoses. memo - Magazine of European Medical Oncology 1:S3, 15-19
CrossRef378
E Castagnola, M Faraci, C Moroni, R Bandettini, C Granata, S Caruso, F Bagnasco, I Caviglia, M Malgorzata, E Furfaro, A R Natalizia, V de Fazio, G Morreale, E Lanino, R Haupt, G Dini, C Viscoli. (2008) Invasive mycoses in children receiving hemopoietic SCT. Bone Marrow Transplantation 41, S107-S111
CrossRef379
K. A. Thursky, E. G. Playford, J. F. Seymour, T. C. Sorrell, D. H. Ellis, S. D. Guy, N. Gilroy, J. Chu, D. R. Shaw. (2008) Recommendations for the treatment of established fungal infections. Internal Medicine Journal 38:6b, 496-520
CrossRef380
L. J. Worth, C. C. Blyth, D. L. Booth, D. C. M. Kong, D. Marriott, M. Cassumbhoy, J. Ray, M. A. Slavin, J. R. Wilkes. (2008) Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Internal Medicine Journal 38:6b, 521-537
CrossRef381
John R. Wingard, Patricia Ribaud, Haran T. Schlamm, Raoul Herbrecht. (2008) Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 112:10, 2309-2312
CrossRef382
M. Richardson, C. Lass-Flörl. (2008) Changing epidemiology of systemic fungal infections. Clinical Microbiology and Infection 14:s4, 5-24
CrossRef383
F. Lanternier, O. Lortholary. (2008) Liposomal amphotericin B: what is its role in 2008?. Clinical Microbiology and Infection 14:s4, 71-83
CrossRef384
Marcio Nucci, John R. Perfect. (2008) When Primary Antifungal Therapy Fails. Clinical Infectious Diseases 46:9, 1426-1433
CrossRef385
Dominique M. Vandijck, Dominique D. Benoit, Pieter O. Depuydt, Fritz C. Offner, Stijn I. Blot, Anna K. Tilborgh, Joke Nollet, Eva Steel, Lucien A. Noens, Johan M. Decruyenaere. (2008) Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies. Intensive Care Medicine 34:5, 847-855
CrossRef386
Ali Akhaddar, Miloudi Gazzaz, Abderrahmane Albouzidi, Badr Lmimouni, Brahim Elmostarchid, Mohammed Boucetta. (2008) Invasive Aspergillus terreus sinusitis with orbitocranial extension: case report. Surgical Neurology 69:5, 490-495
CrossRef387
John Mohr, Melissa Johnson, Travis Cooper, James S Lewis, Luis Ostrosky-Zeichner. (2008) Current Options in Antifungal Pharmacotherapy. Pharmacotherapy 28:5, 614-645
CrossRef388
Kieren A. Marr. (2008) Editorial Commentary: Aspergillus Galactomannan Index: A Surrogate End Point to Assess Outcome of Therapy?. Clinical Infectious Diseases 46:9, 1423-1425
CrossRef389
Bart J. Rijnders, Jan J. Cornelissen, Lennert Slobbe, Martin J. Becker, Jeanette K. Doorduijn, Wim C. J. Hop, Elisabeth J. Ruijgrok, Bob Löwenberg, Arnold Vulto, Pieternella J. Lugtenburg, Siem de Marie. (2008) Aerosolized Liposomal Amphotericin B for the Prevention of Invasive Pulmonary Aspergillosis during Prolonged Neutropenia: A Randomized, Placebo‐Controlled Trial. Clinical Infectious Diseases 46:9, 1401-1408
CrossRef390
Fernanda P Silveira, Shahid Husain. (2008) Fungal infections in lung transplant recipients. Current Opinion in Pulmonary Medicine 14:3, 211-218
CrossRef391
Marisa H. Miceli, Monica L. Grazziutti, Gail Woods, Weizhi Zhao, Mehmet H. Kocoglu, Bart Barlogie, Elias Anaissie. (2008) Strong Correlation between Serum Aspergillus Galactomannan Index and Outcome of Aspergillosis in Patients with Hematological Cancer: Clinical and Research Implications. Clinical Infectious Diseases 46:9, 1412-1422
CrossRef392
Miguel A. Sanz, Rafael de la Cámara, Isidro Jarque, Javier López, Luis Madero, Isabel Ruiz, Lourdes Vázquez, Carlos Vallejo. (2008) Update on pulmonary infections in patients with hematologic malignancies and hematopoietic stem cell recipients. Enfermedades Infecciosas y Microbiología Clínica 26, 58-71
CrossRef393
Bharat Damle, Robert LaBadie, Penelope Crownover, Paul Glue. (2008) Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. British Journal of Clinical Pharmacology 65:4, 523-530
CrossRef394
Helen Pawson, Asantha Jayaweera, Tim Wigmore. (2008) Intensive care management of patients following haematopoietic stem cell transplantation. Current Anaesthesia & Critical Care 19:2, 80-90
CrossRef395
Amparo Solé, Jordi Carratalá, Miguel Montejo, Patricia Muñoz, Guillermo Quindós, Mercedes Palomar, Javier Pemán, Juan Carlos Pozo, Juan Luis Rodríguez Tudela. (2008) Latest developments in fungal lung infection in solid organ transplantation (SOT). Enfermedades Infecciosas y Microbiología Clínica 26, 49-57
CrossRef396
Chih-Cheng Lai, Che-Kim Tan, Yu-Tsung Huang, Pei-Lan Shao, Po-Ren Hsueh. (2008) Current challenges in the management of invasive fungal infections. Journal of Infection and Chemotherapy 14:2, 77-85
CrossRef397
J. Sinkó, J. Csomor, R. Nikolova, S. Lueff, G. Kriván, P. Reményi, Á. Bátai, T. Masszi. (2008) Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey. Transplant Infectious Disease 10:2, 106-109
CrossRef398
A. M. Whittle, S. Ali. (2008) Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity. International Journal of Laboratory Hematology 30:2, 173-174
CrossRef399
James S Lewis, John R Graybill. (2008) Fungicidal versus Fungistatic: what's in a word?. Expert Opinion on Pharmacotherapy 9:6, 927-935
CrossRef400
Mickael Aoun, Jean Klastersky, Kristel Buvé, Johan Maertens. 2008. Management of Fungal Infections in Cancer Patients. , 1-41.
CrossRef401
A. Vanacker, G. Fabré, J. Van Dorpe, W. E. Peetermans, B. Maes. (2008) Aggressive Cutaneous Squamous Cell Carcinoma Associated with Prolonged Voriconazole Therapy in a Renal Transplant Patient. American Journal of Transplantation 8:4, 877-880
CrossRef402
Ray Y. Hachem, Maha R. Boktour, Hend A. Hanna, Rola N. Husni, Harrys A. Torres, Claude Afif, Dimitrios P. Kontoyiannis, Issam I. Raad. (2008) Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 112:6, 1282-1287
CrossRef403
R. Herbrecht, A. Berceanu. (2008) -D-Glucan Detection Test: A Step Toward Preemptive Therapy for Fungal Infections in Leukemic Patients?. Clinical Infectious Diseases 46:6, 886-889
CrossRef404
Nicolas Crassard, Hélène Hadden, Marie-Antoinette Piens, Corinne Pondarré, Richard Hadden, Claire Galambrun, Jean-Pierre Pracros, Gérard Souillet, Thierry Basset, Jean-Claude Berthier, Noel Philippe, Yves Bertrand. (2008) Invasive aspergillosis in a paediatric haematology department: a 15-year review. Mycoses 51:2, 109-116
CrossRef405
Khalil Ullah, Shahid Raza, Parvez Ahmed, Qamar-un-Nisa Chaudhry, Tariq Mahmood Satti, Suhaib Ahmed, Sajjad Hussain Mirza, Fahim Akhtar, Khalid Kamal, Farrukh Mahmood Akhtar. (2008) Post-transplant infections: single center experience from the developing world. International Journal of Infectious Diseases 12:2, 203-214
CrossRef406
Jörg J. Vehreschild, Angelika Böhme, Dietmar Reichert, Michael G. Kiehl, Dorothee Arenz, Karen Pankraz, Matthias Kochanek, Andrew J. Ullmann, Oliver A. Cornely. (2008) Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. International Journal of Hematology 87:2, 126-131
CrossRef407
Georg Maschmeyer, Antje Haas. (2008) The epidemiology and treatment of infections in cancer patients. International Journal of Antimicrobial Agents 31:3, 193-197
CrossRef408
I I Raad, H A Hanna, M Boktour, Y Jiang, H A Torres, C Afif, D P Kontoyiannis, R Y Hachem. (2008) Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 22:3, 496-503
CrossRef409
Joseph D. Conlon, Marie Dauenhauer, Viseslav Tonkovic-Capin, Julie Talano, David Margolis, Beth A. Drolet, Janet A. Fairley. (2008) Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patients. Journal of the American Academy of Dermatology 58:3, 484-487
CrossRef410
Christy Chuang-Stein, Mohan Beltangady, Michael Dunne, Briggs Morrison. (2008) The ethics of non-inferiority trials. The Lancet 371:9616, 895-896
CrossRef411
Russell E. Lewis. (2008) Pharmacokinetic considerations for the use of newer antifungal agents. Current Fungal Infection Reports 2:1, 5-11
CrossRef412
V. Domergue, V. Orlandini, H. Begueret, B. Couprie, M. Huerre, M. Tunon de Lara, M. Beylot-Barry, M.-S. Doutre. (2008) Aspergillose cutanée, pulmonaire et osseuse chez un malade ayant un lupus érythémateux cutané subaigu sans déficit immunitaire associé. Annales de Dermatologie et de Vénéréologie 135:3, 217-221
CrossRef413
Mario Cruciani, Giovanni Serpelloni. (2008) Management of Candida infections in the adult intensive care unit. Expert Opinion on Pharmacotherapy 9:2, 175-191
CrossRef414
Hervé Quintard, Emmanuelle Papy, Laurent Massias, Sigismond Lasocki, Philippe Arnaud, Jean-Marie Desmonts, Philippe Montravers. (2008) The Pharmacokinetic Profile of Voriconazole During Continuous High-volume Venovenous Hemofiltration in a Critically Ill Patient. Therapeutic Drug Monitoring 30:1, 117-119
CrossRef415
Reinhard A. Seger. (2008) Modern management of chronic granulomatous disease. British Journal of Haematology 140:3, 255-266
CrossRef416
Mehmet Fatih Can, Gokhan Yagci, Levent Gorenek, Ergun Tozkoparan, Ismail Ozerhan, Sadettin Cetiner. (2008) Invasive Pulmonary Aspergillosis after Liver Transplantation: Rapid and Complete Response to Combined and Sequential Antifungal Therapy. Surgical Infections 9:1, 99-104
CrossRef417
Carole A. Sable, Kim M. Strohmaier, Jeffrey A. Chodakewitz. (2008) Advances in Antifungal Therapy. Annual Review of Medicine 59:1, 361-379
CrossRef418
Shelley S Magill, Tom M Chiller, David W Warnock. (2008) Evolving strategies in the management of aspergillosis. Expert Opinion on Pharmacotherapy 9:2, 193-209
CrossRef419
J.-P. Gangneux, C. Camus, B. Philippe. (2008) Épidémiologie et facteurs de risque de l’aspergillose invasive du sujet non neutropénique. Revue des Maladies Respiratoires 25:2, 139-153
CrossRef420
Thomas J. Walsh, Elias J. Anaissie, David W. Denning, Raoul Herbrecht, Dimitrios P. Kontoyiannis, Kieren A. Marr, Vicki A. Morrison, Brahm H Segal, William J. Steinbach, David A. Stevens, Jo‐Anne van Burik, John R. Wingard, y Thomas F. Patterson. (2008) Tratamiento de la Aspergilosis: Guías para la práctica clínica de la Sociedad de Enfermedades Infecciosas de los Estados Unidos de América (IDSA). Clinical Infectious Diseases 46:3, T1-T36
CrossRef421
Thomas J. Walsh, Elias J. Anaissie, David W. Denning, Raoul Herbrecht, Dimitrios P. Kontoyiannis, Kieren A. Marr, Vicki A. Morrison, Brahm H Segal, William J. Steinbach, David A. Stevens, Jo‐Anne van Burik, John R. Wingard, Thomas F. Patterson. (2008) Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases 46:3, 327-360
CrossRef422
R. E. Lewis. (2008) What Is the "Therapeutic Range" for Voriconazole?. Clinical Infectious Diseases 46:2, 212-214
CrossRef423
A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille, O. Marchetti. (2008) Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes. Clinical Infectious Diseases 46:2, 201-211
CrossRef424
Chai Ryoung Eun, Jung Yeon Heo, Ji Yun Noh, Young Kyung Youn, Hyun Joo Lee, Bong Kyung Shin, Jacob Lee, Joon Young Song, Hee Jin Cheong, Woo Joo Kim. (2008) Invasive Aspergillosis of the Paranasal Sinuses Invading Skull Base : Successful Treatment with Voriconazole. Infection and Chemotherapy 40:2, 110
CrossRef425
Eric J. Bow. (2008) Considerations in the approach to invasive fungal infection in patients with haematological malignancies. British Journal of Haematology 140:2, 133-152
CrossRef426
Jeremy Brown. 2008. Pneumonia in the Non-HIV Immunocompromised Host. , 365-378.
CrossRef427
Toshikatsu OKUDA, Akiko OKUDA, Noriko WATANABE, Masayoshi TAKAO, Kazunobu TAKAYANAGI. (2008) Retrospective Serological Tests for Determining the Optimal Blood Concentration of Voriconazole for Treating Fungal Infection. YAKUGAKU ZASSHI 128:12, 1811-1818
CrossRef428
Sevtap Arikan, Banu Sancak, Sehnaz Alp, Gulsen Hascelik, Paul Mcnicholas. (2008) Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus , and synergy testing for Rhizopus. Medical Mycology 46:6, 567-573
CrossRef429
Dennis C. Stokes, Surender Rajasekaran. 2008. Respiratory Infections in Immunocompromised Hosts. , 555-574.
CrossRef430
Jan Groetzner, Ingo Kaczmarek, Thorsten Wittwer, Justus Strauch, Bruno Meiser, Thorsten Wahlers, Sabine Daebritz, Bruno Reichart. (2008) Caspofungin as First-Line Therapy for the Treatment of Invasive Aspergillosis After Thoracic Organ Transplantation. The Journal of Heart and Lung Transplantation 27:1, 1-6
CrossRef431
Yasunori Kurahashi, Nariyasu Nakashima, Daisuke Nakajima, Noriyuki Misaki, Kazuya Matsumoto, Shinichi Sumitomo. (2008) A case of pneumonectomy for rapidly deteriorating non-invasive pulmonary aspergillosis. The Journal of the Japanese Associtation for Chest Surgery 22:5, 770-774
CrossRef432
Roshan Lewis, Holly Hogan, Allan Howell, Amar Safdar. (2008) Progressive fusariosis: Unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection. Leukemia & Lymphoma 49:1, 163-165
CrossRef433
Mona Syhre, Jennifer M. Scotter, Stephen T. Chambers. (2008) Investigation into the production of 2-Pentylfuran by Aspergillus fumigatus and other respiratory pathogens in vitro and human breath samples. Medical Mycology 46:3, 209-215
CrossRef434
Hans Jürgen Dornbusch, Petra Sovinz, Herwig Lackner, Wolfgang Schwinger, Martin Benesch, Volker Strenger, Christian Urban. (2008) Effective management of pulmonary aspergillosis invading the thoracic spine in a child with high risk ALL requiring allogeneic bone marrow transplantation. Medical Mycology 46:5, 487-490
CrossRef435
Sachiko Sato, Satoko Ikeda, Yutaka Arimori, Tsuyoshi Ono, Shinsei Saeki. (2008) Nihon Shuchu Chiryo Igakukai zasshi 15:4, 533-538
CrossRef436
Hilde Van Campenhout, Sophie Marbaix, Marie-Paule Derde, Lieven Annemans. (2008) Voriconazole Treatment of Invasive Aspergillosis. Clinical Drug Investigation 28:8, 509-521
CrossRef437
Yoshinobu Kanda. (2008) Management of Fungal Infection in Hematopoietic Stem Cell Transplantation Recipients. Nippon Ishinkin Gakkai Zasshi 49:4, 323-328
CrossRef438
Satoru Joshita, Kiyoshi Kitano, Tadanobu Nagaya, Atsushi Kamijo, Koh Nakazawa, Fumihiro Ishida. (2008) Zygomycosis Presenting as Acute Myocardial Infarction during Hematological Malignancies. Internal Medicine 47:9, 839-842
CrossRef439
Z. A. Kanafani, J. R. Perfect. (2008) Resistance to Antifungal Agents: Mechanisms and Clinical Impact. Clinical Infectious Diseases 46:1, 120-128
CrossRef440
Steven E. Weinberger, Barbara A. Cockrill, Jess Mandel. 2008. Miscellaneous Infections Caused by Fungi and Pneumocystis. , 317-327.
CrossRef441
Keven Flammer, Julie A. Nettifee Osborne, Donna J. Webb, Laura E. Foster, Stacy L. Dillard, Jennifer L. Davis. (2008) Pharmacokinetics of voriconazole after oral administration of single and multiple doses in African grey parrots ( Psittacus erithacus timneh ). American Journal of Veterinary Research 69:1, 114-121
CrossRef442
Christian Garzoni, Lydia Markham, Philippe Bijlenga, Jorge Garbino. (2008) Cladophialophora bantiana : a rare cause of fungal brain abscess. Clinical aspects and new therapeutic options. Medical Mycology 46:5, 481-486
CrossRef443
Tark Kim, Sang-Rok Lee, Oh Hyun Cho, Ki Ho Park, Ryan Oh, Sang-Oh Lee, Yang Soo Kim, Jun Hee Woo, Mi-Na Kim, Sang-Ho Choi. (2008) A Case of Septic Hip Arthritis Caused by Aspergillus fumigatus in a Liver Transplant Recipient. Infection and Chemotherapy 40:3, 170
CrossRef444
Maria J G T Rüping, Jörg J Vehreschild, Oliver A Cornely. (2008) Patients at High Risk of Invasive Fungal Infections. Drugs 68:14, 1941-1962
CrossRef445
Parsia A. Vagefi, A. Benedict Cosimi, Leo C. Ginns, Camille N. Kotton. (2008) Cutaneous Aspergillus Ustus in a Lung Transplant Recipient: Emergence of a New Opportunistic Fungal Pathogen. The Journal of Heart and Lung Transplantation 27:1, 131-134
CrossRef446
A.W. Oosten, H.G. Sprenger, J.T.M. van Leeuwen, N.E.L. Meessen, S. van Assen. (2008) Case Report: Bilateral Renal Aspergillosis in a Patient with AIDS: A Case Report and Review of Reported Cases. AIDS Patient Care and STDs 22:1, 1-6
CrossRef447
Jay M. Lieberman, Felice C. Adler-Shohet. 2008. Fungal Infections. , 627-637.
CrossRef448
Minoru Yoshida. (2008) Diagnosis and treatment of invasive pulmonary aspergillosis in ICU. Nihon Shuchu Chiryo Igakukai zasshi 15:4, 474-476
CrossRef449
Denis Caillot, Anne Thiébaut, Raoul Herbrecht, Stéphane de Botton, Arnaud Pigneux, Frédéric Bernard, Jérôme Larché, Françoise Monchecourt, Serge Alfandari, Lamine Mahi. (2007) Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies. Cancer 110:12, 2740-2746
CrossRef450
RICHARD M. WINN, ADILIA WARRIS, PETER GAUSTAD, TORE G. ABRAHAMSEN. (2007) The effect of antifungal agents and human monocytes on in vitro galactomannan release by Aspergillus spp. in liquid culture medium. APMIS 115:12, 1364-1369
CrossRef451
Simone Cesaro, Giovanni Cecchetto, Federica De Corti, Paolo Dodero, Mareva Giacchino, Ilaria Caviglia, Franca Fagioli, Susanna Livadiotti, Federica Salin, Desireè Caselli, Elio Castagnola. (2007) Results of a multicenter retrospective study of a combined medical and surgical approach to pulmonary aspergillosis in pediatric neutropenic patients. Pediatric Blood & Cancer 49:7, 909-913
CrossRef452
David L. Horn, Jay A. Fishman, William J. Steinbach, Elias J. Anaissie, Kieren A. Marr, Ali J. Olyaei, Michael A. Pfaller, Mark A. Weiss, Karen M. Webster, Dionissios Neofytos. (2007) Presentation of the PATH Alliance® registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagnostic Microbiology and Infectious Disease 59:4, 407-414
CrossRef453
Pei-Lan Shao, Li-Min Huang, Po-Ren Hsueh. (2007) Recent advances and challenges in the treatment of invasive fungal infections. International Journal of Antimicrobial Agents 30:6, 487-495
CrossRef454
Alejandro Sanchez, Robert Larsen. (2007) Fungal infections in solid organ transplantation. Current Opinion in Organ Transplantation 12:6, 579-584
CrossRef455
L. Pagano, M. Caira, A. Nosari, M. T. Van Lint, A. Candoni, M. Offidani, T. Aloisi, G. Irrera, A. Bonini, M. Picardi, C. Caramatti, R. Invernizzi, D. Mattei, L. Melillo, C. de Waure, G. Reddiconto, L. Fianchi, C. G. Valentini, C. Girmenia, G. Leone, F. Aversa. (2007) Fungal Infections in Recipients of Hematopoietic Stem Cell Transplants: Results of the SEIFEM B-2004 Study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clinical Infectious Diseases 45:9, 1161-1170
CrossRef456
C.J. Scott, J.S. Lambert, C.B. Taylor, M.B. Poulton. (2007) Invasive Aspergillus fumigatus associated with liver and bone involvement in a patient with AIDS. International Journal of Infectious Diseases 11:6, 550-553
CrossRef457
John W. Baddley, Peter G. Pappas. (2007) Combination antifungal therapy for the treatment of invasive yeast and mold infections. Current Infectious Disease Reports 9:6, 448-456
CrossRef458
Jörg J. Vehreschild, Angelika Böhme, Dieter Buchheidt, Dorothee Arenz, Urs Harnischmacher, Claus P. Heussel, Andrew J. Ullmann, Sabine Mousset, Margit Hummel, Peter Frommolt, Gernot Wassmer, Ivonne Drzisga, Oliver A. Cornely. (2007) A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). Journal of Infection 55:5, 445-449
CrossRef459
O. A. Cornely, J. Maertens, A. J. Ullmann, C. P. Heussel, R. Herbrecht. (2007) Reply to Denning. Clinical Infectious Diseases 45:8, 1108-1110
CrossRef460
D. W. Denning. (2007) Comparison of 2 Studies of Treatment of Invasive Aspergillosis. Clinical Infectious Diseases 45:8, 1106-1108
CrossRef461
Brahm H Segal, William J Steinbach. (2007) Combination antifungals: an update. Expert Review of Anti-infective Therapy 5:5, 883-892
CrossRef462
Sinthumathi NATESAN, Georgi ABRAHAM, Milly MATHEW, M.K. LALITHA, C.N. SRINIVASAN. (2007) Secondary sternal Aspergillus osteomyelitis in a diabetic hemodialysis patient with previous allograft rejection. Hemodialysis International 11:4, 403-405
CrossRef463
C. Gubler, S. M. Wildi, A. Imhof, M. Schneemann, B. Müllhaupt. (2007) Disseminated Invasive Aspergillosis with Cerebral Involvement Successfully Treated with Caspofungin and Voriconazole. Infection 35:5, 364-366
CrossRef464
Annie-Claude Labbé, Shi Hann Su, Michel Laverdière, Jacques Pépin, Carlos Patiño, Sandra Cohen, Thomas Kiss, Silvy Lachance, Guy Sauvageau, Lambert Busque, Denis-Claude Roy, Jean Roy. (2007) High Incidence of Invasive Aspergillosis Associated with Intestinal Graft-versus-Host Disease following Nonmyeloablative Transplantation. Biology of Blood and Marrow Transplantation 13:10, 1192-1200
CrossRef465
Christine C Chiou, Thomas J Walsh, Andreas H Groll. (2007) Clinical pharmacology of antifungal agents in pediatric patients. Expert Opinion on Pharmacotherapy 8:15, 2465-2489
CrossRef466
S.C. Metcalf, D.H. Dockrell. (2007) Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. Journal of Infection 55:4, 287-299
CrossRef467
Philipp Staber, Stefan Langner, Hans Jürgen Dornbusch, Peter Neumeister. (2007) Antifungal management in cancer patients. Wiener Medizinische Wochenschrift 157:19-20, 503-510
CrossRef468
Charalampos Antachopoulos, Thomas J. Walsh, Emmanuel Roilides. (2007) Fungal infections in primary immunodeficiencies. European Journal of Pediatrics 166:11, 1099-1117
CrossRef469
R. J. Trof, A. Beishuizen, Y. J. Debets-Ossenkopp, A. R. J. Girbes, A. B. J. Groeneveld. (2007) Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Medicine 33:10, 1694-1703
CrossRef470
Wouter Meersseman, Eric Wijngaerden. (2007) Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Medicine 33:10, 1679-1681
CrossRef471
S. Siddiqui, V. L. Anderson, D. M. Hilligoss, M. Abinun, T. W. Kuijpers, H. Masur, F. G. Witebsky, Y. R. Shea, J. I. Gallin, H. L. Malech, S. M. Holland. (2007) Fulminant Mulch Pneumonitis: An Emergency Presentation of Chronic Granulomatous Disease. Clinical Infectious Diseases 45:6, 673-681
CrossRef472
R. S. Traboulsi, M. M. Kattar, O. Dbouni, G. F. Araj, S. S. Kanj. (2007) Fatal brain infection caused by Aspergillus glaucus in an immunocompetent patient identified by sequencing of the ribosomal 18S–28S internal transcribed spacer. European Journal of Clinical Microbiology & Infectious Diseases 26:10, 747-750
CrossRef473
O. A. Cornely, J. Maetens, R. Herbrecht. (2007) Reply to Wolf et al.. Clinical Infectious Diseases 45:5, 668-669
CrossRef474
J.R. Wingard, R. Herbrecht, J. Mauskopf, H.T. Schlamm, A. Marciniak, C.S. Roberts. (2007) Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transplant Infectious Disease 9:3, 182-188
CrossRef475
John Dotis, Elias Iosifidis, Emmanuel Roilides. (2007) Central nervous system aspergillosis in children: a systematic review of reported cases. International Journal of Infectious Diseases 11:5, 381-393
CrossRef476
Lior Dayan, Hannah Sprecher, Amos Hananni, Hana Rosenbaum, Victor Milloul, Ilana Oren. (2007) Aspergillus vertebral osteomyelitis in chronic leukocyte leukemia patient diagnosed by a novel panfungal polymerase chain reaction method. The Spine Journal 7:5, 615-617
CrossRef477
S Trifilio, S Singhal, S Williams, O Frankfurt, L Gordon, A Evens, J Winter, M Tallman, J Pi, J Mehta. (2007) Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplantation 40:5, 451-456
CrossRef478
J. Wolf, J. Buttery, A. J. Daley, S. Hanieh, F. Shann, M. Starr, N. Curtis. (2007) Liposomal Amphotericin B Trial Marred by Conclusions. Clinical Infectious Diseases 45:5, 667-668
CrossRef479
A Nihtinen, V-J Anttila, M Richardson, T Meri, L Volin, T Ruutu. (2007) The utility of intensified environmental surveillance for pathogenic moulds in a stem cell transplantation ward during construction work to monitor the efficacy of HEPA filtration. Bone Marrow Transplantation 40:5, 457-460
CrossRef480
Hiroshi Ouchi, Masaki Fujita, Satoshi Ikegame, Ichiro Inoshima, Eiji Harada, Yoichi Nakanishi. (2007) Successful treatment of refractory chronic necrotizing pulmonary aspergillosis with micafungin. Journal of Infection and Chemotherapy 13:4, 258-262
CrossRef481
M. Stiefel, T. Reiß, M.S. Staege, J. Rengelshausen, J. Burhenne, A. Wawer, J.L. Foell. (2007) Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma. Pediatric Blood & Cancer 49:2, 203-207
CrossRef482
George Petrikkos, Anna Skiada. (2007) Recent advances in antifungal chemotherapy. International Journal of Antimicrobial Agents 30:2, 108-117
CrossRef483
M D Johnson, J R Perfect. (2007) Combination antifungal therapy: what can and should we expect?. Bone Marrow Transplantation 40:4, 297-306
CrossRef484
J. Michael Collaco, W. Adam Gower, Peter J. Mogayzel. (2007) Pulmonary dysfunction in pediatric hematopoietic stem cell transplant patients: Overview, diagnostic considerations, and infectious complications. Pediatric Blood & Cancer 49:2, 117-126
CrossRef485
Reginald Greene, Paul Stark. 2007. The Role of Radiology in the Diagnosis of Fungal Infections. , 41-64.
CrossRef486
P de Fabritiis, A Spagnoli, P Di Bartolomeo, A Locasciulli, L Cudillo, G Milone, A Busca, A Picardi, R Scimè, A Bonini, L Cupelli, P Chiusolo, A Olivieri, S Santarone, M Poidomani, S Fallani, A Novelli, I Majolino. (2007) Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplantation 40:3, 245-249
CrossRef487
W. Meersseman, K. Lagrou, J. Maertens, E. V. Wijngaerden. (2007) Invasive Aspergillosis in the Intensive Care Unit. Clinical Infectious Diseases 45:2, 205-216
CrossRef488
Carlos A. Alvarez, Nathan P. Wiederhold, Jason T. McConville, Jay I. Peters, Laura K. Najvar, John R. Graybill, Jacqueline J. Coalson, Robert L. Talbert, David S. Burgess, Rosie Bocanegra, Keith P. Johnston, Robert O. Williams. (2007) Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. Journal of Infection 55:1, 68-74
CrossRef489
Renaud Gueret, Gourang P. Patel, David Simon, Robert A. Balk. (2007) Invasive Aspergillosis. Clinical Pulmonary Medicine 14:4, 197-205
CrossRef490
Utkarsh Kohli, Jitendra Sahu, Rakesh Lodha, Nidhi Agarwal, Ruma Ray. (2007) Invasive nosocomial aspergillosis associated with heart failure and complete heart block following recovery from dengue shock syndrome. Pediatric Critical Care Medicine 8:4, 389-391
CrossRef491
Marisa H. Miceli, Johan Maertens, Kristel Buvé, Monica Grazziutti, Gail Woods, Mazhar Rahman, Bart Barlogie, Elias J. Anaissie. (2007) Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications. Cancer 110:1, 112-120
CrossRef492
Luis Jara-Palomares, Ingeborg Mateos, Emilia Barrot-Cortés, José Miguel Cisneros. (2007) Infección por Aspergillus terreus en pacientes con EPOC en tratamiento con corticoides. A propósito de tres casos. Enfermedades Infecciosas y Microbiología Clínica 25:6, 415
CrossRef493
Raoul Herbrecht, Ursula Flückiger, Bertrand Gachot, Patricia Ribaud, Anne Thiebaut, Catherine Cordonnier. (2007) Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. European Journal of Cancer Supplements 5:2, 49-59
CrossRef494
Nadine Shehab, Daryl D DePestel, Emily R Mackler, Curtis D Collins, Kathleen Welch, Harry P Erba. (2007) Institutional Experience with Voriconazole Compared with Liposomal Amphotericin B as Empiric Therapy for Febrile Neutropenia. Pharmacotherapy 27:7, 970-979
CrossRef495
José María Aguado, Ana García-Reyne, Carlos Lumbreras. (2007) Infecciones en los pacientes trasplantados de hígado. Enfermedades Infecciosas y Microbiología Clínica 25:6, 401-410
CrossRef496
Deren Özcan, Ayşe Tülin Güleç, Mehmet Haberal. (2007) Multiple subcutaneous nodules leading to the diagnosis of pulmonary aspergillosis in a renal transplant recipient. Clinical Transplantation 0:0, 070627012636001-???
CrossRef497
P. E. Verweij, L. van Die, J. P. Donnelly. (2007) Halo Sign and Improved Outcome. Clinical Infectious Diseases 44:12, 1666-1667
CrossRef498
Susanne Perkhofer, Cornelia Speth, Manfred P. Dierich, Cornelia Lass-Flörl. (2007) In vitro determination of phagocytosis and intracellular killing of Aspergillus species by mononuclear phagocytes. Mycopathologia 163:6, 303-307
CrossRef499
S. Perkhofer, G. Blum, C. Speth, A. Mayr, M. P. Dierich, C. Lass-Flörl. (2007) Influence of amphotericin B and amphotericin B colloidal dispersion on the functions of human phagocytes in defence against Aspergillus species. European Journal of Clinical Microbiology & Infectious Diseases 26:6, 413-417
CrossRef500
Thomas F. Patterson. (2007) The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and Candida. Current Fungal Infection Reports 1:1, 5-11
CrossRef501
Douglas S Kwon, Eleftherios Mylonakis. (2007) Posaconazole: a new broad-spectrum antifungal agent. Expert Opinion on Pharmacotherapy 8:8, 1167-1178
CrossRef502
L. Pagano, M. Caira, M. Picardi, A. Candoni, L. Melillo, L. Fianchi, M. Offidani, A. Nosari. (2007) Invasive Aspergillosis in Patients with Acute Leukemia: Update on Morbidity and Mortality--SEIFEM-C Report. Clinical Infectious Diseases 44:11, 1524-1525
CrossRef503
(2007) Posaconazole Prophylaxis in Hematologic Cancer. New England Journal of Medicine 356:21, 2214-2218
Full Text504
E. J. Anaissie. (2007) Trial Design for Mold-Active Agents: Time to Break the Mold--Aspergillosis in Neutropenic Adults. Clinical Infectious Diseases 44:10, 1298-1306
CrossRef505
O. A. Cornely, J. Maertens, M. Bresnik, R. Ebrahimi, A. J. Ullmann, E. Bouza, C. P. Heussel, O. Lortholary, C. Rieger, A. Boehme, M. Aoun, H.-A. Horst, A. Thiebaut, M. Ruhnke, D. Reichert, N. Vianelli, S. W. Krause, E. Olavarria, R. Herbrecht, . (2007) Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). Clinical Infectious Diseases 44:10, 1289-1297
CrossRef506
M. Cobo, A. Ramos, J. Toquero, E. Muñez, T. Alvárez-Espejo, M. Muñoz, I. Fernández. (2007) Aspergillus infection of implantable cardioverter-defibrillators and pacemakers: case report and literature review. European Journal of Clinical Microbiology & Infectious Diseases 26:5, 357-361
CrossRef507
C. Cordonnier, M. Bresnik, R. Ebrahimi. (2007) Liposomal amphotericin B (AmBisome
) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis. Mycoses 50:3, 205-209
CrossRef508
Alejandro Sanchez, Robert Larsen. (2007) Emerging fungal pathogens in pulmonary disease. Current Opinion in Pulmonary Medicine 13:3, 199-204
CrossRef509
Shirish Huprikar. (2007) Update in Infectious Diseases in Liver Transplant Recipients. Clinics in Liver Disease 11:2, 337-354
CrossRef510
C. O. Morrissey, M. A. Slavin, M. A. O'Reilly, J. R. Daffy, J. F. Seymour, A. P. Schwarer, J. Szer. (2007) Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. Mycoses 50:s1, 24-37
CrossRef511
Johan Maertens, Koen Theunissen, Tom Lodewyck, Katrien Lagrou, Johan Van Eldere. (2007) Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses 50:s1, 2-17
CrossRef512
Andreas Glöckner, Jörg J. Vehreschild, Oliver A. Cornely. (2007) Zygomycosis ? current epidemiological aspects. Mycoses 50:s1, 50-55
CrossRef513
Abhijit M. Bal, Ian M. Gould. (2007) Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia. International Journal of Antimicrobial Agents 29:5, 501-509
CrossRef514
Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Elizabeth Reed, Peter Troke, Eckhard Thiel. (2007) Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. Mycoses 50:3, 196-200
CrossRef515
M. Sandherr, G. Maschmeyer. (2007) Infektionen in der Onkologie. best practice onkologie 2:2, 42-58
CrossRef516
C. E. Wrede, E. Holler. (2007) Intensivmedizinische Betreuung von Patienten nach Stammzelltransplantation. Intensivmedizin und Notfallmedizin 44:3, 129-141
CrossRef517
Calliope Maris, Benoît Martin, Jacques Creteur, Myriam Remmelink, Michael Piagnerelli, Isabelle Salmon, Jean-Louis Vincent, Pieter Demetter. (2007) Comparison of clinical and post-mortem findings in intensive care unit patients. Virchows Archiv 450:3, 329-333
CrossRef518
K. L. McCarthy, E. G. Playford, D. F. M. Looke, M. Whitby. (2007) Severe Photosensitivity Causing Multifocal Squamous Cell Carcinomas Secondary to Prolonged Voriconazole Therapy. Clinical Infectious Diseases 44:5, e55-e56
CrossRef519
J.A. Philips, F.M. Marty, R.M. Stone, B.A. Koplan, J.T. Katz, L.R. Baden. (2007) Torsades de pointes associated with voriconazole use. Transplant Infectious Disease 9:1, 33-36
CrossRef520
Peter H. Michelson, Rakesh Goyal, Geoffrey Kurland. (2007) Pulmonary complications of haematopoietic cell transplantation in children. Paediatric Respiratory Reviews 8:1, 46-61
CrossRef521
Yuko Komase, Hiroyuki Kunishima, Hiromichi Yamaguchi, Mizuki Ikehara, Takahito Yamamoto, Toshihito Shinagawa. (2007) Rapidly progressive invasive pulmonary aspergillosis in a diabetic man. Journal of Infection and Chemotherapy 13:1, 46-50
CrossRef522
A. Upton, K. A. Kirby, P. Carpenter, M. Boeckh, K. A. Marr. (2007) Invasive Aspergillosis following Hematopoietic Cell Transplantation: Outcomes and Prognostic Factors Associated with Mortality. Clinical Infectious Diseases 44:4, 531-540
CrossRef523
Jean Klastersky, Marianne Paesmans. (2007) Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection. Supportive Care in Cancer 15:2, 137-141
CrossRef524
Yun-Seok Rhee, Chun-Woong Park, Kyung-Jin Kim, Sang-Cheol Chi, Eun-Seok Park. (2007) Behavior of itraconazole and benzyl alcohol in aqueous solution containing nonionic surfactants. Archives of Pharmacal Research 30:2, 240-248
CrossRef525
Gregory Eschenauer, Daryl D DePestel, Peggy L Carver. (2007) Comparison of echinocandin antifungals. Therapeutics and Clinical Risk Management 3:1, 71-97
CrossRef526
R. E. Greene, H. T. Schlamm, J.-W. Oestmann, P. Stark, C. Durand, O. Lortholary, J. R. Wingard, R. Herbrecht, P. Ribaud, T. F. Patterson, P. F. Troke, D. W. Denning, J. E. Bennett, B. E. de Pauw, R. H. Rubin. (2007) Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign. Clinical Infectious Diseases 44:3, 373-379
CrossRef527
P H Chandrasekar. (2007) Increased dose of echinocandins for invasive fungal infections: bonanza for the patient or the pharmaceutical industry?. Bone Marrow Transplantation 39:3, 129-131
CrossRef528
Shinichi Kobayashi, Shizuko Murayama, Osamu Tatsuzawa, Goro Koinuma, Kazuteru Kawasaki, Chikako Kiyotani, Masaaki Kumagai. (2007) X-linked severe combined immunodeficiency (X-SCID) with high blood levels of immunoglobulins and Aspergillus pneumonia successfully treated with micafangin followed by unrelated cord blood stem cell transplantation. European Journal of Pediatrics 166:3, 207-210
CrossRef529
De Pauw, Ben E., Donnelly, J. Peter, . (2007) Prophylaxis and Aspergillosis — Has the Principle Been Proven?. New England Journal of Medicine 356:4, 409-411
Full Text530
Ullmann, Andrew J., Lipton, Jeffrey H., Vesole, David H., Chandrasekar, Pranatharthi, Langston, Amelia, Tarantolo, Stefano R., Greinix, Hildegard, Morais de Azevedo, Wellington, Reddy, Vijay, Boparai, Navdeep, Pedicone, Lisa, Patino, Hernando, Durrant, Simon, . (2007) Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease. New England Journal of Medicine 356:4, 335-347
Full Text531
Christopher Blyth, Katherine Hale, Pamela Palasanthiran, Tracey O'Brien, Michael H Bennett, Christopher Blyth. 2007. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. .
CrossRef532
Hideharu Muto, Shin Kaneko, Takayuki Machino, Yasushi Okoshi, Harumi Y. Mukai, Kazumi Suzukawa, Yuichi Hasegawa, Shigehiko Imagawa, Hiroshi Kojima, Yukio Ishii, Shigemi Hitomi, Toshiro Nagasawa. (2007) Quinupristin/dalfopristin and voriconazole controlled Staphylococcus epidermidis pneumonia and chronic necrotizing aspergillosis in a patient with severe lung degradation consequent to multiple treatments for Hodgkin's lymphoma. Journal of Infection and Chemotherapy 12:6, 391-395
CrossRef533
Georg Maschmeyer, Antje Haas, Oliver A Cornely. (2007) Invasive Aspergillosis. Drugs 67:11, 1567-1601
CrossRef534
Fernanda P. Silveira, Shahid Husain. (2007) Fungal infections in solid organ transplantation. Medical Mycology 45:4, 305-320
CrossRef535
Liisa Hovi, Harri Saxen, Ulla M. Saarinen-Pihkala, Kim Vettenranta, Taru Meri, Malcolm Richardson. (2007) Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatric Blood & Cancer 48:1, 28-34
CrossRef536
Koichiro Yoshida, Hisashi Shoji, Yoshihito Niki. (2007) Folia Pharmacologica Japonica 130:1, 52-56
CrossRef537
Markus Ruhnke, Grzegorz Kofla, Kirsten Otto, Stefan Schwartz. (2007) CNS Aspergillosis. CNS Drugs 21:8, 659-676
CrossRef538
Joshua Perlroth, Bryan Choi, Brad Spellberg. (2007) Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Medical Mycology 45:4, 321-346
CrossRef539
Thomas H. Price. (2007) Granulocyte Transfusion: Current Status. Seminars in Hematology 44:1, 15-23
CrossRef540
Koichi Izumikawa, Yoshiko Ohtsu, Masateru Kawabata, Hisashi Takaya, Atsushi Miyamoto, Susumu Sakamoto, Kazuma Kishi, Eiyasu Tsuboi, Sakae Homma, Kunihiko Yoshimura. (2007) Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Medical Mycology 45:3, 273-278
CrossRef541
Rafael Bandrés Gimeno, María José Muñoz Martínez. (2007) Respuesta terapéutica prolongada a voriconazol en un caso de broncoaspergilosis alérgica. Archivos de Bronconeumología 43:1, 49-51
CrossRef542
Thomas J. Walsh, Issam Raad, Thomas F. Patterson, Pranatharthi Chandrasekar, Gerald R. Donowitz, Richard Graybill, Reginald E. Greene, Ray Hachem, Susan Hadley, Raoul Herbrecht, Amelia Langston, Arnold Louie, Patricia Ribaud, Brahm H. Segal, David A. Stevens, Jo‐Anne H. van Burik, Charles S. White, Gavin Corcoran, Jagadish Gogate, Gopal Krishna, Lisa Pedicone, Catherine Hardalo, John R. Perfect. (2007) Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial. Clinical Infectious Diseases 44:1, 2-12
CrossRef543
Virginia Verdaguer, Thomas J Walsh, William Hope, Karoll J Cortez. (2007) Galactomannan antigen detection in the diagnosis of invasive aspergillosis. Expert Review of Molecular Diagnostics 7:1, 21-32
CrossRef544
Michael Borte, Bodo Grimbacher, Tim Niehues, Ellen Renner, Joachim Roesler, Volker Schuster. 2007. Immundefekte. , 667-706.
CrossRef545
Alfonso Dom??nguez-Gil, Isabel Mart??n, Mercedes Garc??a Vargas, Almudena Del Castillo, Silvia D??az, Cristina S??nchez. (2007) Economic Evaluation of Voriconazole versus Caspofungin for the Treatment of Invasive Aspergillosis in Spain. Clinical Drug Investigation 27:3, 197-205
CrossRef546
Tomomi Toubai, Junji Tanaka, Shuichi Ota, Akio Shigematsu, Yusuke Shono, Makoto Ibata, Satoshi Hashino, Takeshi Kondo, Yasutaka Kakinoki, Nobuo Masauzi, Masaharu Kasai, Hiroshi Iwasaki, Mitsutoshi Kurosawa, Masahiro Asaka, Masahiro Imamura. (2007) Efficacy and safety of Micafungin in Febrile NeutropenicPatients Treated for Hematological Malignancies. Internal Medicine 46:1, 3-9
CrossRef547
Claudia Vener, Maria Carrabba, Nicola S. Fracchiolla, Antonella Costa, Giovanna Fabio, Cinzia Hu, Clara Sina, Claudio Guastella, Lorenzo Pignataro, Giorgio Lambertenghi Deliliers. (2007) Invasive fungal sinusitis: An effective combined treatment in five haematological patients. Leukemia & Lymphoma 48:8, 1577-1586
CrossRef548
Ulrich Schuler, Susanne Bammer, Walter E. Aulitzky, Claudia Binder, Angelika Böhme, Gerlinde Egerer, Michael Sandherr, Rainer Schwerdtfeger, Gerda Silling, Hannes Wandt, Axel Glasmacher, Gerhard Ehninger. (2007) Safety and Efficacy of Itraconazole Compared to Amphotericin B as Empirical Antifungal Therapy for Neutropenic Fever in Patients with Haematological Malignancy*. Onkologie 30:4, 185-191
CrossRef549
J. Winkler, U. Müller, P. Nenoff, H.-J. Seyfarth, M. Vogtmann, G. Borte, W. Pönisch, T. Kahn, H. Wirtz, J. Schauer, G. Hoheisel. (2007) Treatment of Invasive Pulmonary Aspergillosis in Neutropenic Patients by Additional Bronchoscopic Amphotericin B Instillation. Respiration 74:6, 663-673
CrossRef550
John S Bradley, Robert Guidos, Steve Baragona, John G Bartlett, Ethan Rubinstein, George G Zhanel, Michael D Tino, David L Pompliano, Frank Tally, Praveen Tipirneni, Glenn S Tillotson, John H Powers, Glenn S Tillotson. (2007) Anti-infective research and development—problems, challenges, and solutions. The Lancet Infectious Diseases 7:1, 68-78
CrossRef551
Ralf Bialek, Andreas Groll, Ulrich Heininger, Volker Schuster. 2007. Infektionserkrankungen. , 439-533.
CrossRef552
Carlos Lumbreras, Francisco Álvarez-Lerma, Enric Carreras, José Miguel Cisneros, José Garnacho, Estrella Martín-Mazuelos, Javier Peman, Guillermo Quindos, Carmen Rubio, Julian Torre-Cisneros, Juan Luis Rodríguez Tudela. (2007) Update on invasive fungal infections: the last two years. Enfermedades Infecciosas y Microbiología Clínica 25, 19-27
CrossRef553
(2006) Echinocandins for Candidemia. New England Journal of Medicine 355:26, 2791-2792
Full Text554
Johan Maertens, Axel Glasmacher, Raoul Herbrecht, Anne Thiebaut, Catherine Cordonnier, Brahm H. Segal, John Killar, Arlene Taylor, Nicholas Kartsonis, Thomas F. Patterson, . (2006) Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107:12, 2888-2897
CrossRef555
S. Husain, D. Zaldonis, S. Kusne, E.J. Kwak, D.L. Paterson, K.R. McCurry. (2006) Variation in antifungal prophylaxis strategies in lung transplantation. Transplant Infectious Disease 8:4, 213-218
CrossRef556
N. G. Almyroudis, D. P. Kontoyiannis, K. A. Sepkowitz, B. E. DePauw, T. J. Walsh, B. H. Segal. (2006) Issues Related to the Design and Interpretation of Clinical Trials of Salvage Therapy for Invasive Mold Infection. Clinical Infectious Diseases 43:11, 1449-1455
CrossRef557
Oliver A Cornely, Jörg-Janne Vehreschild, Andrew J Ullmann. (2006) Is there a role for polyenes in treating invasive mycoses?. Current Opinion in Infectious Diseases 19:6, 565-570
CrossRef558
R. de la Cámara. (2006) Antifungal prophylaxis in haematology patients. Clinical Microbiology and Infection 12:s7, 65-76
CrossRef559
Faisal Khasawneh, Tamam Mohamad, Mahmoud K. Moughrabieh, Zongshan Lai, Joel Ager, Ayman O. Soubani. (2006) Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome. Journal of Critical Care 21:4, 322-327
CrossRef560
M. Kami, N. Murashige, Y. Tanaka, H. Narimatsu. (2006) Antifungal prophylaxis following reduced-intensity stem cell transplantation. Transplant Infectious Disease 8:4, 190-202
CrossRef561
S. Husain, D. L. Paterson, S. Studer, J. Pilewski, M. Crespo, D. Zaldonis, K. Shutt, D. L. Pakstis, A. Zeevi, B. Johnson, E. J. Kwak, K. R. McCurry. (2006) Voriconazole Prophylaxis in Lung Transplant Recipients. American Journal of Transplantation 6:12, 3008-3016
CrossRef562
George A Sarosi. (2006) Fungal infections and their treatment in the intensive care unit. Current Opinion in Internal Medicine 5:6, 553-558
CrossRef563
Georg Maschmeyer, Antje Haas. (2006) Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections. Future Microbiology 1:4, 365-385
CrossRef564
J. M. Cisneros Herreros, E. Cordero Matía. (2006) Therapeutic armamentarium against systemic fungal infections. Clinical Microbiology and Infection 12:s7, 53-64
CrossRef565
P. Eggimann, J.-C. Chevrolet, M. Starobinski, P. Majno, M. Totsch, B. Chapuis, D. Pittet. (2006) Primary Invasive Aspergillosis of the Digestive Tract: Report of Two Cases and Review of the Literature. Infection 34:6, 333-338
CrossRef566
Setareh Mamishi, Nima Parvaneh, Ali Salavati, Sina Abdollahzadeh, Mehdi Yeganeh. (2006) Invasive aspergillosis in chronic granulomatous disease: report of 7 cases. European Journal of Pediatrics 166:1, 83-84
CrossRef567
Thomas F. Patterson. (2006) The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and candida. Current Infectious Disease Reports 8:6, 442-448
CrossRef568
Susan J. Howard, Ian Webster, Caroline B. Moore, Rebecca E. Gardiner, Steven Park, David S. Perlin, David W. Denning. (2006) Multi-azole resistance in Aspergillus fumigatus. International Journal of Antimicrobial Agents 28:5, 450-453
CrossRef569
G. Notheis, L. Tarani, F. Costantino, A. Jansson, J. Rosenecker, D. Friederici, B. H. Belohradsky, D. Reinhardt, R. Seger, D. V. Schweinitz, Uwe Wintergerst. (2006) Posaconazole for treatment of refractory invasive fungal disease. Mycoses 49:s1, 37-41
CrossRef570
Meinolf Karthaus, Oliver A. Cornely. (2006) Second-line treatment in invasive mould infections. Mycoses 49:s1, 23-26
CrossRef571
Arlo Upton, Kieren A. Marr. (2006) Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient. Current Infectious Disease Reports 8:6, 434-441
CrossRef572
David W. Denning, Kieren A. Marr, Wendi M. Lau, David P. Facklam, Voravit Ratanatharathorn, Cornelia Becker, Andrew J. Ullmann, Nita L. Seibel, Patricia M. Flynn, Jo-Anne H. van Burik, Donald N. Buell, Thomas F. Patterson. (2006) Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. Journal of Infection 53:5, 337-349
CrossRef573
K. Stankovic, P. Sève, A. Hot, N. Magy-Bertrand, I. Durieu, C. Broussolle. (2006) Aspergilloses au cours de maladies systémiques traitées par corticoïdes et/ou immunosuppresseurs : analyse de neuf cas et revue de la littérature. La Revue de Médecine Interne 27:11, 813-827
CrossRef574
T. E. Corcoran, R. Venkataramanan, K. M. Mihelc, A. L. Marcinkowski, J. Ou, B. M. McCook, L. Weber, M.-E. Carey, D. L. Paterson, J. M. Pilewski, K. R. McCurry, S. Husain. (2006) Aerosol Deposition of Lipid Complex Amphotericin-B (Abelcet) in Lung Transplant Recipients. American Journal of Transplantation 6:11, 2765-2773
CrossRef575
Elias K. Spanakis, George Aperis, Eleftherios Mylonakis. (2006) Reviews Of Anti‐infective Agents: New Agents for the Treatment of Fungal Infections: Clinical Efficacy and Gaps in Coverage. Clinical Infectious Diseases 43:8, 1060-1068
CrossRef576
Elias J. Anaissie, Brahm H. Segal, John R. Graybill, Carola Arndt, John R. Perfect, Michael Kleinberg, Peter Pappas, Danny Benjamin, Robert Rubin, Judith A. Aberg, Elisabeth E. Adderson, Felice C. Adler‐Shohet, Hamdi Akan, Murat Akova, Nikolaos G. Almyroudis, Barbara D. Alexander, David Andes, Antonio Arrieta, John W. Baddley, Michelle A. Barron, Howard Belzberg, Helen W. Boucher, Thomas G. Boyce, Arturo Casadevall, P. H. Chandrasekar, John D. Cleary, Catherine Cordonnier, Oliver A. Cornely, Manuel Cuenca‐Estrella, Jennifer S. Daly, Nicholas Daoura, David W. Denning, Ben dePauw, Louis de Repentigny, Maria Cecilia Dignani, William E. Dismukes, J. Peter Donnelly, Gerald R. Donowitz, Bertrand Dupont, George Drusano, Michael Ellis, Ana Espinel‐Ingroff, Jay A. Fishman, Rhonda Fleming, Graeme Forrest, Mahmoud Ghannoum, Mitchell Goldman, Monica Grazziutti, John N. Greene, Richard N. Greenberg, Paul O. Gubbins, Susan Hadley, Raoul Herbrecht, John W. Hiemenz, William Hope, Durane R. Hospenthal, Shahid Husain, James I. Ito, Robert M. Jacobson, Melissa Johnson, Michael R. Keating, Daniel H. Kett, Katherine Knapp, Dimitrios P. Kontoyiannis, Vladimir C. Krcmery, Robert Larsen, Michel Laverdiere, Per Ljungman, O. Lortholary, Johan Maertens, Debbie Marriott, Gloria Mattiuzzi, Michael R. McGinnis, Michele Morris, Marcio Nucci, Frank C. Odds, George A. Pankey, Thomas Patterson, Mike Pfaller, Raymond R. Razonable, Annette C. Reboli, Michael G. Rinaldi, Glenn D. Roberts, Juan Luis Rodriguez Tudela, Coleman Rotstein, Markus Ruhnke, Mindy Schuster, Shmuel Shoham, Irene G. Sia, Nita Siebel, Fernanda Silviera, Nina Singh, Jack Sobel, Joseph S. Solomkin, Tania C. Sorrell, William J. Steinbach, Zelalem Temesgen, AnnaMaria Tortorano, Shahe Vartivarian, Paul VerWeij, Claudio Viscoli, Maria Anna Viviani, Randall C. Walker, Joseph L. Wheat, Joseph Wiley, Peter Williamson, John R. Wingard, Victor L. Yu, Theoklis Zaoutis. (2006) Clinical Research in the Lay Press: Irresponsible Journalism Raises a Huge Dose of Doubt. Clinical Infectious Diseases 43:8, 1031-1039
CrossRef577
Carol A Kauffman. (2006) Clinical efficacy of new antifungal agents. Current Opinion in Microbiology 9:5, 483-488
CrossRef578
Claudio Kupfahl, Thorsten Heinekamp, Gernot Geginat, Thomas Ruppert, Albert Härtl, Herbert Hof, Axel A. Brakhage. (2006) Deletion of the gliP gene of Aspergillus fumigatus results in loss of gliotoxin production but has no effect on virulence of the fungus in a low-dose mouse infection model. Molecular Microbiology 62:1, 292-302
CrossRef579
Staci A. Fischer. (2006) Infections Complicating Solid Organ Transplantation. Surgical Clinics of North America 86:5, 1127-1145
CrossRef580
Karen Moeremans, Lieven Annemans. (2006) Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients. Expert Opinion on Pharmacotherapy 7:14, 1931-1943
CrossRef581
Miquel Granell, Alvaro Urbano-Ispizua, Belén Suarez, Montserrat Rovira, Francesc Fernández-Avilés, Carmen Martínez, Mar Ortega, Carla Uriburu, Anna Gaya, Josep M. Roncero, Alfons Navarro, Enric Carreras, Josep Mensa, Jordi Vives, Ciril Rozman, Emili Montserrat, Francisco Lozano. (2006) Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Experimental Hematology 34:10, 1435-1441
CrossRef582
Honar Cherif, Mats Kalin, Magnus Bjorkholm. (2006) Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment?. European Journal of Haematology 77:4, 288-292
CrossRef583
Ayman O. Soubani. (2006) Critical care considerations of hematopoietic stem cell transplantation. Critical Care Medicine 34:Suppl, S251-S267
CrossRef584
Penelope D. Barnes, Kieren A. Marr. (2006) Aspergillosis: Spectrum of Disease, Diagnosis, and Treatment. Infectious Disease Clinics of North America 20:3, 545-561
CrossRef585
E. Linden, D. Restrepo, S. Dikman, B. Murphy, S. Huprikar. (2006) Aspergillus infection limited to renal allograft: case report and review of literature. Transplant Infectious Disease 8:3, 177-181
CrossRef586
Helen L. Leather, John R. Wingard. (2006) New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Blood Reviews 20:5, 267-287
CrossRef587
A Safdar. (2006) Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplantation 38:5, 327-337
CrossRef588
William J. Steinbach, Thomas J. Walsh. (2006) Mycoses in Pediatric Patients. Infectious Disease Clinics of North America 20:3, 663-678
CrossRef589
Thomas Elter, Michal Sieniawski, Axel Gossmann, Claudia Wickenhauser, Ursula Schröder, Harald Seifert, Johannes Kuchta, Jürgen Burhenne, Klaus-Dieter Riedel, Gerd Fätkenheuer, Oliver A. Cornely. (2006) Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. International Journal of Antimicrobial Agents 28:3, 262-265
CrossRef590
A. Cornillet, C. Camus, S. Nimubona, V. Gandemer, P. Tattevin, C. Belleguic, S. Chevrier, C. Meunier, C. Lebert, M. Aupee, S. Caulet‐Maugendre, M. Faucheux, B. Lelong, E. Leray, C. Guiguen, J.‐P. Gangneux. (2006) Comparison of Epidemiological, Clinical, and Biological Features of Invasive Aspergillosis in Neutropenic and Nonneutropenic Patients: A 6‐Year Survey. Clinical Infectious Diseases 43:5, 577-584
CrossRef591
Andrew J. Ullmann, Miguel A. Sanz, Andrea Tramarin, Rosemary A. Barnes, Wenchen Wu, Barbara A. Gerlach, Karl J. Krobot, William C. Gerth, . (2006) Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries. Clinical Infectious Diseases 43:4, e29-e38
CrossRef592
K Frankenbusch, F Eifinger, A Kribs, J Rengelshauseu, B Roth. (2006) Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight. Journal of Perinatology 26:8, 511-514
CrossRef593
Georgios Chamilos, Dimitrios P Kontoyiannis. (2006) The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine. Current Opinion in Infectious Diseases 19:4, 380-385
CrossRef594
E. S. D. Ashley, R. Lewis, J. S. Lewis, C. Martin, D. Andes. (2006) Pharmacology of Systemic Antifungal Agents. Clinical Infectious Diseases 43:Supplement 1, S28-S39
CrossRef595
Zaid Zoumot, Martin Carby, Anne V. Hall. (2006) Radiological resolution of cavitating Aspergillus fumigatus infection following treatment with oral voriconazole in two lung transplant recipients. Transplant International 19:8, 688-690
CrossRef596
Helen L Leather, John R Wingard. (2006) Is combination antifungal therapy for invasive aspergillosis a necessity in hematopoietic stem-cell transplant recipients?. Current Opinion in Infectious Diseases 19:4, 371-379
CrossRef597
M. A. Pfaller, P. G. Pappas, J. R. Wingard. (2006) Invasive Fungal Pathogens: Current Epidemiological Trends. Clinical Infectious Diseases 43:Supplement 1, S3-S14
CrossRef598
Patricia Muñoz, Nina Singh, Emilio Bouza. (2006) Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used?. Current Opinion in Infectious Diseases 19:4, 365-370
CrossRef599
Hans Fuchs, Heike Baum, Martina Meth, Nele Wellinghausen, Wolfgang Lindner, Helmut Hummler. (2006) CNS-manifestation of aspergillosis in an extremely low-birth-weight infant. European Journal of Pediatrics 165:7, 476-480
CrossRef600
Gregory T. Siwek, Michael A. Pfaller, Philip M. Polgreen, Sandra Cobb, Peter Hoth, Margarida Magalheas-Silverman, Daniel J. Diekema. (2006) Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagnostic Microbiology and Infectious Disease 55:3, 209-212
CrossRef601
Catherine Cordonnier, S??bastien Maury, Patricia Ribaud, Mathieu Kuentz, Fran??ois Bassompierre, Eliane Gluckman, Sylvie Chevret. (2006) A Grading System Based on Severity of Infection to Predict Mortality in Allogeneic Stem Cell Transplant Recipients. Transplantation 82:1, 86-92
CrossRef602
Zahida Bhatti, Aasma Shaukat, Nikolaos G. Almyroudis, Brahm H. Segal. (2006) Review of Epidemiology, Diagnosis, and Treatment of Invasive Mould Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Mycopathologia 162:1, 1-15
CrossRef603
Nina Singh, Marilyn M. Wagener. (2006) Combination Antifungal Therapy in Organ Transplant Recipients. Transplantation 82:2, 291-292
CrossRef604
Abdul Alsultan, Marc S. Williams, Sam Lubner, Frederick D. Goldman. (2006) Chronic granulomatous disease presenting with disseminated intracranial aspergillosis. Pediatric Blood & Cancer 47:1, 107-110
CrossRef605
Elio Castagnola, Simone Cesaro, Mareva Giacchino, Susanna Livadiotti, Fabio Tucci, Giulio Zanazzo, Desir?? Caselli, Ilaria Caviglia, Stefano Parodi, Roberto Rondelli, Pier Emilo Cornelli, Rossella Mura, Nicola Santoro, Giovanna Russo, Raffaella De Santis, Salvatore Buffardi, Claudio Viscoli, Riccardo Haupt, Mario R. Rossi. (2006) Fungal Infections in Children With Cancer. The Pediatric Infectious Disease Journal 25:7, 634-639
CrossRef606
Abhijit M. Bal. (2006) Combination Antifungal Therapy in Solid Organ Transplant Recipients. Transplantation 82:2, 291
CrossRef607
Ben E. De Pauw. (2006) Increasing Fungal Infections in the Intensive Care Unit. Surgical Infections 7:supplement 2, s-93-s-96
CrossRef608
Márcia Eliana da Silva Ferreira, Iran Malavazi, Marcela Savoldi, Axel A. Brakhage, Maria Helena S. Goldman, H. Stanley Kim, William C. Nierman, Gustavo H. Goldman. (2006) Transcriptome analysis of Aspergillus fumigatus exposed to voriconazole. Current Genetics 50:1, 32-44
CrossRef609
I. I. Raad, J. R. Graybill, A. B. Bustamante, O. A. Cornely, V. Gaona-Flores, C. Afif, D. R. Graham, R. N. Greenberg, S. Hadley, A. Langston, R. Negroni, J. R. Perfect, P. Pitisuttithum, A. Restrepo, G. Schiller, L. Pedicone, A. J. Ullmann. (2006) Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections. Clinical Infectious Diseases 42:12, 1726-1734
CrossRef610
Elizabeth S Dodds Ashley. (2006) Treatment Options for Invasive Fungal Infections. Pharmacotherapy 26:6part2, 55S-60S
CrossRef611
Élie Azoulay, Benoît Schlemmer. (2006) Diagnostic strategy in cancer patients with acute respiratory failure. Intensive Care Medicine 32:6, 808-822
CrossRef612
Stefan Neuburger, Georg Maschmeyer. (2006) Update on management of infections in cancer and stem cell transplant patients. Annals of Hematology 85:6, 345-356
CrossRef613
Iyona Rajkomar, Tony Moss. (2006) Aspergillus osteomyelitis of the thumb in a 5-year-old child. European Journal of Plastic Surgery 29:1, 41-43
CrossRef614
George Aperis, Eleftherios Mylonakis. (2006) Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opinion on Investigational Drugs 15:6, 579-602
CrossRef615
N. V. Sipsas, D. P. Kontoyiannis. (2006) Clinical Issues Regarding Relapsing Aspergillosis and the Efficacy of Secondary Antifungal Prophylaxis in Patients with Hematological Malignancies. Clinical Infectious Diseases 42:11, 1584-1591
CrossRef616
I. I. Raad, R. Y. Hachem, R. Herbrecht, J. R. Graybill, R. Hare, G. Corcoran, D. P. Kontoyiannis. (2006) Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions. Clinical Infectious Diseases 42:10, 1398-1403
CrossRef617
Francisco M. Marty, Colleen M. Lowry, Corey S. Cutler, Bonnie J. Campbell, Karen Fiumara, Lindsey R. Baden, Joseph H. Antin. (2006) Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 12:5, 552-559
CrossRef618
Michelle S Turner, Richard H Drew, John R Perfect. (2006) Emerging echinocandins for treatment of invasive fungal infections. Expert Opinion on Emerging Drugs 11:2, 231-250
CrossRef619
Zhirong Yao, Wanqing Liao. (2006) Fungal respiratory disease. Current Opinion in Pulmonary Medicine 12:3, 222-227
CrossRef620
W. E. Dismukes. (2006) Antifungal Therapy: Lessons Learned over the Past 27 Years. Clinical Infectious Diseases 42:9, 1289-1296
CrossRef621
J.J. Castón, M.J. Linares Sicilia, A. Rivero Román, J. Torre-Cisneros. (2006) Infecciones fúngicas invasoras por hongos filamentosos. Medicine - Programa de Formación Médica Continuada Acreditado 9:57, 3702-3707
CrossRef622
C. Cordonnier, P. Ribaud, R. Herbrecht, N. Milpied, D. Valteau-Couanet, C. Morgan, A. Wade, . (2006) Prognostic Factors for Death Due to Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation: A 1-Year Retrospective Study of Consecutive Patients at French Transplantation Centers. Clinical Infectious Diseases 42:7, 955-963
CrossRef623
Jerónimo Pachón, José Miguel Cisneros, Antonio Ramón Collado-Romacho, José Manuel Lomas-Cabezas, Fernando Lozano de León-Naranjo, Jorge Parra-Ruiz, Antonio Rivero-Román. (2006) Tratamiento de las infecciones fúngicas invasoras. Enfermedades Infecciosas y Microbiología Clínica 24:4, 254-263
CrossRef624
Javier Pem
CrossRef625
Thomas H. Price. (2006) Granulocyte transfusion therapy. Journal of Clinical Apheresis 21:1, 65-71
CrossRef626
F. WANDROO, P. STABLEFORTH, Y. HASAN. (2006) Aspergillus brain abscess in a patient with acute myeloid leukaemia successfully treated with voriconazole. Clinical and Laboratory Haematology 28:2, 130-133
CrossRef627
Tuhina Raman, Paul E Marik. (2006) Fungal infections in bone marrow transplant recipients. Expert Opinion on Pharmacotherapy 7:3, 307-315
CrossRef628
Paul E Marik. (2006) Fungal infections in solid organ transplantation. Expert Opinion on Pharmacotherapy 7:3, 297-305
CrossRef629
Nina Singh, Ajit P. Limaye, Graeme Forrest, Nasia Safdar, Patricia Mu??oz, Kenneth Pursell, Sally Houston, Fernando Rosso, Jose G. Montoya, Pamela Patton, Ramon del Busto, Jose M. Aguado, Robert A. Fisher, Goran B. Klintmalm, Rachel Miller, Marilyn M. Wagener, Russell E. Lewis, Dimitrios P. Kontoyiannis, Shahid Husain. (2006) Combination of Voriconazole and Caspofungin as Primary Therapy for Invasive Aspergillosis in Solid Organ Transplant Recipients: A Prospective, Multicenter, Observational Study. Transplantation 81:3, 320-326
CrossRef630
I. Molina Romero. (2006) Mujer de 43 años con síndrome mielodisplásico, neutropenia y fiebre. Medicine - Programa de Formación Médica Continuada Acreditado 9:49, 3245-3247
CrossRef631
Daniel H Deck, B Joseph Guglielmo. (2006) Pharmacological advances in the treatment of invasive candidiasis. Expert Review of Anti-infective Therapy 4:1, 137-149
CrossRef632
Karsten Juhl Jørgensen, Peter C Gøtzsche, Helle Krogh Johansen, Karsten Juhl Jørgensen. 2006. Voriconazole versus amphotericin B in cancer patients with neutropenia. .
CrossRef633
Robert Betts, Axel Glasmacher, Johan Maertens, Georg Maschmeyer, Jose A. Vazquez, Hedy Teppler, Arlene Taylor, Robert Lupinacci, Carole Sable, Nicholas Kartsonis. (2006) Efficacy of caspofungin against invasiveCandida or invasiveAspergillus infections in neutropenic patients. Cancer 106:2, 466-473
CrossRef634
Ehab Atallah, Charles A Schiffer. (2006) Granulocyte transfusion. Current Opinion in Hematology 13:1, 45-49
CrossRef635
Mitsuru Itoh, Masahiko Takahashi, Miyuki Mori, Hiromichi Tamekiyo, Hiroshi Yoshida, Kazuhiro Yago, Hideto Shimada, Kazumori Arai. (2006) Myocardial Infarction Caused by Aspergillus Embolization in a Patient with Aplastic Anemia. Internal Medicine 45:8, 547-550
CrossRef636
J. Peter Donnelly. (2006) Consensus definitions for invasive fungal disease: Strengths, limitations, and revisions. Medical Mycology 44:s1, 285-288
CrossRef637
Issei Tokimatsu, Jun-ichi Kadota. (2006) Efficacies and Clinical Roles of New Antifungal Agents. Nippon Ishinkin Gakkai Zasshi 47:3, 155-159
CrossRef638
Sergio M. Borgia, Jeffrey D. Fuller, Alicia Sarabia, Philippe El-Helou. (2006) Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen. Medical Mycology 44:7, 659-664
CrossRef639
Archie G. Prentice. (2006) The debate: The trials have told us very little. Medical Mycology 44:s1, 309-314
CrossRef640
Steven R Mays, Melissa A Bogle, Gerald P Bodey. (2006) Cutaneous Fungal Infections in the Oncology Patient. American Journal of Clinical Dermatology 7:1, 31-43
CrossRef641
2006. Voriconazole. , 3688-3691.
CrossRef642
Emmanuel Roilides. (2006) Early diagnosis of invasive aspergillosis in infants and children. Medical Mycology 44:s1, 199-205
CrossRef643
M. Aoun. (2006) Clinical efficacy of caspofungin in the treatment of invasive aspergillosis. Medical Mycology 44:s1, 363-366
CrossRef644
Yvonne A. Maldonado, Carol J. Baker, Michael J. Miller. 2006. Pneumocystis and Other Less Common Fungal Infections. , 1129-1176.
CrossRef645
Georg Maschmeyer, Antje Haas. (2006) Defining clinical failure for salvage studies. Medical Mycology 44:s1, 315-318
CrossRef646
M. Guarino, J. Benito-Leon, J. Decruyenaere, E. Schmutzhard, K. Weissenborn, A. Stracciari. (2006) EFNS guidelines on management of neurological problems in liver transplantation. European Journal of Neurology 13:1, 2-9
CrossRef647
C. Orla Morrissey, Monica A. Slavin. (2006) Antifungal strategies for managing invasive aspergillosis: The prospects for a pre-emptive treatment strategy. Medical Mycology 44:s1, 333-348
CrossRef648
Claudia Wagner, Wolfgang Graninger, Elisabeth Presterl, Christian Joukhadar. (2006) The Echinocandins: Comparison of Their Pharmacokinetics, Pharmacodynamics and Clinical Applications. Pharmacology 78:4, 161-177
CrossRef649
Patricia Ribaud. (2006) Challenges of patient recruitment for invasive aspergillosis trials. Medical Mycology 44:s1, 295-297
CrossRef650
William J. Steinbach. (2006) Combination antifungal therapy for invasive aspergillosis – Is it indicated?. Medical Mycology 44:s1, 373-382
CrossRef651
Claudio Viscoli, Matteo Bassetti. (2006) Dose finding in aspergillosis. Medical Mycology 44:s1, 299-303
CrossRef652
Rashed A Hasan, Walid Abuhammour. (2006) Invasive Aspergillosis in Children with Hematologic Malignancies. Pediatric Drugs 8:1, 15-24
CrossRef653
Y. Nivoix, C. Fohrer, L. Fornecker, R. Herbrecht. (2006) Clinical antifungal efficacy trials in invasive aspergillosis: Consensus standards for trial design and room for improvement. Medical Mycology 44:s1, 289-294
CrossRef654
V. Rickerts, G. Just-Nübling, F. Konrad, J. Kern, E. Lambrecht, A. Böhme, V. Jacobi, R. Bialek. (2006) Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. European Journal of Clinical Microbiology & Infectious Diseases 25:1, 8-13
CrossRef655
Masahiro Kami, Tomoko Matsumura. (2006) Fungal Infection Following Reduced-Intensity Stem Cell Transplantation (RIST). Nippon Ishinkin Gakkai Zasshi 47:3, 143-153
CrossRef656
Thomas F. Patterson. (2006) Treatment of invasive aspergillosis: Polyenes, echinocandins, or azoles?. Medical Mycology 44:s1, 357-362
CrossRef657
Jeroen P. Jansen, Winfried V. Kern, Oliver A. Cornely, Meinolf Karthaus, Markus Ruhnke, Andrew J. Ullmann, Ansgar Resch. (2006) Economic Evaluation of Voriconazole versus Conventional Amphotericin B in the Treatment of Invasive Aspergillosis in Germany. Value in Health 9:1, 12-23
CrossRef658
Koichiro Yoshida. (2006) Recent Advances of Serodiagnosis for Systemic Fungal Infections. Nippon Ishinkin Gakkai Zasshi 47:3, 135-142
CrossRef659
John E. Bennett. (2006) The debate: A case for randomized controls in invasive aspergillosis. Medical Mycology 44:s1, 305-308
CrossRef660
William J Steinbach, Daniel K Benjamin. (2005) New antifungal agents under development in children and neonates. Current Opinion in Infectious Diseases 18:6, 484-489
CrossRef661
G. Chamilos, D.P. Kontoyiannis. (2005) Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resistance Updates 8:6, 344-358
CrossRef662
G. Flox Benítez, P. Rondón Fernández, M. Quero Escalada, Á. Fernández Ballesteros. (2005) Alucinosis como efecto secundario de voriconazol. Revista Clínica Española 205:12, 632-633
CrossRef663
Tom Hilliard, Siân Edwards, Roger Buchdahl, Jacqueline Francis, Mark Rosenthal, Ian Balfour-Lynn, Andrew Bush, Jane Davies. (2005) Voriconazole therapy in children with cystic fibrosis. Journal of Cystic Fibrosis 4:4, 215-220
CrossRef664
Melissa D Johnson, Michael Kleinberg, Larry Danziger, Luis Ostrosky-Zeichner. (2005) Pharmacoeconomics of antifungal pharmacotherapy – challenges and future directions. Expert Opinion on Pharmacotherapy 6:15, 2617-2632
CrossRef665
Marc Ansari, Hulya Ozsahin, Sophia Taylor, Alain Gervaix, Privat Deucent, Pierre Wacker. (2005) Cutaneous aspergillosis in a child with an acute lymphoblastic leukemia. Pediatric Blood & Cancer 45:7, 1005-1006
CrossRef666
Fani Athanassiadou, Athanassios Tragiannidis, Maria Kourti, Theodotis Papageorgiou, Aristea Velegraki, Anna Kalogera. (2005) Treatment of disseminated aspergillosis with voriconazole/liposomal amphotericin B in a child with leukemia. Pediatric Blood & Cancer 45:7, 1003-1004
CrossRef667
Mirela Scherer, Hans-Gerd Fieguth, Tayfun Aybek, Zsolt Ujvari, Anton Moritz, Gerhard Wimmer-Greinecker. (2005) Disseminated Aspergillus fumigatus Infection with Consecutive Mitral Valve Endocarditis in a Lung Transplant Recipient. The Journal of Heart and Lung Transplantation 24:12, 2297-2300
CrossRef668
Huang Xiao Jun, Shen Zhixiang, Wang Chun, A. Harryanto Reksodiputro, Dody Ranuhardy, Kazuo Tamura, Tetsuro Matsumoto, Dong-Gun Lee, S. Visalachy Purushotaman, Victor Lim, Altaf Ahmed, Yasser Hussain, Manolito Chua, Adrian Ong, Cheng-Yi Liu, Po-Ren Hsueh, Shaeng-Fung Lin, Yung-Ching Liu, Panpit Suwangool, Saengsuree Jootar, Juan J. Picazo. (2005) Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. International Journal of Antimicrobial Agents 26, 128-132
CrossRef669
Fani Athanassiadou, Maria Kourti, Athanasios Tragiannidis, Theodotis Papageorgiou, Afroditi Haritanti, Vasiliki Kaloutsi, Aristea Velegraki. (2005) Pulmonary embolism due to invasive aspergillosis in a child with acute myelogenous leukemia. Pediatric Blood & Cancer 45:7, 1001-1002
CrossRef670
Dorothy A. White. (2005) Aspergillus Pulmonary Infections in Transplant Recipients. Clinics in Chest Medicine 26:4, 661-674
CrossRef671
D. L. Stevens, A. L. Bisno, H. F. Chambers, E. D. Everett, P. Dellinger, E. J. C. Goldstein, S. L. Gorbach, J. V. Hirschmann, E. L. Kaplan, J. G. Montoya, J. C. Wade. (2005) Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections. Clinical Infectious Diseases 41:10, 1373-1406
CrossRef672
T. F. Patterson, H. W. Boucher, R. Herbrecht, D. W. Denning, O. Lortholary, P. Ribaud, R. H. Rubin, J. R. Wingard, B. DePauw, H. T. Schlamm, P. Troke, J. E. Bennett, . (2005) Strategy of Following Voriconazole versus Amphotericin B Therapy with Other Licensed Antifungal Therapy for Primary Treatment of Invasive Aspergillosis: Impact of Other Therapies on Outcome. Clinical Infectious Diseases 41:10, 1448-1452
CrossRef673
Oksana Anatolia Shlobin, Lesia K. Dropulic, Jonathan B. Orens, John F. Mcdyer, John V. Conte, Stephen Y. Yang, Reda Girgis. (2005) Mediastinal Mass Due to Aspergillus fumigatus After Lung Transplantation: A Case Report. The Journal of Heart and Lung Transplantation 24:11, 1991-1994
CrossRef674
Sabine Mousset, Stella Hermann, Stefan A. Klein, Heike Bialleck, Michaele Duchscherer, Barbara Bomke, Barbara Wassmann, Angelika Böhme, Dieter Hoelzer, Hans Martin. (2005) Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Annals of Hematology 84:11, 734-741
CrossRef675
J I Ito, P H Chandrasekar, R Hooshmand-Rad. (2005) Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). Bone Marrow Transplantation 36:10, 873-877
CrossRef676
Gloria Mattiuzzi, Francis J. Giles. (2005) Management of intracranial fungal infections in patients with haematological malignancies. British Journal of Haematology 131:3, 287-300
CrossRef677
P. a. H. Chandrasekar. (2005) The Year in Infection, Volume 2 Edited by Mark Wilcox Oxford, U.K.: Atlas Medical Publishing, 2005. 301 pp., illustrated. $119.95 (cloth). Clinical Infectious Diseases 41:9, 1369-1369
CrossRef678
J. Maertens, K. Theunissen, G. Verhoef, J. Verschakelen, K. Lagrou, E. Verbeken, A. Wilmer, J. Verhaegen, M. Boogaerts, J. V. Eldere. (2005) Galactomannan and Computed Tomography-Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility Study. Clinical Infectious Diseases 41:9, 1242-1250
CrossRef679
L. Nourry, F. Gagnadoux, M. Pierrot, A.L. Gourdier, A. Mercat, J.L. Racineux. (2005) Aspergillose pulmonaire invasive compliquant un choc septique. Revue des Maladies Respiratoires 22:5, 806-810
CrossRef680
José Miguel Cisneros, Ildefonso Espigado, Antonio Rivero, Fernando Lozano de León, Jorge Parra, Antonio Ramón Collado, José Manuel Lomas, Jerónimo Pachón. (2005) Tratamiento antifúngico empírico en pacientes seleccionados con fiebre persistente y neutropenia. Enfermedades Infecciosas y Microbiología Clínica 23:10, 609-614
CrossRef681
Cornelia Lass-Florl, Katharina Griff, Astrid Mayr, Andreas Petzer, Gunter Gastl, Hugo Bonatti, Martin Freund, Gabriele Kropshofer, Manfred P. Dierich, David Nachbaur. (2005) Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. British Journal of Haematology 131:2, 201-207
CrossRef682
BJ Kullberg, JD Sobel, M Ruhnke, PG Pappas, C Viscoli, JH Rex, JD Cleary, E Rubinstein, LWP Church, JM Brown, HT Schlamm, IT Oborska, F Hilton, MR Hodges. (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. The Lancet 366:9495, 1435-1442
CrossRef683
S. Koch, H. Haefner, F. Huenger, G. Haase, J. Wildberger, S. W. Lemmen. (2005) Diagnostik und Therapie invasiver Pilzinfektionen auf der Intensivstation. Der Anaesthesist 54:10, 1047-1066
CrossRef684
Vicki A Morrison. (2005) Caspofungin: an overview. Expert Review of Anti-infective Therapy 3:5, 697-705
CrossRef685
Lijuan Zhang, Mingyue Wang, Ruoyu Li, Richard Calderone. (2005) Expression of Aspergillus fumigatus Virulence-related Genes Detected in Vitro and in Vivo with Competitive RT-PCR. Mycopathologia 160:3, 201-206
CrossRef686
Thomas A O’Bryan. (2005) Pseudallescheriasis in the 21st century. Expert Review of Anti-infective Therapy 3:5, 765-773
CrossRef687
J. P. Jansen, J. F. Meis, N. M. Blijlevens, J. W. van’t Wout. (2005) Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Current Medical Research and Opinion 21:10, 1535-1546
CrossRef688
John R Graybill. (2005) Voriconazole for candidosis: an important addition?. The Lancet 366:9495, 1413-1414
CrossRef689
Rodrigo Fernández Alonso, Ma. Esther González García, Joaquín Fernández García, Francisco Javier Cepeda Piorno. (2005) Fármacos antifúngicos. Situación actual y pautas para su administración. Clinical and Translational Oncology 7:9, 377-388
CrossRef690
B. E. de Pauw, T. F. Patterson. (2005) Should the Consensus Guidelines' Specific Criteria for the Diagnosis of Invasive Fungal Infection Be Changed?. Clinical Infectious Diseases 41:Supplement 6, S377-S380
CrossRef691
J. E. Bennett. (2005) Salvage Therapy for Aspergillosis. Clinical Infectious Diseases 41:Supplement 6, S387-S388
CrossRef692
Vladimir Sabayev, Richard H. Savel, Angela Schiteanu, Deborah Asnis, Alice Veloudios. (2005) Invasive Aspergillosis-Associated Pulmonary Artery Pseudoaneurysm: A Rare Cause of Hemoptysis in an HIV-Infected Patient. Clinical Pulmonary Medicine 12:5, 297-300
CrossRef693
Anna Candoni, Rosalba Mestroni, Daniela Damiani, Mario Tiribelli, Angela Michelutti, Federico Silvestri, Maurizio Castelli, Pierluigi Viale, Renato Fanin. (2005) Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. European Journal of Haematology 75:3, 227-233
CrossRef694
M. Koldehoff, A.H. Elmaagacli, N.K. Steckel, R. Trenschel, M. Hlinka, M. Ditschkowski, D.W. Beelen. (2005) Successful treatment of patients with respiratory failure due to fungal infection after allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease 7:3-4, 137-145
CrossRef695
C. J. Crnich, D. G. Maki. (2005) Are Antimicrobial-Impregnated Catheters Effective? When Does Repetition Reach the Point of Exhaustion?. Clinical Infectious Diseases 41:5, 681-685
CrossRef696
Hamdi Akan. (2005) Management of invasive fungal infections in neutropenic patients. Hematology 10:4, 234-237
CrossRef697
Thomas F Patterson. (2005) Advances and challenges in management of invasive mycoses. The Lancet 366:9490, 1013-1025
CrossRef698
L. J. Reis, T. D. Barton, A. Pochettino, O. Velazquez, M. McGarvey, B. Milas, A. Reboli, M. G. Schuster. (2005) Successful Treatment of Aspergillus Prosthetic Valve Endocarditis with Oral Voriconazole. Clinical Infectious Diseases 41:5, 752-753
CrossRef699
Minerva B Covarrubias, Aaron P Milstone. (2005) An overview of fungal prophylaxis in lung transplantation. Current Opinion in Organ Transplantation 10:3, 227-232
CrossRef700
S R Doffman, S G Agrawal, Jeremy S Brown. (2005) Invasive pulmonary aspergillosis. Expert Review of Anti-infective Therapy 3:4, 613-627
CrossRef701
Gianna Zuccotti, Lynne Strasfeld, David M Weinstock. (2005) New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients. Expert Opinion on Pharmacotherapy 6:10, 1669-1679
CrossRef702
Jacques Bille, Oscar Marchetti, Thierry Calandra. (2005) Changing face of health-care associated fungal infections. Current Opinion in Infectious Diseases 18:4, 314-319
CrossRef703
S. G. Filler, M. R. Yeaman, D. C. Sheppard. (2005) Tumor Necrosis Factor Inhibition and Invasive Fungal Infections. Clinical Infectious Diseases 41:Supplement 3, S208-S212
CrossRef704
G. Chamilos, E. M. Marom, R. E. Lewis, M. S. Lionakis, D. P. Kontoyiannis. (2005) Predictors of Pulmonary Zygomycosis versus Invasive Pulmonary Aspergillosis in Patients with Cancer. Clinical Infectious Diseases 41:1, 60-66
CrossRef705
J. Gavalda, O. Len, R. San Juan, J. M. Aguado, J. Fortun, C. Lumbreras, A. Moreno, P. Munoz, M. Blanes, A. Ramos, G. Rufi, M. Gurgui, J. Torre-Cisneros, M. Montejo, M. Cuenca-Estrella, J. L. Rodriguez-Tudela, A. Pahissa, . (2005) Risk Factors for Invasive Aspergillosis in Solid-Organ Transplant Recipients: A Case-Control Study. Clinical Infectious Diseases 41:1, 52-59
CrossRef706
J. Maertens, A. Glasmacher, D. Selleslag, A. Ngai, D. Ryan, M. Layton, A. Taylor, C. Sable, N. Kartsonis. (2005) Evaluation of Serum Sandwich Enzyme-Linked Immunosorbent Assay for Circulating Galactomannan during Caspofungin Therapy: Results from the Caspofungin Invasive Aspergillosis Study. Clinical Infectious Diseases 41:1, e9-e14
CrossRef707
Constanze Priebe-Richter, Philipp Ivanyi, Jan Buer, Florian Langer, Joachim Lotz, Bernd Hertenstein, Arnold Ganser, Anke Franzke. (2005) Inflammatory pseudotumor of the lung following invasive aspergillosis in a patient with chronic graft-vs.-host disease. European Journal of Haematology 75:1, 68-72
CrossRef708
Ismaïl El-Hamamsy, Nicolas Dürrleman, Louis-Mathieu Stevens, Louis P. Perrault, Michel Carrier. (2005) Aspergillus Endocarditis After Cardiac Surgery. The Annals of Thoracic Surgery 80:1, 359-364
CrossRef709
Friedhelm Schuster, Christian Moelter, Irene Schmid, Ulrike B. Graubner, Birgit Kammer, Bernd H. Belohradsky, Monika Führer. (2005) Successful antifungal combination therapy with voriconazole and caspofungin. Pediatric Blood & Cancer 44:7, 682-685
CrossRef710
K. A. Marr, M. Laverdiere, A. Gugel, W. Leisenring. (2005) Antifungal Therapy Decreases Sensitivity of theAspergillus Galactomannan Enzyme Immunoassay. Clinical Infectious Diseases 40:12, 1762-1769
CrossRef711
Jason C Gallagher. (2005) Amphotericin B deoxycholate: time to retire our old standard?. Expert Review of Anti-infective Therapy 3:3, 313-316
CrossRef712
James S. Lewis, Helen W. Boucher, Teresa J. Lubowski, Ambarish J. Ambegaonkar, David L. Day, Thomas F. Patterson. (2005) Cost Advantage of Voriconazole over Amphotericin B Deoxycholate for Primary Treatment of Invasive Aspergillosis. Pharmacotherapy 25:6, 839-846
CrossRef713
Grzegorz Kofla, Markus Ruhnke. (2005) Voriconazole: review of a broad spectrum triazole antifungal agent. Expert Opinion on Pharmacotherapy 6:7, 1215-1229
CrossRef714
Michael Koldehoff, Johames L. Zakrzewski. (2005) Modern management of respiratory failure due to pulmonary mycoses following allogeneic hematopoietic stem-cell transplantation. American Journal of Hematology 79:2, 158-163
CrossRef715
B. H. Segal, L. A. Barnhart, V. L. Anderson, T. J. Walsh, H. L. Malech, S. M. Holland. (2005) Posaconazole as Salvage Therapy in Patients with Chronic Granulomatous Disease and Invasive Filamentous Fungal Infection. Clinical Infectious Diseases 40:11, 1684-1688
CrossRef716
F. Gutierrez, M. Masia, J. M. Ramos, M. Elia, J. L. Rodriguez-Tudela, M. Cuenca-Estrella. (2005) Lack of Efficacy of Voriconazole Therapy in 2 Patients with Pulmonary Fungus Balls. Clinical Infectious Diseases 40:11, 1706-1707
CrossRef717
Susan S Buchkowsky, Nilufar Partovi, Mary H. H Ensom. (2005) Clinical Pharmacokinetic Monitoring of Itraconazole Is Warranted in Only a Subset of Patients. Therapeutic Drug Monitoring 27:3, 322-333
CrossRef718
G Mele, M Musci, C Musto, L D'Amato, A Traficante, N Di Renzo. (2005) Pneumonia caused by Trichosporon pullulans in an autologous peripheral blood stem cell transplant recipient: possible misidentification. Bone Marrow Transplantation 35:12, 1219-1220
CrossRef719
I. Schedel. (2005) Neue Medikamente zur Behandlung systemischer Mykosen. Der Internist 46:6, 659-670
CrossRef720
A. Lefort. (2005) Endocardites fongiques : quelle prise en charge thérapeutique optimale ?. La Revue de Médecine Interne 26:6, 441-443
CrossRef721
Charalampos Antachopoulos, Emmanuel Roilides. (2005) Cytokines and fungal infections. British Journal of Haematology 129:5, 583-596
CrossRef722
Dimitrios P. Kontoyiannis, Maha Boktour, Hend Hanna, Harrys A. Torres, Ray Hachem, Issam I. Raad. (2005) Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 103:11, 2334-2337
CrossRef723
Stephan Ehrmann, Frédéric Bastides, Valérie Gissot, Emmanuelle Mercier, Pascal Magro, Eric Bailly, Annick Legras. (2005) Cerebral aspergillosis in the critically ill: two cases of successful medical treatment. Intensive Care Medicine 31:5, 738-742
CrossRef724
Robert Dinser, Aleksandar Grgic, Yoo-Jin Kim, Michael Pfreundschuh, Jorg Schubert. (2005) Successful treatment of disseminated aspergillosis with the combination of voriconazole, caspofungin, granulocyte transfusions, and surgery followed by allogeneic blood stem cell transplantation in a patient with primary failure of an autologous stem cell graft. European Journal of Haematology 74:5, 438-441
CrossRef725
T HARRISON. (2005) Systemic fungal infections. Medicine 33:5, 116-119
CrossRef726
Fernanda Silveira, David L Paterson. (2005) Pulmonary fungal infections. Current Opinion in Pulmonary Medicine 11:3, 242-246
CrossRef727
Pranatharthi H. Chandrasekar, James I. Ito. (2005) Amphotericin B Lipid Complex in the Management of Invasive Aspergillosis in Immunocompromised Patients. Clinical Infectious Diseases 40:S6, S392-S400
CrossRef728
Houria Mouas, Irja Lutsar, Bertrand Dupont, Olivier Fain, Raoul Herbrecht, Francois‐Xavier Lescure, Olivier Lortholary, . (2005) Voriconazole for Invasive Bone Aspergillosis: A Worldwide Experience of 20 Cases. Clinical Infectious Diseases 40:8, 1141-1147
CrossRef729
M. Mallié, J.M. Bastide, A. Blancard, A. Bonnin, S. Bretagne, M. Cambon, J. Chandenier, V. Chauveau, B. Couprie, A. Datry, M. Feuilhade, R. Grillot, C. Guiguen, V. Lavarde, V. Letscher, M.D. Linas, A. Michel, O. Morin, A. Paugam, M.A. Piens, H. Raberin, E. Tissot, D. Toubas, A. Wade. (2005) In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest®: results of a French multicentre study. International Journal of Antimicrobial Agents 25:4, 321-328
CrossRef730
Aimee K Zaas, William J Steinbach. (2005) Micafungin: the US perspective. Expert Review of Anti-infective Therapy 3:2, 183-190
CrossRef731
Raoul Herbrecht, Shanti Natarajan-Amé. (2005) Can combination salvage therapy for invasive aspergillosis improve patient outcome?. Nature Clinical Practice Oncology 2:4, 186-187
CrossRef732
Meinolf Karthaus, Oliver A. Cornely. (2005) Recent developments in the management of invasive fungal infections in patients with hematological malignancies. Annals of Hematology 84:4, 207-216
CrossRef733
L. Fischer, M. Sterneck. (2005) Invasive Pilzinfektionen bei Patienten nach Lebertransplantation. Invasive fungal infections in patients after liver transplantation. Mycoses 48:s1, 27-35
CrossRef734
Winter J Gibbs, Richard H Drew, John R Perfect. (2005) Liposomal amphotericin B: clinical experience and perspectives. Expert Review of Anti-infective Therapy 3:2, 167-181
CrossRef735
William J. Steinbach. (2005) Pediatric Aspergillosis. The Pediatric Infectious Disease Journal 24:4, 358-364
CrossRef736
Frauke Mattner, Iris F. Chaberny, H. Weissbrodt, S. Fischer, P. Gastmeier, B. Haubitz, J. Gottlieb, L. Mattner, Martin Strueber. (2005) Surveillance invasiver Fadenpilzmykosen in lungentransplantierten Patienten: Effekt antimykotischer Prophylaxe mit Itraconazol und Voriconazol. Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole. Mycoses 48:s1, 51-55
CrossRef737
Ilana Oren. (2005) Breakthrough Zygomycosis during Empirical Voriconazole Therapy in Febrile Patients with Neutropenia. Clinical Infectious Diseases 40:5, 770-771
CrossRef738
Ahmet Ifran, Kursat Kaptan, Cengiz Beyan. (2005) Efficacy of caspofungin in prophylaxis and treatment of an adult leukemic patient with invasive pulmonary aspergillosis in allogeneic stem cell transplantation. Mycoses 48:2, 146-148
CrossRef739
Amar Safdar, Gilhen Rodriguez, Norio Ohmagari, Dimitrios P. Kontoyiannis, Kenneth V. Rolston, Issam I. Raad, Richard E. Champlin. (2005) The safety of interferon-?-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 103:4, 731-739
CrossRef740
S. Vigouroux, O. Morin, P. Moreau, F. Mechinaud, N. Morineau, B. Mahe, P. Chevallier, T. Guillaume, V. Dubruille, J.-L. Harousseau, N. Milpied. (2005) Zygomycosis after Prolonged Use of Voriconazole in Immunocompromised Patients with Hematologic Disease: Attention Required. Clinical Infectious Diseases 40:4, e35-e37
CrossRef741
L. Elzi. (2005) Invasive apergillosis with myocardial involvement after kidney transplantation. Nephrology Dialysis Transplantation 20:3, 631-634
CrossRef742
Charalampos Antachopoulos, Thomas J Walsh. (2005) New agents for invasive mycoses in children. Current Opinion in Pediatrics 17:1, 78-87
CrossRef743
Aasma Shaukat, Faris Bakri, Paul Young, Theresa Hahn, Donna Ball, Maria R. Baer, Meir Wetzler, James L. Slack, Peter Loud, Myron Czuczman, Philip L. McCarthy, Thomas J. Walsh, Brahm H. Segal. (2005) Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: Clinical, radiologic, and pathologic characteristics. Mycopathologia 159:2, 181-188
CrossRef744
Anne Chen, Jack D Sobel. (2005) Emerging azole antifungals. Expert Opinion on Emerging Drugs 10:1, 21-33
CrossRef745
(2005) Caspofungin versus Liposomal Amphotericin B for Empirical Therapy. New England Journal of Medicine 352:4, 410-414
Full Text746
J. R. Perfect. (2005) Nuances of new anti- Aspergillus antifungals. Medical Mycology 43:s1, 271-276
CrossRef747
Fiona Chionh, Kirsten E Herbert, John F Seymour, H Miles Prince, Max Wolf, Alan Zimet, Constantine Tam, Glen A Kennedy. (2005) Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia. Leukemia & Lymphoma 46:4, 603-605
CrossRef748
M. S. Lionakis, D. P. Kontoyiannis. (2005) Fruit flies as a minihost model for studying drug activity and virulence in Aspergillus. Medical Mycology 43:s1, 111-114
CrossRef749
Vanessa Kulemann, Martin Bauer, Wolfgang Graninger, Christian Joukhadar. (2005) Safety and Potential of Drug Interactions of Caspofungin and Voriconazole in Multimorbid Patients. Pharmacology 75:4, 165-178
CrossRef750
Jaroslav Sterba, Jaroslav Prochazka, Jiri Ventruba, Leos Kren, Dalibor Valik, Dagmar Burgetova, Peter Mudry, Jarmila Skotakova, Jan Blatny. (2005) SUCCESSFUL TREATMENT OF ASPERGILLUS BRAIN ABSCESS IN A CHILD WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND LIVER FAILURE. Pediatric Hematology-Oncology 22:8, 649-655
CrossRef751
Thomas Wieland, Andreas Liebold, Magda Jagiello, Gerald Retzl, Dietrich E. Birnbaum. (2005) Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation. The Journal of Heart and Lung Transplantation 24:1, 102-104
CrossRef752
M. E. Da Silva Ferreira, A. L. Colombo, I. Paulsen, Q. Ren, J. Wortman, J. Huang, M. H. S. Goldman, G. H. Goldman. (2005) The ergosterol biosynthesis pathway, transporter genes, and azole resistance in Aspergillus fumigatus. Medical Mycology 43:s1, 313-319
CrossRef753
William H. Krüger, Bettina Rüssmann, Maike de Wit, Nicolaus Kröger, Helmut Renges, Ingo Sobottka, Axel R. Zander. (2005) Haemopoietic Cell Transplantation of Patients with a History of Deep or Invasive Fungal Infection during Prophylaxis with Liposomal Amphotericin B. Acta Haematologica 113:2, 104-108
CrossRef754
Priya Venkatesan, John R. Perfect, Sarah A. Myers. (2005) Evaluation and management of Fungal infections in Immunocompromised patients. Dermatologic Therapy 18:1, 44-57
CrossRef755
N. G. Almyroudis, S. M. Holland, B. H. Segal. (2005) Invasive aspergillosis in primary immunodeficiencies. Medical Mycology 43:s1, 247-259
CrossRef756
SJ van Hal, K Clezy. (2005) Emergence of invasive cerebral aspergillosis in an HIV-positive patient on voriconazole therapy. HIV Medicine 6:1, 45-46
CrossRef757
Paul L McCormack, Caroline M Perry. (2005) Caspofungin. Drugs 65:14, 2049-2068
CrossRef758
R. Greene. (2005) The radiological spectrum of pulmonary aspergillosis. Medical Mycology 43:s1, 147-154
CrossRef759
R. Herbrecht, A. Moghaddam, L. Mahmal, S. Natarajan-Ame, L.-M. Fornecker, V. Letscher-Bru. (2005) Invasive aspergillosis in the hematologic and immunologic patient: new findings and key questions in leukemia. Medical Mycology 43:s1, 239-242
CrossRef760
Richard F. Hector, Rafael Laniado-Laborin. (2005) Coccidioidomycosis—A Fungal Disease of the Americas. PLoS Medicine 2:1, e2
CrossRef761
John W Baddley, Peter G Pappas. (2005) Antifungal Combination Therapy. Drugs 65:11, 1461-1480
CrossRef762
M. O'Doherty, M. Hannan, T. Fulcher. (2005) Voriconazole in the Treatment of Fungal Osteomyelitis of the Orbit in the Immunocompromised Host. Orbit 24:4, 285-289
CrossRef763
W. J. Steinbach. (2005) New findings and unique aspects in pediatric aspergillosis. Medical Mycology 43:s1, 261-265
CrossRef764
Joseph M. Harrison, Randolph D. Glickman, Charles S. Ballentine, Yolanda Trigo, Melanie A. Pena, Pearl Kurian, Laura K. Najvar, Neeru Kumar, Ankit H. Patel, William E. Sponsel, John R. Graybill, William C. Lloyd, Margaret M. Miller, Gianmarco Paris, Fernando Trujillo, Aaron Miller, Robert Melendez. (2005) Retinal Function Assessed by ERG Before and After Induction of Ocular Aspergillosis and Treatment by the Anti-fungal, Micafungin, in Rabbits. Documenta Ophthalmologica 110:1, 37-55
CrossRef765
N. Singh. (2005) Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis, and management. Medical Mycology 43:s1, 267-270
CrossRef766
Rodrigo Martino, Montserrat Cortés, Maricel Subirá, Rocio Parody, Estela Moreno, Jorge Sierra. (2005) Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies. Leukemia & Lymphoma 46:10, 1429-1435
CrossRef767
M. Kleinberg. (2005) Aspergillosis in the CLEAR outcomes trial: working toward a real-world clinical perspective. Medical Mycology 43:s1, 289-294
CrossRef768
Vladimir C. Krcmery, Jr.. (2005) Antifungal Chemotherapeutics. Medical Principles and Practice 14:3, 125-135
CrossRef769
Curtis D. Holt, Drew J. Winston. 2005. Infections After Liver Transplantation. , 963-994.
CrossRef770
Shang-Miao Chang, Hsu-Tah Kuo, Fung-J Lin, Chi-Yuan Tzen, Chin-Yin Sheu. (2005) Pseudomembranous tracheobronchitis caused by Aspergillus in immunocompromised patients. Scandinavian Journal of Infectious Diseases 37:11-12, 937-942
CrossRef771
M. Bishton, R. Chopra. (2004) The role of granulocyte transfusions in neutropenic patients. British Journal of Haematology 127:5, 501-508
CrossRef772
S. F. Mekan, O. Saeed, J. A. Khan. (2004) Invasive aspergillosis with polyarthritis. Fallbericht. Invasive Aspergillose mit Polyarthritis. Mycoses 47:11-12, 518-520
CrossRef773
Jashin J. Wu, Katie R. Pang, David B. Huang, Stephen K. Tyring. (2004) Therapy of systemic fungal infections. Dermatologic Therapy 17:6, 532-538
CrossRef774
J.Stephen Dummer, Nikoloz Lazariashvilli, Jean Barnes, Mathew Ninan, Aaron P. Milstone. (2004) A survey of anti-fungal management in lung transplantation. The Journal of Heart and Lung Transplantation 23:12, 1376-1381
CrossRef775
Johann Maertens, Issam Raad, George Petrikkos, Marc Boogaerts, Dominik Selleslag, Finn B. Petersen, Carole A. Sable, Nicholas A. Kartsonis, Angela Ngai, Arlene Taylor, Thomas F. Patterson, David W. Denning, Thomas J. Walsh, . (2004) Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy. Clinical Infectious Diseases 39:11, 1563-1571
CrossRef776
Brian G. Keevil, Sheila Newman, Stephen Lockhart, Susan J. Howard, Caroline B. Moore, David W. Denning. (2004) Validation of an Assay for Voriconazole in Serum Samples Using Liquid Chromatography-Tandem Mass Spectrometry. Therapeutic Drug Monitoring 26:6, 650-657
CrossRef777
R. R. Klont, M. A. S. H. Mennink-Kersten, P. E. Verweij. (2004) Utility of Aspergillus Antigen Detection in Specimens Other than Serum Specimens. Clinical Infectious Diseases 39:10, 1467-1474
CrossRef778
Melissa Rubenstein, Moise L. Levy, Denise Metry. (2004) Voriconazole-Induced Retinoid-Like Photosensitivity in Children. Pediatric Dermatology 21:6, 675-678
CrossRef779
David B. Huang, Jashin J. Wu, Christopher J. Lahart. (2004) Toxic Epidermal Necrolysis as a Complication of Treatment with Voriconazole. Southern Medical Journal 97:11, 1116-1117
CrossRef780
&NA;. (2004) saving lives in invasive aspergillosis. Oncology Times 1:10, 12-13
CrossRef781
Juan C. Gea-Banacloche, Steven M. Opal, James Jorgensen, Joseph A. Carcillo, Kent A. Sepkowitz, Catherine Cordonnier. (2004) Sepsis associated with immunosuppressive medications: An evidence-based review. Critical Care Medicine 32:Supplement, S578-S590
CrossRef782
R. de Paz Arias, T. Cobo Rodríguez, J. Gracia Colldeforns, F. Hernández Navarro. (2004) Complicaciones infecciosas en el paciente neutropénico. Medicine - Programa de Formación Médica Continuada Acreditado 9:21, 1347-1354
CrossRef783
G. L. Drusano. (2004) How Does a Patient Maximally Benefit from Anti-infective Chemotherapy?. Clinical Infectious Diseases 39:8, 1245-1246
CrossRef784
J. R. Wingard. (2004) Design Issues in a Prospective Randomized Double-Blinded Trial of Prophylaxis with Fluconazole versus Voriconazole after Allogeneic Hematopoietic Cell Transplantation. Clinical Infectious Diseases 39:Supplement 4, S176-S180
CrossRef785
A. E. Boyd, S. Modi, S. J. Howard, C. B. Moore, B. G. Keevil, D. W. Denning. (2004) Adverse Reactions to Voriconazole. Clinical Infectious Diseases 39:8, 1241-1244
CrossRef786
B. J. Kullberg, A. M. L. O. Lashof, M. G. Netea. (2004) Design of Efficacy Trials of Cytokines in Combination with Antifungal Drugs. Clinical Infectious Diseases 39:Supplement 4, S218-S223
CrossRef787
J. H. Rex, J. R. Wingard, R. Wenzel, R. Herbrecht, J. Sobel, J. E. Edwards. (2004) The Design of Clinical Trials That Evaluate Antifungal Prophylaxis and Combination Therapy: Introduction and Overview. Clinical Infectious Diseases 39:Supplement 4, S165-S169
CrossRef788
J. H. Powers. (2004) Considerations in Clinical Trials of Combination Antifungal Therapy. Clinical Infectious Diseases 39:Supplement 4, S228-S235
CrossRef789
P. Tattevin, F. Bruneel, F. Lellouche, T. de Broucker, S. Chevret, M. Wolff, B. Regnier. (2004) Successful treatment of brain aspergillosis with voriconazole. Clinical Microbiology and Infection 10:10, 928-931
CrossRef790
P. H. Chandrasekar, J. L. Cutright, E. K. Manavathu. (2004) Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clinical Microbiology and Infection 10:10, 925-928
CrossRef791
Ravi Radhakrishnan, Michele L. Donato, Victor G. Prieto, Steven R. Mays, Issam I. Raad, Henry M. Kuerer. (2004) Invasive cutaneous fungal infections requiring radical resection in cancer patients undergoing chemotherapy. Journal of Surgical Oncology 88:1, 21-26
CrossRef792
(2004) Fungal infections. American Journal of Transplantation 4:s10, 110-134
CrossRef793
Sureka Thiagalingam, Glen T Fernando, Kimberley Tan, Brett A O'Donnell, Kerry Weeks, Michael Branley. (2004) Clinical Case Notes. Orbital apex syndrome secondary to Pseudallescheria boydii fungal sinusitis in an immunocompetent patient. Clinical and Experimental Ophthalmology 32:5, 545-547
CrossRef794
Karin M. Dunst, Ludwig C. Mueller. (2004) Surgical management of bilateral multiple invasive pulmonary aspergillosis. The Journal of Thoracic and Cardiovascular Surgery 128:4, 621-622
CrossRef795
Shakhsanam E. Aliyeva, Andrew J. Ullmann, Ulrike B. Kottler, Martine Frising, Oliver Schwenn. (2004) Histological examination of an eye with endogenous Aspergillus endophthalmitis treated with oral voriconazole: a case report. Graefe's Archive for Clinical and Experimental Ophthalmology 242:10, 887-891
CrossRef796
Rajesh M. Prabhu, Mark Bonnell, Bradford L. Currier, Robert Orenstein. (2004) Successful Treatment of Disseminated Nonmeningeal Coccidioidomycosis with Voriconazole. Clinical Infectious Diseases 39:7, e74-e77
CrossRef797
K. A. Marr, M. Boeckh, R. A. Carter, H. W. Kim, L. Corey. (2004) Combination Antifungal Therapy for Invasive Aspergillosis. Clinical Infectious Diseases 39:6, 797-802
CrossRef798
Walid Abuhammour, Rashed A. Hasan. (2004) Treatment of invasive aspergillosis in children with hematologic malignancies. The Indian Journal of Pediatrics 71:9, 837-843
CrossRef799
Dieter Buchheidt, Margit Hummel, Georg Engelich, Rüdiger Hehlmann. (2004) Management of infections in critically ill neutropenic cancer patients. Journal of Critical Care 19:3, 165-173
CrossRef800
Arshad A. Siddiqui, Ahmed Ali Shah, Saad H. Bashir. (2004) Craniocerebral Aspergillosis of Sinonasal Origin in Immunocompetent Patients: Clinical Spectrum and Outcome in 25 Cases. Neurosurgery 55:3, 602-613
CrossRef801
Johan Maertens, Koen Theunissen, Eric Verbeken, Katrien Lagrou, Jan Verhaegen, Marc Boogaerts, Johan Van Eldere. (2004) Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. British Journal of Haematology 126:6, 852-860
CrossRef802
T. Levin, B. Suh, D. Beltramo, R. Samuel. (2004) Aspergillus mediastinitis following orthotopic heart transplantation: case report and review of the literature. Transplant Infectious Disease 6:3, 129-131
CrossRef803
P. J. Shaw. (2004) Antifungal guidelines. Internal Medicine Journal 34:9-10, 585-586
CrossRef804
A. Imhof, S. A. Balajee, D. N. Fredricks, J. A. Englund, K. A. Marr. (2004) Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving Voriconazole. Clinical Infectious Diseases 39:5, 743-746
CrossRef805
Raoul Herbrecht. (2004) Voriconazole: therapeutic review of a new azole antifungal. Expert Review of Anti-infective Therapy 2:4, 485-497
CrossRef806
G. Maschmeyer, M. Ruhnke. (2004) Update on antifungal treatment of invasive Candida and Aspergillus infections. Derzeitiger Kenntnisstand in der antimykotischen Behandlung invasiver Candida- und Aspergillus-Infektionen. Mycoses 47:7, 263-276
CrossRef807
W. J. Steinbach, D. K. Benjamin, D. P. Kontoyiannis, J. R. Perfect, I. Lutsar, K. A. Marr, M. S. Lionakis, H. A. Torres, H. Jafri, T. J. Walsh. (2004) Infections Due to Aspergillus terreus: A Multicenter Retrospective Analysis of 83 Cases. Clinical Infectious Diseases 39:2, 192-198
CrossRef808
Simone Cesaro, Tiziana Toffolutti, Chiara Messina, Elisabetta Calore, Rita Alaggio, Riccardo Cusinato, Marta Pillon, Luigi Zanesco. (2004) Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. European Journal of Haematology 73:1, 50-55
CrossRef809
Monique ASH Mennink-Kersten, J Peter Donnelly, Paul E Verweij. (2004) Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. The Lancet Infectious Diseases 4:6, 349-357
CrossRef810
G. Damaj, V. Ivanov, B. Brigand, E. D’incan, M. F. Doglio, K. Bilger, C. Faucher, N. Vey, J. A. Gastaut. (2004) Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient. Annals of Hematology 83:6, 390-393
CrossRef811
Luis Ostrosky-Zeichner. (2004) Novel approaches to antifungal prophylaxis. Expert Opinion on Investigational Drugs 13:6, 665-672
CrossRef812
R. Herbrecht. (2004) Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. International Journal of Clinical Practice 58:6, 612-624
CrossRef813
Angela Rösen-Wolff, Anne Koch, Wilhelm Friedrich, Gabriele Hahn, Manfred Gahr, Joachim Roesler. (2004) Successful Elimination of an Invasive Aspergillus nidulans Lung Infection by Voriconazole After Failure of a Combination of Caspofungin and Liposomal Amphotericin B in a Boy With Chronic Granulomatous Disease. The Pediatric Infectious Disease Journal 23:6, 584-586
CrossRef814
M. Nucci, K. A. Marr, F. Queiroz-Telles, C. A. Martins, P. Trabasso, S. Costa, J. C. Voltarelli, A. L. Colombo, A. Imhof, R. Pasquini, A. Maiolino, A. S. Carmino, E. Anaissie. (2004) Fusarium Infection in Hematopoietic Stem Cell Transplant Recipients. Clinical Infectious Diseases 38:9, 1237-1242
CrossRef815
C. J. Crnich, D. G. Maki. (2004) Are Antimicrobial-Impregnated Catheters Effective? Don't Throw Out the Baby with the Bathwater. Clinical Infectious Diseases 38:9, 1287-1292
CrossRef816
Delia Bethell, Georgina Hall, T. Robin Goodman, Nigel Klein, Andrew J. Pollard. (2004) Resolution of Orbitocerebral Aspergillosis During Combination Treatment With Voriconazole and Amphotericin Plus Adjunctive Cytokine Therapy. Journal of Pediatric Hematology/Oncology 26:5, 304-307
CrossRef817
O. Johnston. (2004) Aspergillus 'fungus ball' within a cadaveric renal transplant graft. Nephrology Dialysis Transplantation 19:5, 1317-1318
CrossRef818
Donald C. Sheppard, John E. Edwards, Jr.. (2004) Editorial Commentary: Development of a Vaccine for Invasive Aspergillosis. Clinical Infectious Diseases 38:8, 1137-1138
CrossRef819
K.H Vandewoude, S.I Blot, D Benoit, F Colardyn, D Vogelaers. (2004) Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. Journal of Hospital Infection 56:4, 269-276
CrossRef820
Zachary A Rubin, Jyoti Somani. (2004) New options for the treatment of invasive fungal infections. Seminars in Oncology 31, 91-98
CrossRef821
W. W. Hope, D. W. Denning. (2004) Optimising antifungal therapy for individual patients. Internal Medicine Journal 34:4, 147-149
CrossRef822
M. A. Slavin, J. Szer, A. P. Grigg, A. W. Roberts, J. F. Seymour, J. Sasadeusz, K. Thursky, S. C. Chen, C. O. Morrissey, C. H. Heath, and T. Sorrell. (2004) Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Internal Medicine Journal 34:4, 192-200
CrossRef823
Anjali Shetty, Rosemary A Barnes. (2004) New developments in antifungal strategy. Expert Review of Anti-infective Therapy 2:2, 269-277
CrossRef824
Jason C Gallagher, Conan MacDougall, Elizabeth S Dodds Ashley, John R Perfect. (2004) Recent advances in antifungal pharmacotherapy for invasive fungal infections. Expert Review of Anti-infective Therapy 2:2, 253-268
CrossRef825
Claudio Viscoli, Marco Machetti, Paola Cappellano, Barbara Bucci, Paolo Bruzzi, Maria Teresa Van Lint, Andrea Bacigalupo. (2004) False‐Positive Galactomannan Platelia Aspergillus Test Results for Patients Receiving Piperacillin‐Tazobactam. Clinical Infectious Diseases 38:6, 913-916
CrossRef826
Walid Abuhammour, Eyassu Habte-Gaber. (2004) Newer antifungal agents. The Indian Journal of Pediatrics 71:3, 253-259
CrossRef827
D. L. Paterson. (2004) New clinical presentations of invasive aspergillosis in non-conventional hosts. Clinical Microbiology and Infection 10:s1, 24-30
CrossRef828
J. R. Azanza Perea, B. Sadaba Diaz de Rada, E. Garcia Quetglas, M. J. Munoz Juarez. (2004) Oral versus intravenous therapy in the treatment of systemic mycosis. Clinical Microbiology and Infection 10:s1, 96-106
CrossRef829
David A. Stevens. (2004) Azoles in the Management of Systemic Fungal Infections. Infectious Diseases in Clinical Practice 12:2, 81-92
CrossRef830
J. P. Donnelly, B. E. De Pauw. (2004) Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity. Clinical Microbiology and Infection 10:s1, 107-117
CrossRef831
Dorothy A White. (2004) Drug-induced pulmonary infection. Clinics in Chest Medicine 25:1, 179-187
CrossRef832
Marty, Francisco M., Cosimi, Lisa A., , Baden, Lindsey R., . (2004) Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell Transplants. New England Journal of Medicine 350:9, 950-952
Full Text833
Robert P. Rapp. (2004) Changing Strategies for the Management of Invasive Fungal Infections. Pharmacotherapy 24:2 Part 2, 4S-28S
CrossRef834
Jean Klastersky. (2004) Empirical antifungal therapy. International Journal of Antimicrobial Agents 23:2, 105-112
CrossRef835
Alvaro Lassaletta, A. Perez, M. A. D??az, J. Sevilla, M. Gonz??lez-Vicent, L. Madero. (2004) Successful Treatment of Invasive Aspergillosis With Oral Voriconazole Following Intravenous Liposomal Amphotericin in a Child With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 26:2, 117-119
CrossRef836
John H. Powers, Renata Albrecht. (2004) Lipid Amphotericin B Formulations as Comparators in Clinical Trials. Clinical Infectious Diseases 38:2, 305-306
CrossRef837
Helen W Boucher, Andreas H Groll, Christine C Chiou, Thomas J Walsh. (2004) Newer Systemic Antifungal Agents. Drugs 64:18, 1997-2020
CrossRef838
Brandon Hayes-Lattin, Richard T Maziarz. (2004) Update in the Epidemiology, Prophylaxis, and Treatment of Fungal Infections in Patients with Hematologic Disorders. Leukemia & Lymphoma 45:4, 669-680
CrossRef839
P. Gothard, T. R. Rogers. (2004) Voriconazole for serious fungal infections. International Journal of Clinical Practice 58:1, 74-80
CrossRef840
Markus Ruhnke. (2004) Mucosal and Systemic Fungal Infections in Patients with AIDS. Drugs 64:11, 1163-1180
CrossRef841
Nicolas Blin, Nadine Morineau, Fanny Gaillard, Odile Morin, Noël Milpied, Jean-Luc Harousseau, Philippe Moreau. (2004) Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma. Leukemia & Lymphoma 45:10, 2161-2163
CrossRef842
Takahiko Yamanoi, Ken Shibano, Tomoko Soeda, Akihiko Hoshi, Yutaka Matsuura, Yoshihiro Sugiura, Kazuhiro Endo, Teiji Yamamoto. (2004) Intracranial Invasive Aspergillosis Originating in the Sphenoid Sinus: A Successful Treatment with High-Dose Itraconazole in Three Cases. The Tohoku Journal of Experimental Medicine 203:2, 133-139
CrossRef843
W. W. Hope, D. W. Denning. (2004) Invasive aspergillosis: current and future challenges in diagnosis and therapy. Clinical Microbiology and Infection 10:1, 2-4
CrossRef844
Nathan P. Wiederhold, Russell E. Lewis, Dimitrios P. Kontoyiannis. (2003) Invasive Aspergillosis in Patients with Hematologic Malignancies. Pharmacotherapy 23:12, 1592-1610
CrossRef845
Philippe Eggimann, Jorge Garbino, Didier Pittet. (2003) Management of candidiasis Management of Candida species infections in critically ill patients. The Lancet Infectious Diseases 3:12, 772-785
CrossRef846
Emilie Chow, Theodore Moore, Karin Nielsen. (2003) Case report: invasive aspergillosis successfully treated with voriconazole without recurrence during subsequent bone marrow transplantation. The Pediatric Infectious Disease Journal 22:12, 1109-1110
CrossRef847
L. R. Baden, J. T. Katz, J. A. Fishman, C. Koziol, A. DelVecchio, M. Doran, R. H. Rubin. (2003) Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 76:11, 1632-1637
CrossRef848
Ana Espinel-Ingroff. (2003) Utility of mould susceptibility testing. Current Opinion in Infectious Diseases 16:6, 527-532
CrossRef849
Kieren A. Marr. (2003) New approaches to invasive fungal infections. Current Opinion in Hematology 10:6, 445-450
CrossRef850
Nina Singh. (2003) Treatment of opportunistic mycoses: how long is long enough?. The Lancet Infectious Diseases 3:11, 703-708
CrossRef851
Peter K Linden. (2003) Amphotericin B lipid complex for the treatment of invasive fungal infections. Expert Opinion on Pharmacotherapy 4:11, 2099-2110
CrossRef852
Annie Wong-Beringer, Jane Kriengkauykiat. (2003) Systemic Antifungal Therapy: New Options, New Challenges. Pharmacotherapy 23:11, 1441-1462
CrossRef853
David W Denning. (2003) Echinocandin antifungal drugs. The Lancet 362:9390, 1142-1151
CrossRef854
Angelika Böhme, Markus Ruhnke, Dieter Buchheidt, Meinolf Karthaus, Hermann Einsele, Stefan Guth, Gudrun Heussel, Claus-Peter Heussel, Christian Junghanss, Winfried K. Kern, Thomas Kubin, Georg Maschmeyer, Orhan Sezer, Gerda Silling, Thomas Südhoff, Hubert Szelényi†, Andrew J. Ullmann. (2003) Treatment of fungal infections in hematology and oncology. Annals of Hematology 82:S2, S133-S140
CrossRef855
Sandro Vento, Francesca Cainelli. (2003) Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. The Lancet Oncology 4:10, 595-604
CrossRef856
Elizabeth Shouldice, Conrad Fernandez, Barbara McCully, Matthias Schmidt, Robert Fraser, Chris Cook. (2003) Voriconazole Treatment of Presumptive Disseminated Aspergillus Infection in a Child With Acute Leukemia. Journal of Pediatric Hematology/Oncology 25:9, 732-734
CrossRef857
L. D. Saravolatz, L. Ostrosky-Zeichner, K. A. Marr, J. H. Rex, S. H. Cohen. (2003) Amphotericin B: Time for a New "Gold Standard". Clinical Infectious Diseases 37:3, 415-425
CrossRef858
Harumi Yamada, Hajime Kotaki, Takashi Takahashi. (2003) Recommendations for the treatment of fungal pneumonias. Expert Opinion on Pharmacotherapy 4:8, 1241-1258
CrossRef859
Hassan F. Nadrous, Bekele Afessa, Eric A. Pfeifer, Steve G. Peters. (2003) The Role of Autopsy in the Intensive Care Unit. Mayo Clinic Proceedings 78:8, 947-950
CrossRef860
H. F. Nadrous, B. Afessa, E. A. Pfeifer, S. G. Peters. (2003) The Role of Autopsy in the Intensive Care Unit. Mayo Clinic Proceedings 78:8, 947-950
CrossRef861
Dimitrios P. Kontoyiannis, Ray Hachem, Russell E. Lewis, Gustavo A. Rivero, Harrys A. Torres, John Thornby, Richard Champlin, Hagop Kantarjian, Gerald P. Bodey, Issam I. Raad. (2003) Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98:2, 292-299
CrossRef862
S. Consigny, N. Dhedin, A. Datry, S. Choquet, V. Leblond, O. Chosidow. (2003) Successsful Voriconazole Treatment of Disseminated Fusarium Infection in an Immunocompromised Patient. Clinical Infectious Diseases 37:2, 311-313
CrossRef863
Corrado Girmenia, Pietro Martino. (2003) New antifungal drugs and new clinical trials. Current Opinion in Oncology 15:4, 283-288
CrossRef864
W Garrett Nichols. (2003) Combating infections in hematopoietic stem cell transplant recipients. Expert Review of Anti-infective Therapy 1:1, 57-73
CrossRef865
Antonella Lupetti, Peter H. Nibbering, Mario Campa, Mario Del Tacca, Romano Danesi. (2003) Molecular targeted treatments for fungal infections: the role of drug combinations. Trends in Molecular Medicine 9:6, 269-276
CrossRef866
LilyAnn Jeu, Frank J. Piacenti, Aleksandr G. Lyakhovetskiy, Horatio B. Fung. (2003) Voriconazole. Clinical Therapeutics 25:5, 1321-1381
CrossRef867
Remzi Bag. (2003) Fungal pneumonias in transplant recipients. Current Opinion in Pulmonary Medicine 9:3, 193-198
CrossRef868
John R. Perfect, Kieren A. Marr, Thomas J. Walsh, Richard N. Greenberg, Bertrand DuPont, Julian de la Torre‐Cisneros, Gudrun Just‐Nubling, Haran T Schlamm, Irja Lutsar, Ana Espinel‐Ingroff, Elizabeth Johnson. (2003) Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections. Clinical Infectious Diseases 36:9, 1122-1131
CrossRef869
&NA;. (2003) Voriconazole in the treatment of invasive aspergillosis: profile report. Drugs & Therapy Perspectives 19:5, 5-7
CrossRef870
J. E. Bennett, J. Powers, B. de Pauw, W. Dismukes, J. Galgiani, M. Glauser, R. Herbrecht, C. Kauffman, J. Lee, P. Pappas, J. Rex, P. Verweij, C. Viscoli, T. Walsh. (2003) Forum Report: Issues in the Design of Trials of Drugs for the Treatment of Invasive Aspergillosis. Clinical Infectious Diseases 36:Supplement 3, S113-S116
CrossRef871
Alexander Imhof, Roland B. Walter, Andreas Schaffner. (2003) Continuous Infusion of Escalated Doses of Amphotericin B Deoxycholate: An Open‐Label Observational Study. Clinical Infectious Diseases 36:8, 943-951
CrossRef872
Irja Lutsar, Mike R. Hodges, Konrad Tomaszewski, Peter F. Troke, Nolan D. Wood. (2003) Safety of Voriconazole and Dose Individualization. Clinical Infectious Diseases 36:8, 1087-1088
CrossRef873
David W Denning, Christopher C Kibbler, Rosemary A Barnes. (2003) British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. The Lancet Infectious Diseases 3:4, 230-240
CrossRef874
Leonard B. Johnson, Carol A. Kauffman. (2003) Voriconazole: A New Triazole Antifungal Agent. Clinical Infectious Diseases 36:5, 630-637
CrossRef875
Nina Singh. (2003) Fungal infections in the recipients of solid organ transplantation. Infectious Disease Clinics of North America 17:1, 113-134
CrossRef876
Andreas H Groll, Juan C Gea-Banacloche, Axel Glasmacher, Gudrun Just-Nuebling, Georg Maschmeyer, Thomas J Walsh. (2003) Clinical pharmacology of antifungal compounds. Infectious Disease Clinics of North America 17:1, 159-191
CrossRef877
Markus Ruhnke. (2003) Systemmykosen: Risiko Immunsuppression. Pharmazie in unserer Zeit 32:2, 104-109
CrossRef878
John M. Valgus. (2003) What’s new in antifungals?. Current Infectious Disease Reports 5:1, 16-21
CrossRef879
Jason C Gallagher, Elizabeth S Dodds Ashley, Richard H Drew, John R Perfect. (2003) Antifungal pharmacotherapy for invasive mould infections. Expert Opinion on Pharmacotherapy 4:2, 147-164
CrossRef880
Andrew J. Ullmann. (2003) Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Current Medical Research and Opinion 19:4, 263-271
CrossRef881
(2002) Voriconazole versus Amphotericin B for Invasive Aspergillosis. New England Journal of Medicine 347:25, 2080-2081
Full Text882
Kieren A Marr, Thomas Patterson, David Denning. (2002) Aspergillosis. Infectious Disease Clinics of North America 16:4, 875-894
CrossRef883
A. Safdar, E.B. Papadopoulos, J.W. Young. (2002) Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoietic stem cell transplantation. Scedosporiasis and recent advances in antifungal ther. Transplant Infectious Disease 4:4, 212-217
CrossRef884
Thomas F. Patterson. (2002) Early use of antifungal therapy in high-risk patients. Current Opinion in Infectious Diseases 15:6, 561-563
CrossRef885
Brian A. Potoski, Jack Brown. (2002) The Safety of Voriconazole. Clinical Infectious Diseases 35:10, 1273-1275
CrossRef886
Laura Chow, Neil E. Brown, Dennis Kunimoto. (2002) An Unusual Case of Pulmonary Invasive Aspergillosis and Aspergilloma Cured with Voriconazole in a Patient with Cystic Fibrosis. Clinical Infectious Diseases 35:9, e106-e110
CrossRef887
&NA;. (2002) Voriconazole superior to amphotericin B in aspergillosis. Inpharma Weekly &NA;:1351, 10
CrossRef888
Susan S. Huang, Iris T. Chan, Richard M. Stone, Lindsey R. Baden. (2002) Successful Treatment of Angioinvasive Aspergillosis During Prolonged Neutropenia with Liposomal Amphotericin, Voriconazole, and Caspofungin. Infectious Diseases in Clinical Practice 11:6, 355-358
CrossRef889
M. Ruhnke. (2002) Voriconazol - Perspektiven und klinische Aspekte. Mycoses 45:S3, 42-47
CrossRef890
Richard B.R. Muijsers, Karen L. Goa, Lesley J. Scott. (2002) Voriconazole. Drugs 62:18, 2655-2664
CrossRef891
Thomas F. Patterson. (2002) Voriconazole. Drugs 62:18, 2665-2666
CrossRef
- Letters
